Document:

EX-10.5

 Exhibit 10.5 

200 STATE STREET 

BOSTON, MASSACHUSETTS 

OFFICE LEASE AGREEMENT 

BETWEEN 
 GLL 200 STATE STREET,
L.P., 
 a Delaware limited partnership 

(“LANDLORD”) 
 AND 

CENTREXION THERAPEUTICS CORPORATION 

a Delaware corporation 

(“TENANT”) 

 TABLE OF CONTENTS 

 

							
	 1.
	  	Basic Lease Information	  	 	1	 
	 2.
	  	Lease Grant	  	 	4	 
	 3.
	  	Possession 	  	 	5	 
	 4.
	  	Rent	  	 	5	 
	 5.
	  	Compliance with Laws; Use	  	 	12	 
	 6.
	  	Security Deposit	  	 	12	 
	 7.
	  	Services to be Furnished by Landlord	  	 	14	 
	 8.
	  	Leasehold Improvements	  	 	15	 
	 9.
	  	Repairs and Alterations	  	 	15	 
	 10.
	  	Use of Electrical Services by Tenant	  	 	17	 
	 11.
	  	Entry by Landlord	  	 	18	 
	 12.
	  	Assignment and Subletting	  	 	18	 
	 13.
	  	Liens	  	 	20	 
	 14.
	  	Indemnity and Waiver of Claims	  	 	21	 
	 15.
	  	Insurance	  	 	22	 
	 16.
	  	Subrogation	  	 	22	 
	 17.
	  	Casualty Damage	  	 	22	 
	 18.
	  	Condemnation	  	 	23	 
	 19.
	  	Events of Default	  	 	24	 
	 20.
	  	Remedies	  	 	25	 
	 21.
	  	Limitation Of Liability	  	 	27	 
	 22.
	  	No Waiver	  	 	27	 
	 23.
	  	Quiet Enjoyment	  	 	27	 
	 24.
	  	[Intentionally Omitted]	  	 	27	 
	 25.
	  	Holding Over	  	 	27	 
	 26.
	  	Subordination to Mortgages; Estoppel Certificate	  	 	28	 
	 27.
	  	Attorneys’ Fees	  	 	28	 
	 28.
	  	Notice	  	 	29	 
	 29.
	  	Excepted Rights	  	 	29	 
	 30.
	  	Surrender of Premises	  	 	29	 
	 31.
	  	Miscellaneous	  	 	30	 
	 32.
	  	Entire Agreement	  	 	33	 

  
 i 

 OFFICE LEASE AGREEMENT 

THIS OFFICE LEASE AGREEMENT (the “Lease”) is made and entered into as of the
24th day of October 2016, by and between GLL 200 STATE STREET, L.P., a Delaware limited partnership (“Landlord”), and CENTREXION THERAPEUTICS CORPORATION, a Delaware
corporation (“Tenant”). 
  

	1.	 Basic Lease Information. 

 

	 	A.	 “Building” shall mean the Office Unit in the commercial condominium located at and known as 200 State
Street, Boston, Massachusetts; and as further defined in Section 2 hereof. 

  

	 	B.	 The “Rentable Square Footage of the Building” is the rentable square footage of the Office Unit and
is deemed to be 301,896 square feet. 

  

	 	C.	 The “Condominium” is that certain commercial condominium known as 200 State Street Condominium,
created by that certain Master Deed dated June 30, 2005, recorded with the Suffolk County Registry of Deeds at Book 37481, Page 1, as amended and restated by that certain Amended and Restated Master Deed dated April 28, 2006, recorded with
the Suffolk County Registry of Deeds at Book 39523, Page 221, as the same may be amended and in effect from time to time. The Office Unit is defined in the Master Deed of the Condominium. 

 

	 	D.	 “Premises” shall mean the area shown on Exhibit A to this Lease. The Premises are located on
the 6th floor of the Building. The “Rentable Square Footage of the Premises” is deemed to be 11,486 square feet on the 6th floor. If the Premises include one or more floors in their entirety, all corridors and restroom facilities
located on such full floor(s) shall be considered part of the Premises. Landlord and Tenant stipulate and agree that the Rentable Square Footage of the Building and the Rentable Square Footage of the Premises are correct and shall not be remeasured.

  

	 	E.	 “Base Rent”: 

 

													
	 Period
	  	Annual Rate
Per Square Foot	 	  	Annual
Base Rent	 	  	Monthly
Base Rent	 
	 Commencement Date to the day prior to Rent Commencement Date
	  	$	0	 	  	$	0	 	  	$	0	 
	 Lease Year 1
	  	$	49.75	 	  	$	571,428.50	 	  	$	47,619.04	 
	 Lease Year 2
	  	$	50.75	 	  	$	582,914.50	 	  	$	48,576.21	 
	 Lease Year 3
	  	$	51.75	 	  	$	594,400.50	 	  	$	49,533.38	 
	 Lease Year 4
	  	$	52.75	 	  	$	605,886.50	 	  	$	50,490.54	 
	 Lease Year 5
	  	$	53.75	 	  	$	617,372.50	 	  	$	51,447.71	 
	 Lease Year 6
	  	$	54.75	 	  	$	628,858.50	 	  	$	52,404.88	 
	 Lease Year 7
	  	$	55.75	 	  	$	640,344.50	 	  	$	53,362.04	 

  
 1 

	 	F.	 “Tenant’s Pro Rata Share”: Tenant’s Pro Rata Share shall mean the percentage derived by
dividing the rentable square feet in the Premises by the total rentable square feet of the Building; in the event that either the rentable square feet of the Premises or the rentable square feet of the Building changes,Tenant’s Pro Rata Share
will be appropriately adjusted and, as to the calendar year (or Fiscal Year, with respect to Taxes) in which such change occurs,Tenant’s Pro Rata Share shall be determined on the basis of the number of days during such calendar year or Fiscal
Year at each such percentage. As of the date hereof, Tenant’s Pro Rata Share shall be deemed to be 3.80% 

  

	 	G.	 “Base Year” for Taxes: Fiscal Year (defined below) 2017 (i.e., July 1, 2016 to June 30,
2017). 

	 	 	 “Base Year” for Expenses: calendar year 2017. 

 

	 	 	 For purposes hereof, “Fiscal Year” shall mean (with respect to the Base Year for Taxes) the period of
July 1, 2016 to June 30, 2017 and each period of July 1 to June 30 thereafter. 

  

	 	H.	 “Term”: The Term shall commence on the date that Landlord delivers possession of the Premises to
Tenant free of all occupants and tenants in accordance with Article 3 of this Lease (the “Commencement Date”) and, unless terminated early in accordance with this Lease, end seven (7) years following the Rent Commencement Date,
subject to extension as provided in this Lease (the” Termination Date”). The “Rent Commencement Date” shall be the earlier of (i)seven (7) months following the date on which Tenant has completed Tenant’sWork (described
in Exhibit C) and commences to occupy the Premises for its Permitted Use (the “Business Occupancy Date”) or (ii) June 1, 2017. If the Rent Commencement Date is not the first day of a calendar month, then the first
“Lease Year” (consisting of the first 12 calendar months following the Rent Commencement Date) and the Term shall be expanded to include the partial month following the Rent Commencement Date so that the first Lease Year shall expire at
the end of the 12th full calendar month following the month in which the Rent Commencement Date occurs. The second and succeeding “LeaseYear(s)” shall be periods of twelve (12) full
calendar months following the end of the first Lease Year. Promptly after the determination of the Business Occupancy Date, Landlord and Tenant shall enter into a commencement date letter agreement in the form of Exhibit C-1 attached hereto 

  

	 	I.	 Tenant allowances: An amount equal to $574,300.00, as further described in the attached Exhibit
C. 

  

	 	J.	 “Security Deposit”: $300,000.00 (which amount shall be reduced as set forth in Article 6) in the form
of a letter of credit in accordance with Article 6. 

  
 2 

	 	K.	 “Guarantor”: None 

 

	 	L.	 “Brokers”: Landmark Real Estate Advisors (Tenant’s broker) and Newmark Grubb Knight Frank
(Landlord’s broker) 

  

	 	M.	 “Permitted Use”: general office use, and uses incidental thereto consistent with general business
offices in first-class office buildings in downtown Boston, Massachusetts, and for no other purpose.. 

  

	 	N.	 “Notice Addresses”: 

Tenant: 
 On and after the
Business Occupancy Date, notices shall be sent to Tenant at the Premises with a copy in like manner to Hinckley, Allen & Snyder LLP, 28 State Street, Boston, Massachusetts 02109 (Attention: Thomas Bhisitkul, Esquire) (“Tenant’s
Attorney”). Prior to the Business Occupancy Date, notices shall be sent to Tenant at the following address: 
  

					
		 	Centrexion Therapeutics Corporation	  	 With a copy to:
  

Tenant’s Attorney

		 	509 South Exeter Street, Suite 202
		 	Baltimore, MD 21202
		 	Attention: Mr. Gregg Beloff

  

					
		 	Landlord:	  	With a copy to:
			
		 	GLL Real Estate Partners	  	Colliers International
		 	200 South Orange Avenue	  	200 State Street, Suite 105
		 	Suite 1375	  	Boston, Massachusetts 02109
		 	Orlando, Florida 32801	  	Attention: Building Manager
		 	Attention: Mr. Edward Rime	  	
			
		 		  	And
			
		 		  	Sherin and Lodgen LLP
		 		  	101 Federal Street
		 		  	Boston, Massachusetts 02110
		 		  	Attention: Edward M. Bloom, Esquire

 Rent (defined in Section 4.A) is payable as follows: 

 

					
	 	 	 By US Mail
	  	 By Overnight Courier

			
		 	Wells Fargo Lockbox	  	Wells Fargo Lockbox—E2001-049
		 	GLL 200 State Street, L.P.—Rent	  	Ref: GLL 200 State Street, L,P.-79677
		 	P.O. Box 79677	  	3440 Flair Drive
		 	City of Industry, CA 91716-9677	  	El Monte, CA 91731

  
 3 

					
	 	 	 	  	 By Wire

			
		 		  	Wells Fargo Bank
		 		  	420 Montgomery Street, 9th Floor
		 		  	San Francisco, CA 94104
		 		  	ABA #: 121-000-248
		 		  	Account Name: GLL 200 State Street LP.—Rent
		 		  	Account # 20000-42922526
		 		  	Contact: Michelle Broussard
		 		  	 415-243-7596

		 		  	

  

	 	O.	 “Business Day(s)” are Monday through Friday of each week, exclusive of New Year’s Day, Memorial
Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day (“Holidays”). Landlord may designate up to 3 additional Holidays, provided that the additional Holidays are commonly recognized by other office buildings in the area
where the Building is located. 

  

	 	P.	 [Intentionally Omitted] 

 

	 	Q.	 “Law(s)” means all applicable statutes, codes, ordinances, orders, rules and regulations of any
municipal or governmental entity. 

  

	 	R.	 “Normal Business Hours” for the Building are 8:00 A.M. to 6:00
P.M. on Business Days and 8:00 A.M. to 1:00 P.M. on Saturdays. 

  

	2.	 Lease Grant. 

Landlord leases the Premises to Tenant and Tenant leases the Premises from Landlord, together with the right in common with others to use any
portions of the Building that are designated by Landlord for the common use of tenants and others. The term “Building” as used in this Lease shall mean: (i) the Office Unit; (ii) the Building Common Areas (as hereinafter
defined); and (iii) at Landlord’s discretion, any additional real property, areas, land, buildings or other improvements added thereto. 

Tenant shall have the non-exclusive right to use in common with other tenants and occupants in the
Building, and subject to the Rules and Regulations referred to in Article 5 of this Lease, those portions of the Building which are provided, from time to time, for use in common by Landlord, Tenant and any other tenants or occupants of the Building
which shall include, notwithstanding anything to the contrary in this Lease, the Building lobby and entrances, passenger and freight elevators, common bathrooms, common parking areas, and all common hallways necessary for Tenant’s access to the
Building and the Premises (such areas, together with such other portions of the Building designated by Landlord, in its discretion, including certain areas designated for the exclusive use of certain tenants, or to be shared by Landlord and certain
tenants or occupants, referred to herein as the “Building Common Areas”). Tenant shall have the non-exclusive right to use in common with other tenants and occupants in the Condominium, and subject
to: (i) the Rules and Regulations referred to in Article 5 of this Lease; (ii) any other rules or regulations of the Condominium in effect from time to time; and (iii) the condominium documents of the Condominium, as the same may be
amended and in effect from time to time, including, without limitation, the Master Deed, the Declaration of Trust, the 

  
 4 

 
bylaws and any other document concerning the relationship between the unit owners of Condominium and the operation and maintenance of the Condominium (the “Condominium Documents”),
those portions of the Condominium which are provided, from time to time, for use in common by Landlord, Tenant and any other tenants or occupants of the Condominium (such areas, together with such other portions of the Condominium designated by
Landlord, in its discretion, including certain areas designated for the exclusive use of certain tenants, or to be shared by Landlord and certain tenants or occupants, referred to herein as the “Condominium Common Areas”). The
“Common Areas” as used in this Lease shall mean the Condominium Common Areas and the Building Common Areas. 
  

	3.	 Possession. 

  

	 	A.	 Subject to Landlord’s obligations under Section 9.B., and subject to satisfaction of all Delivery
Conditions (as hereinafter defined) the Premises will be delivered by Landlord in “as is” condition. 

  

	 	B.	 If Tenant takes possession of the Premises before the Commencement Date, such possession shall be subject to
the terms and conditions of this Lease. However, except for the cost of services requested by Tenant (e.g. freight elevator usage after Normal Business Hours, electricity and fire alarm/smoke detector disconnects), Tenant shall not be required to
pay Rent for any days of possession before the Rent Commencement Date during which Tenant is in possession of the Premises whether for the purpose of performing improvements or installing furniture, equipment or other personal property or, after the
Business Occupancy Date, occupying the Premises for its Permitted Use. 

  

	 	C.	 “Delivery Conditions” shall mean and include the following terms and conditions: (i) the Premises are
vacant, broom clean, with all personal property of any prior tenant (other than the Retained FF&E, as defined in Exhibit F) and otherwise in condition such that Tenant can immediately occupy the Premises and perform
Tenant’s Work; (ii) all Building systems, utilities and facilities serving the Premises, including, without limitation, heating, ventilation and air conditioning, electricity, water, plumbing and sewerage systems shall be in good working
order, condition and repair and adequate in all respects for Tenant’s use; and (iii) all means of access to the Premises, including, without limitation, the Building elevators and other facilities reasonably necessary for Tenant to undertake
the Tenant Work, shall be free of obstruction, intact and in good working order. 

  

	4.	 Rent. 

  

	 	A.	 Payments. As consideration for this Lease, Tenant shall pay Landlord, without any setoff or deduction
except to the extent otherwise provided in this Lease, the total amount of Base Rent and Additional Rent due for the Term. “Additional Rent” means all sums (exclusive of Base Rent) that Tenant is required to pay Landlord pursuant to the
terms of this Lease. Additional Rent and Base Rent are sometimes collectively referred to as “Rent”. Tenant shall pay and be liable for all rental, sales and use taxes (but excluding income taxes), if any, imposed upon or measured by Rent
under applicable Law. Monthly installments of Base Rent and recurring monthly charges of Additional Rent shall be due and payable in advance on the first day of each calendar month without notice or demand. All

  
 5 

	 	
other items of Rent shall be due and payable by Tenant on or before 30 days after billing by Landlord. All payments of Rent shall be by good and sufficient check or by other means (such as
automatic debit or electronic transfer) acceptable to Landlord. If Tenant fails to pay any item or installment of Rent when due, Tenant shall pay Landlord an administration fee equal to 5% of the past due Rent, provided that Tenant shall be entitled
to a grace period of 5 Business Days for the first 2 late payments of Rent in a given calendar year. If the Term terminates on a day other than the last day of a calendar month, the monthly Base Rent and Tenant’s Pro Rata Share of any Tax
Excess (defined in Section 4.B.) or Expense Excess (defined in Section 4.B.) for the month shall be prorated based on the number of days in such calendar month. Landlord’s acceptance of less than the correct amount of Rent shall be
considered a payment on account of the earliest Rent due. No endorsement or statement on a check or letter accompanying a check or payment shall be considered an accord and satisfaction, and either party may accept the check or payment without
prejudice to that party’s right to recover the balance or pursue other available remedies. Tenant’s covenant to pay Rent is independent of every other covenant in this Lease. 

 

	 	B.	 Expense Excess and Tax Excess. Tenant shall pay Tenant’s Pro Rata Share of the amount, if any, by
which Expenses (defined in Section 4.C.) for each calendar year during the Term (commencing with calendar year 2018) exceed Expenses for the Base Year (the “Expense Excess”) and also the amount, if any, by which Taxes (defined in
Section 4.D.) for each Fiscal Year during the Term (commencing with Fiscal Year 2018) exceed Taxes for the Base Year (the “Tax Excess”). If Expenses and/or Taxes in any calendar year or Fiscal Year decrease below the amount of
Expenses and/or Taxes for the Base Year, Tenant’s Pro Rata Share of Expenses and/or Taxes, as the case may be, for that calendar year or Fiscal Year shall be $0. Landlord shall provide Tenant with a good faith estimate of the Expense Excess and
of the Tax Excess for each calendar year or Fiscal Year during the Term. On or before the first day of each month following the conclusion of the applicable Base Year, Tenant shall pay to Landlord a monthly installment equal to one-twelfth of Tenant’s Pro Rata Share of Landlord’s estimate of the Expense Excess and one-twelfth of Tenant’s Pro Rata Share of Landlord’s estimate of
the Tax Excess. If Landlord determines that its good faith estimate of the Expense Excess or of the Tax Excess was incorrect by a material amount, Landlord may provide (but not more than once in any calendar year) Tenant with a revised estimate, as
the case may be. After its receipt of the revised estimate, Tenant’s monthly payments shall be based upon the revised estimate. If Landlord does not provide Tenant with an estimate of the Expense Excess by January 1 of a calendar year, or
the Tax Excess by the start of each new Fiscal Year, Tenant shall continue to pay monthly installments based on the previous calendar year’s or Fiscal Year’s estimate(s), as the case may be, until Landlord provides Tenant with the new
estimate. Upon delivery of the new estimate, an adjustment shall be made for any month for which Tenant paid monthly installments based on the previous calendar or Fiscal Year’s estimate(s). Tenant shall pay Landlord the amount of any
underpayment within 30 days after receipt of the new estimate. Any overpayment shall be refunded to Tenant within 30 days or, at Tenant’s election, credited against the next due future installment(s) of Additional Rent. 

  
 6 

	 	As soon as is practical following the end of each calendar year or Fiscal Year, as the case may be, but in no event more than 120 days thereafter, Landlord shall furnish Tenant with a statement of the actual Expenses
and Expense Excess and the actual Taxes and Tax Excess for the prior calendar year or Fiscal Year, as the case may be. The failure of Landlord to timely furnish any statement shall not prejudice Landlord from enforcing its rights under this
Section 4. Any statement of actual Expenses will be furnished in reasonable detail, prepared on an accrual basis of accounting consistently applied from year to year. If the estimated Expense Excess and/or estimated Tax Excess for the prior
calendar year or Fiscal Year, as the case may be, is more than the actual Expense Excess and/or actual Tax Excess for the prior calendar year or Fiscal Year, as the case may be, Landlord shall apply any overpayment by Tenant against Additional Rent
due or next becoming due, provided if the Lease terminates before the determination of the overpayment, Landlord shall refund any overpayment to Tenant after first deducting the amount of Rent due within 30 days of its delivery of the statement of
Expenses and/or Taxes. If the estimated Expense Excess and/or estimated Tax Excess for the prior calendar year or Fiscal Year, as the case may be, is less than the actual Expense Excess and/or actual Tax Excess for such prior calendar year or Fiscal
Year, as the case may be, Tenant shall pay Landlord, within 30 days after its receipt of the statement of Expenses and/or Taxes, any underpayment for the prior calendar year. 

 

	 	C.	 Expenses Defined. “Expenses” means all reasonable and customary costs and expenses incurred in
each calendar year in connection with operating, maintaining, repairing, and managing the Building, which shall be calculated in a commercially reasonable manner consistently applied from year to year, including, but not limited to:

  

	 	1.	 Labor costs, including, wages, salaries, social security and employment taxes, medical and other types of
insurance, uniforms, training, and retirement and pension plans, but excluding such labor costs for personnel above the grade of building manager and other supervisors. 

 

	 	2.	 Management fees paid to a third party manager (provided the same are comparable to management fees generally
charged for first class office buildings in Boston), the cost of equipping and maintaining a management office (including the fair rental value of said management office), accounting and bookkeeping services, legal fees not attributable to leasing
or collection activity, and other administrative costs. Landlord, by itself or through an affiliate, shall have the right to directly perform or provide any services under this Lease (including management services if a third party has not been hired
or paid to provide management services), provided that the cost of any such services shall not exceed the cost that would have been incurred had Landlord entered into an arms-length contract for such services with an unaffiliated entity of
comparable skill and experience. 

  

	 	3.	 The cost of services, including amounts paid to service providers and the rental and purchase cost of parts,
supplies, tools and equipment. 

  
 7 

	 	4.	 Premiums and deductibles paid by Landlord for insurance, including workers compensation, fire and extended
coverage, earthquake, general liability, rental loss, elevator, boiler and other insurance customarily carried from time to time by owners of comparable office buildings. 

 

	 	5.	 The costs to operate, repair and maintain and replace all systems and equipment and components of the Building,
including the structural portions of the Building, the roof and roof coverings of the Building, the exterior walls and windows and the mechanical, gas, steam, electrical, sanitary, HVAC, elevator, plumbing and life-safety systems of the Building and
the costs incurred in connection with the parking garage servicing the Building, provided that none of the foregoing costs are capital expenses or costs for capital improvements, repairs, or replacements under generally accepted accounting
principles. 

  

	 	6.	 Electrical Costs (defined below) and charges for water, gas, steam and sewer, but excluding those charges for
which Landlord is reimbursed by tenants. “Electrical Costs” means: (a) charges paid by Landlord for electricity provided to the Building Common Areas; and (b) costs incurred in connection with an energy management program for the
Building. Electrical Costs shall be adjusted as follows: (i) amounts received by Landlord as reimbursement for above standard electrical consumption shall be deducted from Electrical Costs; (ii) the cost of electricity incurred to provide
overtime HVAC to specific tenants (as reasonably estimated by Landlord) shall be deducted from Electrical Costs; and (iii) the cost of electricity to individual tenant spaces in the Building shall be deducted from Electrical Costs.

  

	 	7.	 The amortized cost of capital improvements (as distinguished from replacement parts or components installed in
the ordinary course of business that are not in themselves capital improvements, repairs or replacements under generally accepted accounting principles) made to the Building which are: (a) performed primarily to reduce operating expense costs
of the Building; or (b) required to comply with any Laws that are enacted, or first interpreted to apply to the Building, after the date of this Lease. The cost of any such capital improvements shall be amortized by Landlord over the
improvement’s useful life, as reasonably determined by Landlord in accordance with generally accepted accounting principles consistently applied. The amortized cost of capital improvements may, at Landlord’s option, include actual or
imputed interest at the rate that Landlord would reasonably be required to pay to finance the cost of the capital improvement. 

  

	 	8.	 Payments, fees or charges assessed to the owner of the Office Unit under the Condominium Documents (including,
without limitation, any Condominium Charges, as hereinafter defined) and/or under any easement, license, operating agreement, declaration, restrictive covenant or any instrument pertaining to the sharing of costs by the Office Unit. Whereas the
Office Unit is part of the Condominium, Condominium 

  
 8 

	 	
Charges include, without limitation, the Office Unit’s proportionate share of the following costs: all charges and rates connected with water supplied to the Building and related sewer use
charges; all charges connected with security and HVAC supplied to the Building, the cost of labor and material for cleaning the grounds and paved areas of the Building, fire, casualty, liability, and such other insurance as may be required under any
mortgage on the Condominium or any ground lease to which the Condominium is subject. Notwithstanding the foregoing, Condominium Charges shall not include: (i) costs, assessments or charges for capital improvements, repairs or replacements; or
(ii) any costs or expenses that are separately included in Expenses or Taxes. 

 If Landlord incurs Expenses for the
Building together with one or more other buildings or properties, or one or more other units of the Condominium, whether pursuant to a reciprocal easement agreement, the Condominium Documents, common area agreement or otherwise, the shared costs and
expenses shall be equitably prorated and apportioned between the Building and the other buildings, units or properties. Notwithstanding anything to the contrary in this Lease, Expenses shall not include: (i) costs, including permit, license and
inspection costs, incurred with respect to the installation of tenants’ or other occupants’ improvements in the Building or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space in the Building;
(ii) the cost of capital improvements, including, without limitation, capital repairs or replacements (except as set forth in clause 7 above); (iii) depreciation, interest or amortizations (except as provided above for the amortization of
capital improvements), or ground lease rents or charges; (iv) principal and interest payments, points or fees of mortgage and other debts encumbering the Building or the property of which the Building is part; (v) the cost of repairs or
other work, or any other cost or expenditure, to the extent Landlord is reimbursed by insurance or condemnation proceeds or by any third party; (vi) costs in connection with marketing and leasing space in the Building, including without
limitation, brokerage commissions, space planning costs, legal fees relating to the review or negotiation of leases and related agreements or relating to tenant disputes, construction costs, advertising and promotional expenses, lease concessions,
including rental abatements and construction allowances, granted to specific tenants; (vii) costs incurred in connection with the sale, financing or refinancing of the Building; (viii) fines, interest and penalties incurred due to the late
payment of Taxes (defined in Section 4.D) or Expenses, and any penalties or damages that Landlord pays to Tenant under this Lease or to other tenants in the Building under their respective leases; (ix) organizational expenses associated
with the creation and operation of the entity which constitutes Landlord; (x) costs of services or other benefits which are not provided to Tenant or for which Tenant is charged for directly but which are provided to another tenant or occupant
of the Building; (xi) overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third
parties on a competitive basis; (xii) costs arising from the presence of hazardous materials or substances or asbestos in or about the Premises, the Building or the Condominium; and (xiii) any Expenses not billed to Tenant within 18 months
after the expiration of the calendar year in which such Expenses were incurred. 

  
 9 

 If the Building is not at least 95% leased during any calendar year, those Expenses that are
Variable Expenses (defined below), shall, at Landlord’s option, be determined as if the Building had been 95% leased during that calendar year. If Tenant pays for its Pro Rata Share of Expenses based on increases over a “Base Year”
and Expenses for a calendar year are determined as provided in the prior sentence, Variable Expenses for the Base Year shall also be determined as if the Building had been 95% leased during the Base Year. The extrapolation of Expenses under this
Section shall be performed by appropriately adjusting the cost of those components of Expenses that vary materially based on changes in the occupancy of the Building including, without limitation, expenses for electricity, water, sewage and
janitorial services (collectively, “Variable Expenses”); the foregoing extrapolation of Variable Expenses is intended to enable Landlord (where the Building is less than 95% leased) to distribute a portion of the Variable Expenses
otherwise attributable to the vacant space to the remaining tenants in the Building; however, in no event shall the extrapolation of Variable Expenses herein result in the Landlord recovering more than the Variable Expenses actually incurred by
Landlord. If any amounts comprising Expenses are incurred not just with respect to the office area of the Building, but also with respect to the retail area of the Building, then Landlord shall reasonably allocate such amounts between the office and
retail areas and such allocation shall be made on a fair and equitable basis, based on the usage of and benefits received from the Expense amounts involved. 
  

	 	D.	 Taxes Defined. “Taxes” shall mean: (1) all real estate taxes and other assessments on the
Building including, but not limited to, assessments for special improvement districts and building improvement districts, taxes and assessments levied in substitution or supplementation in whole or in part of any such taxes and assessments and the
Building’s share of any real estate taxes and assessments under any reciprocal easement agreement, common area agreement or similar agreement as to the Building; (2) all personal property taxes for property that is owned by Landlord and
used in connection with the operation, maintenance and repair of the Building; and (3) all reasonable costs and fees incurred in connection with seeking reductions in any tax liabilities described in (1) and (2), including, without
limitation, any costs incurred by Landlord for compliance, review and appeal of tax liabilities. Without limitation, Taxes shall not include any income, capital levy, franchise, capital stock, gift, estate or inheritance tax. If a betterment
assessment is payable in installments, Taxes for the year shall include the amount of the installment and any interest due and payable during that year. For all other real estate taxes, Taxes for that year shall, at Landlord’s election, include
either the amount accrued, assessed or otherwise imposed for the year or the amount due and payable for that year, provided that Landlord’s election shall be applied consistently throughout the Term. If a change in Taxes is obtained for any
year of the Term during which Tenant paid Tenant’s Pro Rata Share of any Tax Excess, then Taxes for that year will be retroactively adjusted and Landlord shall provide Tenant with a credit, if any, based on the adjustment. Likewise, if a change
is obtained for Taxes for the Base Year, Taxes for the Base Year shall be restated and the Tax Excess for all subsequent years shall be recomputed. Tenant shall pay Landlord the amount of Tenant’s Pro Rata Share of any such increase in the Tax
Excess within 30 days after Tenant’s receipt of a statement from Landlord. 

  
 10 

	 	E.	 Audit Rights. Tenant may, within 90 days after receiving Landlord’s statement of Expenses, give
Landlord written notice (“Review Notice”) that Tenant intends to review Landlord’s records of the Expenses for that calendar year. Within a reasonable time after receipt of the Review Notice, Landlord shall make all pertinent records
available for inspection that are reasonably necessary for Tenant to conduct its review. If any records are maintained at a location other than the office of the Building, Tenant may either inspect the records at such other location or pay for the
reasonable cost of copying and shipping the records. If Tenant retains an agent to review Landlord’s records, the agent must be with a licensed CPA firm, or other reasonably qualified third party with expertise in and familiarity with general
industry practice with respect to the operation of and accounting for a first class office building, provided said third party’s compensation shall in no way be contingent upon or correspond to the financial savings to Tenant resulting from
such review. Tenant shall be solely responsible for all costs, expenses and fees incurred for the audit, provided, however, that if said audit determines that Expenses for the Building for the year in question were overstated by 5% or more, then
Landlord shall reimburse Tenant, within 30 days after receipt of paid invoices from Tenant, for reasonable amounts paid by Tenant to its auditing agent for such audit. Within 60 days after the records are made available to Tenant, Tenant shall have
the right to give Landlord written notice (an “Objection Notice”) stating in reasonable detail any objection to Landlord’s statement of Expenses for that year. If Tenant fails to give Landlord an Objection Notice within the 60 day
period or fails to provide Landlord with a Review Notice within the 90 day period described above, Tenant shall be deemed to have approved Landlord’s statement of Expenses and shall be barred from raising any claims regarding the Expenses for
that year. Tenant, however, shall always have the right to audit and examine the Expenses for the Base Year. If Tenant provides Landlord with a timely Objection Notice, Landlord and Tenant shall work together in good faith to resolve any issues
raised in Tenant’s Objection Notice. If Landlord and Tenant determine that Expenses for the calendar year are less than reported, Landlord shall provide Tenant with a credit against the next installment of Rent in the amount of the overpayment
by Tenant, provided that if the Term expires before such determination, Landlord shall promptly refund any overpayment to Tenant. Likewise, if Landlord and Tenant determine that Expenses for the calendar year are greater than reported, Tenant shall
pay Landlord the amount of any underpayment within 30 days. The records obtained by Tenant shall be treated as confidential and, as a condition to Tenant’s audit rights, Tenant and its examiners shall be required to execute and deliver to
Landlord a confidentiality agreement in form reasonably acceptable to Landlord and Tenant. In no event shall Tenant be permitted to examine Landlord’s records or to dispute any statement of Expenses unless Tenant has paid and continues to pay
all Rent when due. 

  
 11 

	5.	 Compliance with Laws; Use. 

The Premises shall be used only for the Permitted Use and for no other use whatsoever. Tenant shall not use or permit the use of the Premises
for any purpose which is illegal, dangerous to persons or property or which, in Landlord’s reasonable opinion, unreasonably disturbs any other tenants of the Building or interferes with the operation of the Building. Tenant shall comply with
all Laws, including the Americans with Disabilities Act, regarding the operation of Tenant’s business and the use, condition, configuration and occupancy of the Premises. Notwithstanding the foregoing, Tenant shall not be obligated to make any
structural alterations or capital improvements to the Premises to comply with any Laws unless such compliance is required as the result of the specific nature of Tenant’s business in the Premises (other than general office use) or is the result
of the acts or omissions of Tenant or its agents, employees or contractors or any design or configuration of the Premises specifically installed by Tenant. Tenant, within 10 days after receipt, shall provide Landlord with copies of any notices it
receives regarding a violation or alleged violation of any Laws. Tenant shall reimburse and compensate Landlord for all expenditures made by, or damages or fines sustained or incurred by, Landlord due to any violations of Laws by Tenant or any
Tenant Related Parties (as defined in Section 14.B hereof) with respect to the Premises. Tenant shall comply with the rules and regulations of the Building attached as Exhibit B and such other reasonable rules and regulations adopted by
Landlord from time to time. Tenant shall also cause its agents, contractors, subcontractors, employees and subtenants to comply with all rules and regulations. Landlord shall not knowingly discriminate against Tenant in Landlord’s enforcement
of the rules and regulations. 
  

	6.	 Security Deposit. 

The Security Deposit, in the form of an unconditional irrevocable standby commercial letter of credit (the “Letter of Credit”) in the
amount of $300,000.00 (the “Letter of Credit Amount”) shall be delivered to Landlord upon the execution of this Lease by Tenant and shall be held by Landlord without liability for interest (unless required by Law) as security for the
performance of Tenant’s obligations. The Security Deposit is not an advance payment of Rent or a measure of Tenant’s liability for damages. Landlord may, from time to time, after any applicable notice and grace periods have expired, and
without prejudice to any other remedy, use all or a portion of the Security Deposit to satisfy past due Rent or to cure any uncured Event of Default by Tenant. The Letter of Credit shall terminate and Landlord shall return the Letter of Credit
within 45 days after the earlier to occur of: (1) the Termination Date and Tenant’s surrender of possession of the Premises to Landlord in accordance with this Lease; or (2) the earlier termination of this Lease and Tenant’s
surrender of possession of the Premises to Landlord in accordance with this Lease. If the Letter of Credit is returned pursuant to this Article 6 prior to the determination of Tenant’s Pro Rata Share of any Tax Excess and Expense Excess for the
final year of the Term, then Tenant shall deliver to the Landlord a cash deposit, to be held in a segregated, non-interest-bearing account as security for the performance of Tenant’s obligations, in the
amount of 50% of Tenant’s Pro Rata Share of any Tax Excess and Expense Excess that Landlord reasonably estimates remains unpaid by Tenant on the Termination Date for (i) any prior calendar or fiscal year for which final adjustments have
not been made and (ii) the period commencing on the first day of the then calendar or fiscal year, as applicable, and ending on the Termination Date. Such cash deposit, without interest, shall be returned to Tenant within 45 days after the
determination of Tenant’s Pro Rata Share of any Tax Excess and Expense Excess for the periods set forth in (i) and (ii) in the foregoing sentence, and payment is made by Tenant for any unpaid amount. If Landlord transfers its interest in
the Premises, Landlord may assign the Security Deposit to the transferee and, following the assignment, Landlord shall have no further liability for the return of the Security Deposit. 

  
 12 

 The Letter of Credit shall be issued by a reputable domestic commercial bank or other
domestic financial institution (i) which accepts deposits, maintains accounts and whose deposits are insured by the FDIC (ii) whose long term debt is rated at least A or the equivalent thereof by Standard & Poors Ratings Group or
A or the equivalent thereof by Moody’s Investors Services, Inc. and (iii) whose capital and surplus is in excess of $500,000,000.00 (the “Bank”). The Letter of Credit shall be in a form and content as set forth in Exhibit D
or any form substantially similar thereto. Tenant shall pay all expenses, points and/or fees incurred by Tenant in obtaining the Letter of Credit. The Letter of Credit shall be maintained in effect throughout the Term. 

If, as a result of any drawing by Landlord on the Letter or Credit, the amount of the Letter of Credit shall be less than the Letter of Credit
Amount, Tenant shall, within 10 Business Days after receipt of notice from Landlord, provide Landlord with additional letter(s) of credit in an amount equal to the deficiency, and any such additional letter(s) of credit shall comply with all of the
provisions of this Article. Without limiting the generality of the foregoing, if the Letter of Credit expires earlier than the expiration of the Term, Landlord will accept a renewal thereof (such renewal letter of credit to be in effect and
delivered to Landlord, as applicable, not later than 30 days prior to the expiration of the Letter of Credit), which shall be upon the same terms as the expiring Letter of Credit or such other terms as may be reasonably acceptable to Landlord. 

Notwithstanding the foregoing, if (a) there has been no Event of Default by Tenant during the preceding twelve (12) months and
(b) Landlord has not had to draw on the Letter of Credit at all to satisfy past due Rent or to cure any uncured Event of Default by Tenant, then the Letter of Credit may be reduced to $100,000.00 as of the first day of the Fourth Lease Year.
The foregoing reductions may be implemented either by replacing the original Letter of Credit with a new Letter of Credit in each instance or by amendments to the original Letter of Credit in such form and substance as are acceptable to Landlord.

 It is specifically agreed and understood that if at any time during the Term of this Lease Landlord shall consider the Bank issuing the
Letter of Credit to be in an unsatisfactory financial condition because it does not meet the financial criteria set forth above, or in the event the Bank shall be the subject of an insolvency proceeding or be placed under management of a controller,
Tenant shall, upon Landlord’s demand, replace said Letter of Credit within ten (10) Business Days with a substitute Letter of Credit from a bank or financial institution then approved by Landlord or, at Landlord’s election, replace
said Letter of Credit with a cash security deposit in the amount of the Letter of Credit, in which event, Landlord may draw down on said cash security deposit for the same purposes and to the same extent as it could have drawn down the Letter of
Credit upon any Event of Default by Tenant. Tenant’s failure to so replace the Letter of Credit within ten (10) Business Days of Landlord’s demand shall be an Event of Default under this Lease. 

  
 13 

	7.	 Services to be Furnished by Landlord. 

 

	 	A.	 Landlord agrees to furnish Tenant with the following services: (1) Water service for use in the lavatories
on each floor on which the Premises are located and for use in any kitchenette area approved by Landlord (but Tenant shall be responsible for providing hot water service to any such kitchenette area); (2) Heat and air conditioning (HVAC) in season
during Normal Business Hours, at such temperatures and in such amounts as are standard for comparable Class A buildings in downtown Boston or at such higher standards as required by governmental authority; (3) Maintenance and repair of the
Building as described in Section 9.B.; (4) Janitor service on Business Days in accordance with the cleaning specifications attached hereto as Exhibit E, or such other reasonably comparable specifications designated by Landlord from time
to time. If Tenant’s use, floor covering or other improvements require special services in excess of the standard services for the Building, Tenant shall pay the additional cost attributable to the special services; (5) Elevator service;
(6) Electricity to the Premises for general office use, in accordance with and subject to the terms and conditions in Article 10; (7) access to the Building and the Premises (by elevator) for Tenant and its employees 24 hours per day, 7 days
per week every day of the year; subject to the terms of the Lease; (8) Security for the Building, including the stationing of security guards in the Building lobby 24 hours per day, 7 days a week; and (9) such other services as Landlord
reasonably determines are necessary or appropriate for the Building and that are typical with first class office buildings. Tenant, upon such advance notice as is reasonably required by Landlord (which in no event shall be greater than 24 hour
advance notice), shall have the right to receive HVAC service during hours other than Normal Business Hours. Landlord represents that the current charge for after-hours HVAC is $75.00 per hour per floor. Landlord agrees that any increases in such
after-hours HVAC service charge shall be limited to increases in Landlord’s actual, reasonable costs of supplying the after-hours HVAC services. Tenant shall pay Landlord the standard charge for the additional service as reasonably determined
by Landlord from time to time. 

  

	 	B.	 Landlord’s failure to furnish, or any interruption or termination of, services due to governmental action,
the failure of any equipment, or the occurrence of any event or cause beyond the reasonable control of Landlord (a “Service Failure”) shall not render Landlord liable to Tenant, constitute a constructive eviction of Tenant, give rise to an
abatement of Rent, nor relieve Tenant from the obligation to fulfill any covenant or agreement and Landlord shall use commercially reasonable efforts to correct such Service Failure. However, if the Premises, or a material portion of the Premises,
is made untenantable for a period in excess of 4 consecutive Business Days as a result of the Service Failure, then Tenant, as its sole remedy, shall be entitled to receive an abatement of Rent payable hereunder during the period beginning on the
5th consecutive Business Day of the Service Failure and ending on the day the service has been restored. If the entire Premises has not been rendered untenantable by the Service Failure, the amount of abatement that Tenant is entitled to receive
shall be prorated based upon the percentage of the Premises rendered untenantable and not used by Tenant. In no event, however, shall Landlord be liable to Tenant for any loss or damage, including the theft of Tenant’s Property (defined in
Article 15), arising out of or in connection with the failure of any security services, personnel or equipment. 

  
 14 

	8.	 Leasehold Improvements. 

All improvements to the Premises (collectively, “Leasehold Improvements”) shall be owned by Landlord and shall remain upon the
Premises without compensation to Tenant. Notwithstanding the foregoing, all Tenant’s Property (as defined in Article 15) shall remain the property of Tenant and shall not remain upon the Premises. It is understood and agreed that any
Tenant’s Property which is minimally attached to the walls or floor of the Premises may be removed by Tenant, provided Tenant repairs any damage caused by such removal. However, Landlord, by written notice to Tenant not later than 30 days prior
to the Termination Date, may require Tenant to remove, at Tenant’s expense: (1) Cable (defined in Section 9.A) installed by or for the exclusive benefit of Tenant and located in the Premises or other portions of the Building; and
(2) any Leasehold Improvements that are performed by or for the benefit of Tenant and, in Landlord’s reasonable judgment, are of a nature that would require removal and repair costs that are materially in excess of the removal and repair
costs associated with standard office improvements (collectively referred to as “Required Removables”). Without limitation, it is agreed that Required Removables include internal stairways, raised floors, personal baths and showers,
vaults, rolling file systems and structural alterations and modifications of any type. The Required Removables designated by Landlord shall be removed by Tenant before the Termination Date, provided that upon prior written notice to Landlord, Tenant
may remain in the Premises for up to 5 days after the Termination Date for the sole purpose of removing the Required Removables. Tenant’s possession of the Premises shall be subject to all of the terms and conditions of this Lease, including
the obligation to pay Rent on a per diem basis at the rate in effect for the last month of the Term. Tenant shall repair damage caused by the installation or removal of Required Removables. If Tenant fails to remove any Required Removables or
perform related repairs in a timely manner, Landlord, at Tenant’s expense, may remove and dispose of the Required Removables and perform the required repairs. Tenant, within 30 days after receipt of an invoice, shall reimburse Landlord for the
reasonable costs incurred by Landlord. Notwithstanding the foregoing, Tenant, at the time it requests approval for a proposed Alteration (defined in Section 9.C), may request in writing that Landlord advise Tenant whether the Alteration or any
portion of the Alteration will be designated as a Required Removable. Within 10 days after receipt of Tenant’s request, Landlord shall advise Tenant in writing as to which portions of the Alterations, if any, will be considered to be a Required
Removable. Any Required Removable identified by Landlord at the time Tenant requests approval for a proposed Alteration must be removed by Tenant whether or not Landlord provides the written notice (to be sent not later than 30 days prior to the
Termination Date) to Tenant as set forth above, and all other Alterations not so designated by Landlord as a Required Removable need not be removed by Tenant. 
  

	9.	 Repairs and Alterations. 

 

	 	A.	 Tenant’s Repair Obligations. Tenant shall, at its sole cost and expense, promptly perform all
maintenance and repairs to the Premises that are not Landlord’s express responsibility under this Lease, and shall keep the Premises in good order, condition and repair, damage due to fire, casualty, taking and reasonable wear and tear
excepted. For purposes of this Lease, the term “reasonable wear and tear” constitutes that normal, gradual deterioration which occurs due to aging and ordinary use of the Premises despite reasonable and timely maintenance and repair, but
in no event shall “reasonable wear and tear” excuse Tenant from its duty to keep the Premises in good maintenance and repair or otherwise usable, serviceable and tenantable. Tenant’s repair

  
 15 

	 	
obligations include, without limitation, repairs to: (1) floor covering; (2) interior partitions; (3) doors; (4) the interior side of demising walls; (5) electronic, phone,
telecommunications and data cabling and related equipment (collectively, “Cable”) that is installed by or for the exclusive benefit of Tenant and located in the Premises or other portions of the Building (and Tenant’s contractor shall
have access to the Building electrical and telephone closets for connection and maintenance without any charge from Landlord); (6) supplemental air conditioning units, private showers and kitchens, including hot water heaters, plumbing, and similar
facilities serving Tenant exclusively; and (7) Alterations performed by contractors retained by Tenant, including related HVAC balancing. All work shall be performed in accordance with the rules and procedures described in Section 9.C.
below. If Tenant fails to make any repairs to the Premises for more than 15 days after notice from Landlord (although notice shall not be required if there is an emergency involving risk of imminent injury to persons or imminent and significant
property damage), Landlord may make the repairs, and Tenant shall pay the reasonable cost of the repairs to Landlord within 30 days after receipt of an invoice, together with an administrative charge in an amount equal to 10% of the cost of the
repairs. Notwithstanding the foregoing, if the repair required of Tenant cannot be completed within 15 days after Landlord’s notice to Tenant, Landlord shall not exercise its right to make such repair on Tenant’s behalf so long as Tenant
has commenced such repair within said 15 day period and is diligently pursuing the same to completion. 

  

	 	B.	 Landlord’s Repair Obligations. Landlord shall, consistent with the standards of a first class
office building, keep and maintain in good repair and working order and make repairs to and perform maintenance upon: (1) structural elements of the Building; (2) mechanical (including HVAC), electrical, plumbing and fire/life safety
systems serving the Building in general; (3) Common Areas; (4) the roof of the Building; (5) exterior windows of the Building; and (6) elevators serving the Building. Landlord shall promptly make repairs (considering the nature
and urgency of the repair) for which Landlord is responsible. Landlord shall use commercially reasonable efforts to minimize any disruption to Tenant’s business in performing its repair obligations. 

 

	 	C.	 Alterations. Tenant shall not make alterations, additions or improvements to the Premises or install any
Cable in the Premises or other portions of the Building (collectively referred to as “Alterations”) without first obtaining the written consent of Landlord in each instance, which consent shall not be unreasonably withheld or delayed.
However, Landlord’s consent shall not be required for any Alteration that satisfies all of the following criteria (a “Cosmetic Alteration”): (1) it is of a cosmetic nature such as painting, wallpapering, hanging pictures and
installing carpeting; (2) it is not visible from the exterior of the Premises or Building; (3) it will not affect the systems or structure of the Building; and (4) it does not require work to be performed inside the walls or above the
ceiling of the Premises (other than Cable). However, even though consent is not required, the performance of Cosmetic Alterations shall be subject to all the other provisions of this Section 9.C unless otherwise provided. Prior to starting work
(other than for Cosmetic Alterations), Tenant shall furnish Landlord with plans and specifications (if and to the extent necessary for the issuance of building permits) reasonably acceptable to Landlord; names of contractors reasonably acceptable to
Landlord (provided 

  
 16 

	 	
that Landlord may designate specific contractors with respect to Building systems); copies of contracts; necessary permits and approvals; and evidence of contractor’s and
subcontractor’s insurance in amounts reasonably required by Landlord. Material changes to the plans and specifications must also be submitted to Landlord for its approval. Landlord agrees to respond to Tenant with respect to plans and
specifications and to material changes thereof within fifteen (15) Business Days (except with respect to plans and specifications, and material changes thereto, for the initial Tenant’s Work under Exhibit C, to which Landlord hereby
agrees to respond within fifteen (15) calendar days). Alterations shall be constructed in a good and workmanlike manner using materials of a quality that is at least equal to the quality designated by Landlord as the minimum standard for the
Building. Landlord may designate reasonable rules, regulations and procedures for the performance of work in the Building and, to the extent reasonably necessary to avoid unreasonable disruption to the occupants of the Building, shall have the right
to reasonably designate the time when Alterations may be performed. Tenant shall reimburse Landlord within 30 days after receipt of an invoice for sums paid by Landlord for third party examination of Tenant’s plans for Non-Cosmetic Alterations. In addition, within 30 days after receipt of an invoice from Landlord, Tenant shall pay Landlord a fee for Landlord’s oversight and coordination of any
Non-Cosmetic Alterations equal to 2% of the cost of the Non-Cosmetic Alterations. Upon completion of Non-Cosmetic Alterations
that involve the relocation or construction of walls, Tenant shall furnish Landlord “as-built” plans, completion affidavits, full and final waivers of lien and receipted bills covering all labor and
materials. Tenant shall assure that the Alterations comply with all insurance requirements and Laws. Landlord’s approval of an Alteration shall not be a representation by Landlord that the Alteration complies with applicable Laws or will be
adequate for Tenant’s use. In addition, Landlord’s consent and approval in connection with an Alteration is given solely for the benefit of Landlord and neither Tenant nor any third party shall have the right to rely upon such approval for
any purpose whatsoever. Without limiting the foregoing, in no event shall such consent or approval be deemed to be the consent of the Landlord within the meaning of Section 2 of Chapter 254 of the General Laws of Massachusetts.

  

	10.	 Use of Electrical Services by Tenant. 

 

	 	A.	 Electricity used by Tenant in the Premises shall be paid for by Tenant by separate charge billed by the
applicable utility company and payable directly by Tenant. Electrical service to the Premises (and separately for both suites constituting the Premises) shall be separately metered at Landlord’s expense and may be furnished by one or more
companies providing electrical generation, transmission and distribution services, and the cost of electricity may consist of several different components or separate charges for such services, such as generation, distribution and stranded cost
charges. 

  

	 	B.	 Tenant’s use of electrical service shall not exceed, either in voltage, rated capacity or overall load,
that which Landlord deems to be standard for the Building. If Tenant requests permission to consume excess electrical service, Landlord may refuse to consent or may condition consent upon conditions that Landlord reasonably elects (including,
without limitation, the installation of utility 

  
 17 

	 	
service upgrades, meters, submeters, air handlers or cooling units), and the additional usage (to the extent permitted by Law), installation and maintenance costs shall be paid by Tenant.
Landlord shall have the right to separately meter electrical usage for the Premises and to measure electrical usage by survey or other commonly accepted methods. 

  

	 	C.	 In order to assist Landlord in complying with any governmental energy reporting requirements for the Building,
Tenant, if requested by Landlord, shall provide Landlord with information that relates to Tenant’s separately metered energy use, use of space and operating hours for the Premises and other information reasonably required by Landlord for
compliance with said governmental energy reporting requirements, which requests by Landlord Tenant shall endeavor to respond to within thirty (30) days thereafter. 

 

	11.	 Entry by Landlord. 

Landlord, its agents, contractors and representatives may enter the Premises to inspect or show the Premises (with respect to showing to
prospective tenants, only within the last 12 months of the Term unless Tenant has exercised the Extension Option, in which case only within the last 12 months of the Extension Term), to clean and make repairs (or alterations involving Building
services or utility lines referred to in Article 29 hereof or as otherwise permitted in the Lease), alterations or additions to the Premises, and to conduct or facilitate repairs, alterations or additions to any portion of the Building, including
other tenants’ premises. Except in emergencies (involving risk of imminent personal injury or imminent significant property damage) or to provide janitorial and other Building services after Normal Business Hours, Landlord shall provide Tenant
with reasonable prior notice of entry into the Premises, which may be given orally or by email. If reasonably necessary for the protection and safety of Tenant and its employees, Landlord shall have the right to temporarily close all or a portion of
the Premises to perform repairs, alterations and additions. However, except in such emergencies, Landlord will not close the Premises if the work can reasonably be completed on weekends and after Normal Business Hours. Entry by Landlord shall not
constitute constructive eviction or entitle Tenant to an abatement or reduction of Rent, but Landlord shall use commercially reasonable efforts to minimize interference with the operation of Tenant’s business in the Premises. 

 

	12.	 Assignment and Subletting. 

 

	 	A.	 Except in connection with a Permitted Transfer (defined in Section 12.E. below), Tenant shall not assign,
sublease, transfer or encumber any interest in this Lease or allow any third party to use any portion of the Premises (collectively or individually, a “Transfer”) without the prior written consent of Landlord, which consent shall not be
unreasonably withheld or delayed if Landlord does not elect to exercise its termination rights under Section 12.B below. Without limitation, it is agreed that Landlord’s consent shall not be considered unreasonably withheld if: (1) in
the case of an assignment of this Lease, the proposed transferee’s financial condition does not meet the criteria Landlord uses to select Building tenants having similar leasehold obligations; (2) the proposed transferee’s business is
not, in Landlord’s reasonable determination, suitable for the Building considering the business of the other tenants and the Building’s prestige, or would result in a violation of another tenant’s rights; (3) the proposed
transferee 

  
 18 

	 	
is a governmental agency or occupant of the Building; (4) Tenant is in default after the expiration of the notice and cure periods in this Lease; (5) any portion of the Building or
Premises would likely become subject to additional or different Laws as a consequence of the proposed Transfer; or (6) Landlord has, within the three (3) months prior to the request for consent, commenced negotiations with the proposed
transferee for other space in the Building. Notwithstanding subsection (3) above, Landlord will not withhold its consent solely because a proposed subtenant or assignee is an occupant of the Building if Landlord does not have (or will not have
within 6 months of the commencement date of the proposed sublease or assignment) space available for lease in the Building that is comparable to the space Tenant desires to sublet or assign. Tenant shall not be entitled to receive monetary damages
based upon a claim that Landlord unreasonably withheld its consent to a proposed Transfer and Tenant’s sole remedy shall be an action to enforce any such provision through specific performance or declaratory judgment. Any attempted Transfer in
violation of this Article shall, at Landlord’s option, be void. Consent by Landlord to one or more Transfer(s) shall not operate as a waiver of Landlord’s rights to approve any subsequent Transfers. In no event shall any Transfer or
Permitted Transfer release or relieve Tenant from any obligation under this Lease. 

  

	 	B.	 As part of its request for Landlord’s consent to a Transfer, Tenant shall provide Landlord with financial
statements for the proposed transferee (in the case of an assignment of this Lease), a complete copy of the letter of intent, term sheet or proposed assignment, sublease and other contractual documents and such other information as Landlord may
reasonably request. Landlord shall, by written notice to Tenant within 15 days of its receipt (or 7 Business Days for a sublease of less than 50% of the Premises) of the required information and documentation, either: (1) consent to the
Transfer by the execution of a consent agreement in a form reasonably designated by Landlord or reasonably refuse to consent to the Transfer in writing; or (2) exercise its right to terminate this Lease with respect to (a) an assignment of
this Lease or (b) a sublease of the entire Premises for the then remaining Term of the Lease. Any such termination shall be effective on the proposed effective date of the Transfer for which Tenant requested consent. Tenant shall pay Landlord a
review fee of $750.00 for Landlord’s review of any Permitted Transfer or requested Transfer, provided however, that if Landlord’s actual reasonable costs and expenses (including reasonable attorney’s fees) exceed $750.00, Tenant shall
reimburse Landlord for its actual reasonable costs and expenses in lieu of a fixed review fee (not to exceed $5,000.00). 

  

	 	C.	 Tenant shall pay Landlord 50% of all rent and other consideration which Tenant receives as a result of a
Transfer that is in excess of the Rent (or Attributed Rent, if applicable as provided below) payable to Landlord for the portion of the Premises and Term covered by the Transfer. Tenant shall pay Landlord for Landlord’s share of any excess
within 30 days after Tenant’s receipt of such excess consideration. Tenant may deduct from the excess all reasonable and customary expenses directly incurred by Tenant attributable to the Transfer (other than Landlord’s review fee),
including marketing costs, brokerage fees, legal fees, tenant improvement allowances, other reasonable and customary concessions and construction costs, all of which shall be amortized over the term of the Transfer,

  
 19 

	 	
and the costs of any services which Tenant shall supply to a subtenant, such as electricity, which are not being supplied by Landlord to Tenant under the Lease. If Tenant is in Monetary Default
(defined in Section 19.A. below), Landlord may require that all sublease payments be made directly to Landlord, in which case Tenant shall receive a credit against Rent in the amount of any payments received (less Landlord’s share of any
excess). For the period from the Commencement Date to the Rent Commencement Date, during which Tenant is not obligated to pay Rent, the excess rent and other consideration which Tenant receives as a result of a transfer shall be calculated as the
amount of such rents and other consideration in excess of $47,619.04 per month (the “Attributed Rent”). 

  

	 	D.	 Except as provided below with respect to a Permitted Transfer, if Tenant is a corporation, limited liability
company, partnership, or similar entity, and if the entity which owns or controls a majority of the voting shares/rights at any time changes for any reason (including but not limited to a merger, consolidation or reorganization), such change of
ownership or control shall constitute a Transfer. The foregoing shall not apply so long as Tenant is an entity whose outstanding stock is listed on a recognized security exchange, or if at least 80% of its voting stock is owned by another entity,
the voting stock of which is so listed. 

  

	 	E.	 Tenant may (i) assign its entire interest under this Lease to a successor to Tenant by purchase, merger,
consolidation or reorganization without the consent of Landlord or (ii) assign this Lease or sublet any portion of the Premises to any entity which controls Tenant or is controlled by Tenant or is under common control with Tenant without the
consent of Landlord and without Landlord having any right to recapture all or any portion of the Premises or share in any Excess Rent, provided that all of the following conditions in either case are satisfied (a “Permitted Transfer”): (1)
Tenant is not in default under this Lease beyond applicable notice and grace periods; (2) Tenant’s successor under subpart (i) shall own all or substantially all of the assets of Tenant; (3) Tenant’s successor under subpart
(i) shall have a net worth which is at least equal to the greater of Tenant’s net worth at the date of this Lease or Tenant’s net worth as of the day prior to the proposed purchase, merger, consolidation or reorganization;
(4) the Permitted Use does not allow the Premises to be used for retail purposes; and (5) Tenant shall give Landlord written notice at least 20 days prior to the effective date of the proposed purchase, merger, consolidation or reorganization
under subpart (i) or any Transfer under subpart (ii) (provided, however, that, if prohibited by confidentiality requirements in connection with such purchase, merger, consolidation or reorganization, then Tenant shall give Landlord written
notice within 10 days after the effective date of such transaction). Tenant’s notice to Landlord shall include information and documentation showing that each of the above conditions has been satisfied. If requested by Landlord, Tenant’s
successor shall sign a commercially reasonable form of assumption agreement. 

  

	13.	 Liens. 

Tenant shall not permit mechanic’s or other liens to be placed upon the Building, Premises or Tenant’s leasehold interest in
connection with any work or service done or purportedly done by or at the direction of Tenant. If a lien is so placed, Tenant shall, within 20 days of notice from Landlord of the filing of the lien, fully discharge the lien by settling the claim

  
 20 

 which resulted in the lien or by bonding or insuring over the lien in the manner prescribed by the
applicable lien Law. If Tenant fails to discharge the lien, then, in addition to any other right or remedy of Landlord, Landlord may bond or insure over the lien or otherwise discharge the lien. Tenant shall reimburse Landlord for any amount paid by
Landlord to bond or insure over the lien or discharge the lien, including, without limitation, reasonable attorneys’ fees (if and to the extent permitted by Law) within 30 days after receipt of an invoice from Landlord. 

 

	14.	 Indemnity and Waiver of Claims. 

 

	 	A.	 Except to the extent caused by the negligence or willful misconduct of Landlord or any Landlord Related Parties
(defined below), Tenant shall indemnify, defend and hold Landlord, its trustees, members, principals, beneficiaries, partners, officers, directors, employees, Mortgagee(s) (defined in Article 26) and agents (“Landlord Related Parties”)
harmless against and from all liabilities, obligations, damages, penalties, claims, actions, costs, charges and expenses, including, without limitation, reasonable attorneys’ fees and other professional fees (if and to the extent permitted by
Law), which may be imposed upon, incurred by or asserted by third parties against Landlord or any of the Landlord Related Parties and arising out of or in connection with (i) any damage or injury occurring in the Premises or (ii) any acts
or omissions (including violations of Law) of Tenant, the Tenant Related Parties (defined below) or any of Tenant’s subtenants, contractors or licensees. 

 

	 	B.	 Except to the extent caused by the negligence or willful misconduct of Tenant or any Tenant Related Parties
(defined below), Landlord shall indemnify, defend and hold Tenant, its trustees, members, principals, beneficiaries, partners, officers, directors, employees and agents (“Tenant Related Parties”) harmless against and from all liabilities,
obligations, damages, penalties, claims, actions, costs, charges and expenses, including, without limitation, reasonable attorneys’ fees and other professional fees (if and to the extent permitted by Law), which may be imposed upon, incurred by
or asserted by third parties against Tenant or any of the Tenant Related Parties and arising out of or in connection with the acts or omissions (including violations of Law) of Landlord, the Landlord Related Parties or any of Landlord’s
contractors or licensees. 

  

	 	C.	 To the extent permitted by Law and except to the extent caused by the negligence or willful misconduct of
Landlord or any Landlord Related Parties, Landlord and the Landlord Related Parties shall not be liable for, and Tenant waives, all claims for loss or damage to Tenant’s business or loss, theft or damage to Tenant’s Property (defined in
Article 15) or the property of any person claiming by, through or under Tenant resulting from: (1) wind or weather; (2) the failure of any sprinkler, heating or air-conditioning equipment, any
electric wiring or any gas, water or steam pipes; (3) the backing up of any sewer pipe or downspout; (4) the bursting, leaking or running of any tank, water closet, drain or other pipe; (5) water, snow or ice upon or coming through
the roof, skylight, stairs, doorways, windows, walks or any other place upon or near the Building; (6) any act or omission of any party other than Landlord or Landlord Related Parties; and (7) any causes not reasonably within the control of
Landlord. Tenant shall insure itself against such losses under Article 15 below. 

  
 21 

	15.	 Insurance. 

Tenant shall carry and maintain the following insurance (“Tenant’s Insurance”), at its sole cost and expense:
(1) Commercial General Liability Insurance applicable to the Premises and its appurtenances providing, on an occurrence basis, a minimum combined single limit of $3,000,000.00; (2) All Risk Property/Business Interruption Insurance, including
flood and earthquake, written at replacement cost value and with a replacement cost endorsement covering all of Tenant’s trade fixtures, equipment, furniture and other personal property within the Premises (“Tenant’s Property”);
(3) Workers’ Compensation Insurance as required by the state in which the Premises is located and in amounts as may be required by applicable statute; and (4) Employers Liability Coverage of at least $1,000,000.00 per occurrence. Any
company writing any of Tenant’s Insurance shall have an A.M. Best rating of not less than A-VIII. All Commercial General Liability Insurance policies shall name Tenant as a named insured and Landlord (or any successor), and its respective
members, principals, beneficiaries, partners, officers, directors, employees, and agents, and other designees of Landlord as the interest of such designees shall appear, as additional insureds. Tenant shall use commercially reasonable efforts to
require that the insurer(s) give Landlord and its designees at least 30 days’ advance written notice of any change, cancellation, termination or lapse of insurance. Tenant shall provide Landlord with a certificate of insurance evidencing
Tenant’s Insurance prior to the earlier to occur of the Commencement Date or the date Tenant is provided with possession of the Premises for any reason, and upon renewals at least 15 days prior to the expiration of the insurance coverage.
Landlord shall maintain so called All Risk or Special Form property insurance on the Building at not less than 95% of replacement cost value, as reasonably estimated by Landlord, and Commercial General Liability Insurance applicable to the Building
and Common Areas, providing, on an occurrence basis, a minimum combined single limit of at least $3,000,000.00. Except as specifically provided to the contrary, the limits of either party’s’ insurance shall not limit such party’s
liability under this Lease. 
  

	16.	 Subrogation. 

Notwithstanding anything in this Lease to the contrary, Landlord and Tenant hereby waive and shall cause their respective insurance carriers to
waive any and all rights of recovery, claim, action or causes of action against the other and their respective trustees, principals, beneficiaries, partners, officers, directors, agents, and employees, for any loss or damage that may occur to
Landlord or Tenant or any party claiming by, through or under Landlord or Tenant, as the case may be, with respect to Tenant’s Property, the Building, the Premises, any additions or improvements to the Building or Premises, or any contents
thereof, including all rights of recovery, claims, actions or causes of action arising out of the negligence of Landlord or any Landlord Related Parties or the negligence of Tenant or any Tenant Related Parties, which loss or damage is (or would
have been, had the insurance required by this Lease been carried) covered by insurance. 
  

	17.	 Casualty Damage. 

 

	 	A.	 If all or any part of the Premises is damaged by fire or other casualty, Tenant shall immediately notify
Landlord in writing. During any period of time that all or a material portion of the Premises is rendered untenantable as a result of a fire or other casualty (whether to the Premises or to the Building), the Rent shall abate for the portion of the
Premises that is untenantable and not used by Tenant. Landlord shall have the right to terminate this Lease if: (1) the Building 

  
 22 

	 	
shall be damaged so that, in Landlord’s reasonable judgment, substantial alteration or reconstruction of the Building shall be required constituting more than 30% of the full replacement
cost value of the Building (whether or not the Premises has been damaged); (2) Landlord is not permitted by Law to rebuild the Building in substantially the same form as existed before the fire or casualty; (3) the Premises have been materially
damaged and there is less than 2 years of the Term remaining on the date of the casualty; or (4) a material uninsured loss to the Building occurs (provided that the lack of insurance is not due to Landlord’s failure to maintain the
insurance required by this Lease). Landlord may exercise its right to terminate this Lease by notifying Tenant in writing within 90 days after the date of the casualty. Landlord shall only exercise its right to terminate this Lease in a good faith
and non-discriminatory manner so as to avoid treating Tenant in a fashion different than other tenants in the Building similarly affected by the fire or other casualty. If Landlord does not terminate this
Lease, Landlord shall commence and proceed with reasonable diligence to repair and restore the Building and the Leasehold Improvements (excluding any Alterations that were performed by Tenant in violation of this Lease). However, in no event shall
Landlord be required to spend more than the insurance proceeds received by Landlord (provided that the lack of insurance is not due to Landlord’s failure to maintain the insurance required by this Lease). Landlord shall not be liable for any
loss or damage to Tenant’s Property or to the business of Tenant resulting in any way from the fire or other casualty or from the repair and restoration of the damage. Landlord and Tenant hereby waive the provisions of any Law relating to the
matters addressed in this Article, and agree that their respective rights for damage to or destruction of the Premises shall be those specifically provided in this Lease. 

 

	 	B.	 If all or any portion of the Premises shall be made untenantable by fire or other casualty (whether to the
Premises or to the Building), Landlord shall, with reasonable promptness, cause an architect or general contractor selected by Landlord to provide Landlord and Tenant with a written estimate of the amount of time required to substantially complete
the repair and restoration of the Premises and make the Premises tenantable again, using standard working methods (“Completion Estimate”). If the Completion Estimate indicates that the Premises cannot be made tenantable within 210 days
from the date the repair and restoration is started, then regardless of anything in Section 17.A above to the contrary, either party shall have the right to terminate this Lease by giving written notice to the other of such election within 10
days after receipt of the Completion Estimate. Tenant, however, shall not have the right to terminate this Lease if the fire or casualty was caused by the negligence or intentional misconduct of Tenant, Tenant Related Parties or any of the
Tenant’s contractors or licensees. 

  

	18.	 Condemnation. 

Either party may terminate this Lease if the whole or any material part of the Premises shall be taken or condemned for any public or
quasi-public use under Law, by eminent domain or private purchase in lieu thereof (a “Taking”) or shall become inaccessible by reason of a Taking. Landlord shall also have the right to terminate this Lease if there is a Taking of any
portion of the Building which would leave the remainder of the Building unsuitable for use as an office building in a manner comparable to the Building’s use prior to the Taking. In order to 

  
 23 

 
exercise its right to terminate the Lease, Landlord or Tenant, as the case may be, must provide written notice of termination to the other within 45 days after the terminating party first
receives notice of the Taking. Any such termination shall be effective as of the date the physical taking of the Premises or the portion of the Building occurs. If this Lease is not terminated, the Rentable Square Footage of the Building, the
Rentable Square Footage of the Premises and Tenant’s Pro Rata Share shall, if applicable, be appropriately adjusted. In addition, Rent for any portion of the Premises taken or condemned shall be abated during the unexpired Term of this Lease
effective when the physical taking of the portion of the Premises occurs. All compensation awarded for a Taking, or sale proceeds, shall be the property of Landlord, any right to receive compensation or proceeds being expressly waived by Tenant.
However, Tenant may file a separate claim at its sole cost and expense for Tenant’s Property and Tenant’s reasonable relocation expenses, provided the filing of the claim does not diminish the award which would otherwise be receivable by
Landlord. In addition, if neither party terminates this Lease, then Landlord, with reasonable diligence and at Landlord’s expense (but only to the extent of the Taking award actually received by Landlord), will restore the Building and the
Premises, including access thereto, as nearly as may be practical to the same condition as existed prior to the Taking. 
  

	19.	 Events of Default. 

Tenant shall be considered to be in default of this Lease upon the occurrence of any of the following events of default (each an “Event of
Default”): 
  

	 	A.	 Tenant’s failure to pay when due all or any portion of the Rent, if the failure continues for 7 days after
written notice to Tenant (“Monetary Default”). 

  

	 	B.	 Tenant’s failure to comply with the terms and provisions of Articles 5, 12 or 15 if the failure is not
cured within 10 days after written notice to Tenant. 

  

	 	C.	 Tenant’s failure (other than a Monetary Default or an Event of Default under Section 19.B) to comply with
any term, provision or covenant of this Lease, if the failure is not cured within 30 days after written notice to Tenant. However, if Tenant’s failure to comply cannot reasonably be cured within 30 days, Tenant shall be allowed additional time
(not to exceed 90 days) as is reasonably necessary to cure the failure so long as: (1) Tenant commences to cure the failure within 30 days, and (2) Tenant diligently pursues a course of action that will cure the failure and bring Tenant
back into compliance with the Lease with respect to such failure. However, if Tenant’s failure to comply creates a hazardous condition, the failure must be cured immediately upon notice to Tenant. In addition, if Landlord provides Tenant with
notice of Tenant’s failure to comply with any specific term, provision or covenant of this Lease on 3 occasions during any 12 month period, Tenant’s subsequent violation of the same term, provision or covenant of this Lease shall, at
Landlord’s option by written notice to Tenant, be an incurable Event of Default by Tenant. 

  

	 	D.	 Tenant or any Guarantor becomes insolvent, makes a transfer in fraud of creditors or makes an assignment for
the benefit of creditors, or admits in writing its inability to pay its debts when due. 

  

	 	E.	 The leasehold estate is taken by process or operation of Law. 

  
 24 

	20.	 Remedies. 

  

	 	A.	 Upon an Event of Default by Tenant which is continuing, Landlord shall have the right without notice or demand
(except as provided in Article 19) to pursue any of its rights and remedies at Law or in equity, including any one or more of the following remedies: 

  

	 	1.	 Terminate this Lease by notice in writing to Tenant, in which case Tenant shall immediately surrender the
Premises to Landlord. If Tenant fails to surrender the Premises, Landlord may, in compliance with applicable Law and without prejudice to any other right or remedy, seek a summary process judgment to enter upon and take possession of the Premises
and expel and remove Tenant, Tenant’s Property and any party occupying all or any part of the Premises. Tenant shall pay Landlord on demand the amount of all past due Rent and other losses and damages which Landlord may suffer as a result of
Tenant’s default, whether by Landlord’s inability to relet the Premises on satisfactory terms or otherwise, and any deficiency that may arise from reletting or the failure to relet the Premises. 

 

	 	2.	 Following termination of this Lease, Landlord shall use commercially reasonable efforts to relet all or any
part of the Premises, without notice to Tenant, for a term that may be greater or less than the balance of the Term and on such conditions (which may include concessions, free rent and alterations of the Premises) and for such uses as Landlord in
its absolute discretion shall determine. The foregoing obligation to use commercially reasonable efforts shall not apply if Landlord seeks liquidated damages under Sections 20.A.3 or 20.A.4. Landlord may collect and receive all rents and other
income from the reletting which (less Landlord’s Costs of Reletting, as hereinafter defined) shall be credited against Rent otherwise payable by Tenant hereunder. Notwithstanding the termination of this Lease, Tenant shall remain liable to
Landlord for the Rent as it becomes due under this Lease subsequent to its termination and Tenant shall pay Landlord on demand all past due Rent and any deficiency arising from the reletting or failure to relet the Premises. Provided Landlord has
used commercially reasonable efforts, Landlord shall not be responsible or liable for the failure to relet all or any part of the Premises or for the failure to collect any Rent. The re-entry or taking of
possession of the Premises shall not be construed as an election by Landlord to terminate this Lease unless a written notice of termination is given to Tenant. “Costs of Reletting” shall include all costs and expenses incurred by Landlord
in reletting or attempting to relet the Premises, including, without limitation, reasonable legal fees, brokerage commissions, the cost of alterations and the value of other concessions or allowances granted to a new tenant. 

  
 25 

	 	3.	 In lieu of calculating damages under Sections 20.A.1 or 20.A.2 above, Landlord may elect by written notice to
Tenant at any time following a termination of this Lease to receive as liquidated damages the sum of (a) all Rent accrued through the later of the date of termination of this Lease or date of Landlord’s election, and (b) an amount equal to
the total Rent that Tenant would have been required to pay for the remainder of the Term following the date of Landlord’s election discounted to present value at the Prime Rate (defined in Section 20.B. below) then in effect, minus the
then present fair rental value of the Premises (inclusive, without limitation, of Taxes, Expenses, and other elements of Rent under this Lease) for the remainder of the Term, similarly discounted, after deducting all anticipated Costs of Reletting.
If Landlord elects to receive the liquidated damages set forth in this Section 20.A.3, such liquidated damages shall be in lieu of any other further damages or indemnity and in lieu of full recovery by Landlord of all other sums payable under
the other provisions of this Lease. 

  

	 	4.	 In lieu of any other damages or indemnity and in lieu of full recovery by Landlord of all sums payable under
the other provisions of this Section, Landlord may, by written notice to Tenant, at any time after termination of this Lease elect to recover, and Tenant shall thereupon pay, Liquidated Damages. “Liquidated Damages” shall be equal to:
(a) the aggregate of the Base Rent and Additional Rent accrued either (i) in the twelve (12) months next following such termination, if such termination occurs during the first three Lease Years of the initial Term, or (ii) in
the six (6) months next following such termination, if such termination occurs on or after the first day of the fourth Lease Year of the initial Term (but in the latter case the amount payable shall not exceed the Base Rent and Additional Rent
due for the then remainder of the Term); plus (b) the amount of Rent of any kind accrued and unpaid at the time of termination. Nothing contained in this Lease shall, however, limit or prejudice the right of Landlord to prove for and obtain in
proceedings for bankruptcy or insolvency by reason of the termination of this Lease, an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which, the damages are to be
proved, whether or not the amount be greater, equal to, or less than the amount of the loss or damages referred to above (except that in no event shall the Landlord be entitled to recover damages under both this Lease and under such statute or rule
of law; and if Landlord has received a sum payable hereunder as liquidated damages, then Landlord may not then seek to recover any further or additional damages under this Lease, under such statute or rule of law, or otherwise).

  

	 	B.	 Unless expressly provided in this Lease, the termination and repossession or
re-entering of all or any part of the Premises shall not relieve Tenant of its liabilities and obligations under the Lease. Unless expressly provided, no right or remedy of Landlord shall be exclusive of any
other right or remedy. Each right and remedy shall be cumulative and in addition to any other right and remedy now or subsequently available to Landlord at Law or in equity. If Landlord declares an Event of Default by Tenant, Landlord shall be
entitled to receive interest on any unpaid item of Rent at a rate equal to the Prime Rate plus 4%. For purposes hereof, the “Prime Rate” shall be the per annum interest rate publicly announced as its prime or base rate by a federally
insured bank selected by Landlord in the state in which the Building is located. Forbearance by Landlord to enforce one or more remedies shall not constitute a waiver of any default. 

  
 26 

	21.	 Limitation Of Liability. 

NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS LEASE, THE LIABILITY OF LANDLORD (AND OF ANY SUCCESSOR LANDLORD) TO TENANT SHALL BE
LIMITED TO THE INTEREST OF LANDLORD IN THE BUILDING. TENANT SHALL LOOK SOLELY TO LANDLORD’S INTEREST IN THE BUILDING FOR THE RECOVERY OF ANY JUDGMENT OR AWARD AGAINST LANDLORD. NEITHER LANDLORD NOR ANY LANDLORD RELATED PARTY SHALL BE PERSONALLY
LIABLE FOR ANY JUDGMENT OR DEFICIENCY. BEFORE FILING SUIT FOR AN ALLEGED DEFAULT BY LANDLORD, TENANT SHALL GIVE LANDLORD AND THE MORTGAGEE(S) (DEFINED IN ARTICLE 26 BELOW) WHOM TENANT HAS BEEN NOTIFIED HOLD MORTGAGES (DEFINED IN ARTICLE 26 BELOW) ON
THE BUILDING OR PREMISES, NOTICE AND REASONABLE TIME TO CURE THE ALLEGED DEFAULT. WITHOUT LIMITING THE FOREGOING, IN NO EVENT SHALL LANDLORD OR ANY MORTGAGEES OR LANDLORD RELATED PARTIES EVER BE LIABLE FOR ANY CONSEQUENTIAL OR INCIDENTAL DAMAGES OR
ANY LOST PROFITS OF TENANT. 
  

	22.	 No Waiver. 

Either party’s failure to declare a default immediately upon its occurrence, or delay in taking action for a default shall not constitute
a waiver of the default, nor shall it constitute an estoppel. Either party’s failure to enforce its rights for a default shall not constitute a waiver of its rights regarding any subsequent default. Receipt by Landlord of Tenant’s keys to
the Premises shall not constitute an acceptance or surrender of the Premises. 
  

	23.	 Quiet Enjoyment. 

Tenant shall, and may peacefully have, hold and enjoy the Premises, subject to the terms of this Lease, provided Tenant pays the Rent and fully
performs all of its covenants and agreements. This covenant and all other covenants of Landlord shall be binding upon Landlord and its successors only during its or their respective periods of ownership of the Building, and shall not be a personal
covenant of Landlord or the Landlord Related Parties. 
  

	24.	 [Intentionally Omitted] 

 

	25.	 Holding Over. 

Except for any permitted occupancy by Tenant under Article 8, if Tenant fails to surrender the Premises at the expiration or earlier
termination of this Lease, occupancy of the Premises after the termination or expiration shall be that of a tenancy at sufferance. Tenant’s occupancy of the Premises during the holdover shall be subject to all the terms and provisions of this
Lease and Tenant shall pay an amount (on a per month basis without reduction for partial months during the holdover) equal to 150% of the Base Rent due for the period immediately preceding the holdover, plus Additional Rent that would have been
payable for the applicable monthly period. No holdover by Tenant or payment by Tenant after the expiration or early termination of this Lease shall be construed to extend the Term or prevent Landlord from immediate recovery of possession of the
Premises by summary proceedings or otherwise. In 

  
 27 

 
addition to the payment of the amounts provided above, if Landlord is unable to deliver possession of the Premises to a new tenant, or to perform improvements for a new tenant, as a result of
Tenant’s holdover and Tenant fails to vacate the Premises within 10 Business Days after the later of (i) the expiration or earlier termination of the Term, or (ii) the date that Landlord notifies Tenant of Landlord’s inability to
deliver possession, or perform improvements for a new tenant, Tenant shall be liable to Landlord for all damages, including, without limitation, consequential damages, that Landlord suffers from the holdover. 

 

	26.	 Subordination to Mortgages; Estoppel Certificate. 

Tenant accepts this Lease subject and subordinate to any mortgage(s), deed(s) of trust, ground lease(s) or other lien(s) now or subsequently
arising upon the Premises or the Building, and to renewals, modifications, refinancings and extensions thereof (collectively referred to as a “Mortgage”). The party having the benefit of a Mortgage shall be referred to as a
“Mortgagee”. Upon request from a Mortgagee, Tenant shall execute a commercially reasonable subordination agreement in favor of the Mortgagee, provided such Mortgagee agrees not to disturb Tenant in its tenancy hereunder should the
Mortgagee foreclose Landlord’s interest in the Building. In lieu of having the Mortgage be superior to this Lease, a Mortgagee shall have the right at any time to subordinate its Mortgage to this Lease. If requested by a successor-in-interest to all or a part of Landlord’s interest in the Lease, Tenant shall, without charge, attorn to the successor-in-interest. Landlord and Tenant shall each, within 10 days after receipt of a written request from the other, execute and deliver an estoppel certificate to those parties as are reasonably
requested by the other (including a Mortgagee or prospective purchaser). The estoppel certificate shall include a statement certifying that this Lease is unmodified (except as identified in the estoppel certificate) and in full force and effect,
describing the dates to which Rent and other charges have been paid, representing that, to such party’s actual knowledge, there is no default (or stating the nature of the alleged default) and indicating other matters with respect to the Lease
that may reasonably be requested. 
 Landlord will use reasonable efforts to obtain, within sixty (60) days of the execution and
delivery of this Lease, a subordination, non-disturbance and attornment agreement from the current Mortgagee (the “SNDA”). “Reasonable efforts” of Landlord shall not require Landlord to
incur any cost, expense or liability, Tenant hereby agreeing to pay all costs and charges in connection with Landlord’s efforts to obtain an SNDA. Landlord’s failure to obtain an SNDA for Tenant shall have no effect on the rights,
obligations and liabilities of Landlord and Tenant or be considered to be a default by Landlord hereunder. Notwithstanding the foregoing, if Landlord fails to obtain the SNDA within such sixty (60) day period, Tenant shall have the right, but
not the obligation, to attempt to obtain the SNDA at Tenant’s sole cost and expense. Landlord hereby agrees to cooperate in a reasonable manner with such attempts. 
  

	27.	 Attorneys’ Fees. 

If either party institutes a suit against the other for violation of or to enforce any covenant or condition of this Lease, or if either party
intervenes in any suit in which the other is a party to enforce or protect its interest or rights, the prevailing party shall be entitled to all of its costs and expenses, including, without limitation, reasonable attorneys’ fees. 

  
 28 

	28.	 Notice. 

If a demand, request, approval, consent or notice (collectively referred to as a “notice”) shall or may be given to either party by
the other, the notice shall be in writing and delivered by registered or certified mail with return receipt requested, or sent by overnight or same day courier service at the party’s respective Notice Address(es) set forth in Article 1, except
that if Tenant has vacated the Premises (or if the Notice Address for Tenant is other than the Premises, and Tenant has vacated such address) without providing Landlord a new Notice Address, Landlord may serve notice in any manner described in this
Article or in any other manner permitted by Law. Each notice shall be deemed to have been received or given on the earlier to occur of actual delivery or the date on which delivery is refused, or, if Tenant has vacated the Premises or the other
Notice Address of Tenant without providing a new Notice Address, 3 days after notice is deposited in the U.S. mail or with a courier service in the manner described above. Either party may, at any time, change its Notice Address (other than to a
post office box address) by giving the other party written notice of the new address in the manner described in this Article. 
  

	29.	 Excepted Rights. 

This Lease does not grant any rights to light or air over or about the Building. Landlord excepts and reserves exclusively to itself the use
of: (1) roofs, (2) telephone, electrical and janitorial closets, (3) equipment rooms, Building risers or similar areas that are used by Landlord for the provision of Building services, (4) rights to the land and improvements below the
floor of the Premises, (5) the improvements and air rights above the Premises, (6) the improvements and air rights outside the demising walls of the Premises, and (7) the areas within the Premises used for the installation of utility
lines and other installations serving occupants of the Building. Landlord has the right to change the Building’s name or address. Landlord also has the right to make such other changes to the Building as Landlord deems appropriate, provided the
changes do not materially affect Tenant’s ability to use the Premises for the Permitted Use. Landlord shall also have the right (but not the obligation) to temporarily close the Building if Landlord reasonably determines that there is an
imminent danger of significant damage to the Building or of personal injury to Landlord’s employees or the occupants of the Building. The circumstances under which Landlord may temporarily close the Building shall include, without limitation,
electrical interruptions, hurricanes and civil disturbances. A closure of the Building under such circumstances shall not constitute a constructive eviction nor entitle Tenant to an abatement or reduction of Rent, subject, however, to the provisions
of Section 7.B. 
  

	30.	 Surrender of Premises. 

At the expiration or earlier termination of this Lease, Tenant shall remove Tenant’s Property (defined in Article 15) from the Premises,
and quit and surrender the Premises to Landlord, broom clean, and in good order, condition and repair, reasonable wear and tear and damage by or repairs that are Landlord’s responsibility and repairs due to fire or other casualty or a result of
a Taking excepted. Tenant shall also be required to remove the Required Removables in accordance with Article 8. If Tenant fails to remove any of Tenant’s Property within 2 days after the termination of this Lease, Landlord, at Tenant’s
sole cost and expense, shall be entitled (but not obligated) to remove and store Tenant’s Property. Landlord shall not be responsible for the value, preservation or safekeeping of Tenant’s Property. Tenant shall pay Landlord, upon demand,
the expenses and storage charges incurred for Tenant’s Property. 

  
 29 

 
In addition, if Tenant fails to remove Tenant’s Property from the Premises or storage, as the case may be, within 30 days after written notice, Landlord may deem all or any part of
Tenant’s Property to be abandoned, and title to Tenant’s Property shall be deemed to be immediately vested in Landlord. 
  

	31.	 Miscellaneous. 

 

	 	A.	 This Lease and the rights and obligations of the parties shall be interpreted, construed and enforced in
accordance with the Laws of the state in which the Building is located and Landlord and Tenant hereby irrevocably consent to the jurisdiction and proper venue of such state. If any term or provision of this Lease shall to any extent be invalid or
unenforceable, the remainder of this Lease shall not be affected, and each provision of this Lease shall be valid and enforced to the fullest extent permitted by Law. The headings and titles to the Articles and Sections of this Lease are for
convenience only and shall have no effect on the interpretation of any part of this Lease. 

  

	 	B.	 Tenant shall not record this Lease or any memorandum or notice without Landlord’s prior written consent;
provided, however, Landlord agrees to consent to the recordation or registration of a memorandum or notice of this Lease, at Tenant’s cost and expense (and in a form reasonably satisfactory to Landlord), if the initial term of this Lease or the
initial term plus any renewal terms granted exceed, in the aggregate, 7 years. If this Lease is terminated before the Term, expires, upon Landlord’s request the parties shall execute, deliver and record an instrument acknowledging the above and
the date of the termination of this Lease. 

  

	 	C.	 Landlord and Tenant hereby waive any right to trial by jury in any proceeding based upon a breach of this
Lease. 

  

	 	D.	 Whenever a period of time is prescribed for the taking of an action by Landlord or Tenant, the period of time
for the performance of such action shall be extended by the number of days that the performance is actually delayed due to strikes, acts of God, shortages of labor or materials, war, civil disturbances and other causes beyond the reasonable. control
of the performing party. (“Force Majeure”). However, events of Force Majeure shall not extend any period of time for the payment of Rent or other sums payable by either party or any period of time for the written exercise of an option or
right by either party. 

  

	 	E.	 Landlord shall have the right to transfer and assign, in whole or in part, all of its rights and obligations
under this Lease and in the Building referred to herein, and upon such transfer Landlord shall be released from any obligations arising or accruing after such transfer, and Tenant agrees to look solely to the successor in interest of Landlord for
the performance of such obligations. 

  

	 	F.	 Tenant represents that it has dealt directly with and only with the Brokers as a broker in connection with this
Lease. Tenant shall indemnify and hold Landlord and the Landlord Related Parties harmless from all claims of any other brokers claiming to have represented Tenant in connection with this Lease. Landlord agrees to indemnify and hold Tenant and the
Tenant Related Parties harmless from all claims of any brokers claiming to have represented Landlord in connection with this Lease. Landlord agrees to pay a brokerage commission to the Brokers in accordance with the terms of a separate agreement
between Landlord and Newmark Grubb Knight Frank. 

  
 30 

	 	G.	 Tenant covenants, warrants and represents that: (1) each individual executing, attesting and/or delivering
this Lease on behalf of Tenant is authorized to do so on behalf of Tenant; (2) this Lease is binding upon Tenant; and (3) Tenant is a duly organized and legally existing in the state of its organization and is qualified to do business in
the state in which the Premises are located. If there is more than one Tenant, or if Tenant is comprised of more than one party or entity, the obligations imposed upon Tenant shall be joint and several obligations of all the parties and entities.
Notices, payments and agreements given or made by, with or to any one person or entity shall be deemed to have been given or made by, with and to all of them. Landlord covenants, warrants and represents that (1) each individual executing, attesting
and/or delivering this Lease on behalf of Landlord is authorized to do so on behalf of Landlord; (2) this Lease is binding upon Landlord; (3) Landlord is duly organized and legally existing in the state of its organization and is qualified
to do business in the state in which the Premises are located; and (4) Landlord is the record owner in fee title to the Building. 

  

	 	H.	 Time is of the essence with respect to Tenant’s exercise of any expansion, renewal or extension rights
granted to Tenant. This Lease shall create only the relationship of landlord and tenant between the parties, and not a partnership, joint venture or any other relationship. This Lease and the covenants and conditions in this Lease shall inure only
to the benefit of and be binding only upon Landlord and Tenant and their permitted successors and assigns. 

  

	 	I.	 The expiration of the Term, whether by lapse of time or otherwise, shall not relieve either party of any
obligations which accrued prior to or which may continue to accrue after the expiration or early termination of this Lease. Without limiting the scope of the prior sentence, it is agreed that Tenant’s obligations under Sections 4.A and 4.B. and
Articles 8, 14, 20, 25 and 30, as well as Sections 31.F and 31.N, shall survive the expiration or early termination of this Lease. 

  

	 	J.	 Landlord has delivered a copy of this Lease to Tenant for Tenant’s review only, and the delivery of it
does not constitute an offer to Tenant or an option. This Lease shall not be effective unless and until an original copy of this Lease has been signed by both parties and a counterpart original delivered to each party. 

 

	 	K.	 All understandings and agreements previously made between the parties are superseded by this Lease, and neither
party is relying upon any warranty, statement or representation not contained in this Lease. This Lease may be modified only by a written agreement signed by Landlord and Tenant. 

 

	 	L.	 Tenant, within 15 days after request, shall provide Landlord with Tenant’s most recent financial statement
if Landlord is requested to produce the information in connection with a proposed financing or sale of the Building but such request shall not be made by Landlord more frequently than once every calendar year and only in connection with a proposed
financing or sale of the Building. Upon written request by Tenant, Landlord shall enter into a commercially reasonable confidentiality agreement covering any confidential information that is disclosed by Tenant. 

  
 31 

	 	M.	 Failure by Landlord to observe any of its obligations under this Lease will constitute a default only if such
failure continues for a period of thirty (30) days (and such additional time, not to exceed 120 days in the aggregate, as may be reasonably necessary for Landlord to remedy such failure) after Landlord receives written notice of such failure
from Tenant, setting forth in reasonable detail the nature and extent of Landlord’s failure and identifying the provisions of this Lease alleged to have been violated. 

 

	 	N.	 Should Tenant bring use, store or treat any Hazardous Materials (as hereinafter defined) in or upon the
Premises, Tenant shall comply with all Environmental Regulations (as hereinafter defined) which regulate, govern or impact Tenant’s possession, use, storage, treatment or disposal of said Hazardous Materials. Tenant shall indemnify and hold
Landlord harmless from all claims, liens, losses, damages and expenses, including without limitation reasonable attorneys’ fees and expenses, resulting from any release of Hazardous Materials at the Premises in violation of Environmental
Regulations caused by Tenant. The obligations of Tenant under this Section 31.N shall survive the termination of this Lease. As used in this Lease, the term “Environmental Regulations” shall mean all applicable environmental laws,
rules, regulations and orders regulating the presence or release of Hazardous Materials of any applicable governmental authority having jurisdiction over the Premises. As used in this Lease, the term “Hazardous Materials” shall mean any
hazardous, toxic or radioactive substance, material, matter or waste which is or becomes regulated by any Environmental Regulation, and shall include asbestos, petroleum products and the terms “Hazardous Substance” and “Hazardous
Waste” as defined in the Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) as amended, 42 U.S.C. § 9601 et seq., the Resource Conservation and Recovery Act (“RCRA”), as amended, 42. U.S.C.
§ 6901 et seq., and all environmental protection statutes of the state and municipality in which the Premises are located. 

  

	 	O.	 Tenant represents and warrants that neither Tenant nor any of its affiliates, nor any of their respective
partners, members, shareholders or other equity owners, and none of their respective employees, officers, directors, representatives or agents is, nor will they become, a person or entity with whom U.S. persons or entities are restricted from doing
business under regulations of the Office of Foreign Asset Control (“OFAC”) of the Department of the Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) or under any statute, executive order
(including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action and is not and will not transfer this Lease to,
contract with or otherwise engage in any dealings or transactions or be otherwise associated with such persons or entities. 

  
 32 

	 	P.	 Landlord shall provide and maintain in the main lobby of the Building an alphabetical directory board or other
directory device listing all tenants in the Building, including Tenant, and Landlord shall provide and maintain directory signage for Tenant in the elevator lobby of the 6th floor. Tenant shall be responsible for any signage at the entrance to the
Premises, subject to Landlord’s reasonable approval. 

  

	 	Q.	 Landlord shall provide Tenant with access to the Premises 24 hours a day, 7 days a week, subject to
Landlord’s security requirements both during and after Normal Business Hours. Landlord shall provide on-site security, including the stationing of security guards in the main lobby of the Building 24
hours a day, 7 days a week. Tenant may install a compatible security card system to the Premises subject to Landlord’s approval, which approval shall not be unreasonably withheld, conditioned or delayed. 

 

	 	R.	 The Building’s current telecommunication providers include Comcast, Verizon, Cogent, XO Communications,
AT&T and RCN cable. 

  

	 	S.	 Any legal action or proceeding with respect to this Lease shall be brought by Landlord or Tenant in any court
of competent jurisdiction in Massachusetts. By its execution and delivery of this Lease, Tenant and any Tenant Related Parties submit and accept, for themselves and their property, generally and unconditionally the jurisdiction of the Massachusetts
courts. Tenant and any Tenant Related Parties, and Landlord and any Landlord Related Parties, waive any claim that the Commonwealth of Massachusetts is not a convenient forum or the proper venue for any such action or proceeding. Tenant shall
qualify to do business in the Commonwealth of Massachusetts by making the appropriate filings with the Massachusetts Secretary of State. 

  

	32.	 Entire Agreement. 

This Lease and the following exhibits and attachments which are hereby incorporated into and made a part of this Lease constitute the entire
agreement between the parties and supersede all prior agreements and understandings related to the Premises, including all lease proposals, letters of intent and other documents: Exhibit A (Outline and Location of Premises), Exhibit B
(Building Rules and Regulations), Exhibit C (Work Letter), Exhibit C-1 (Commencement Date Letter Agreement), Exhibit D (Form of Letter of Credit), Exhibit E (Janitorial Specifications), Exhibit F
(Additional Provisions) and Schedule A (Retained FF&E). 
 (Signature block on next page) 

  
 33 

 Landlord and Tenant have executed this Lease as of the day and year first above written.

  

					
	LANDLORD:
	
	GLL 200 STATE STREET, L.P., a Delaware limited partnership
		
	By:	 	GLL 200 State Street Corp., its general partner
			
		 	By:	 	/s/ Christopher E. Qulett
		 	Name:	 	Christopher E. Qulett
		 	Title:	 	Executive Vice President
			
		 	By:	 	/s/ James H. Cunningham, Jr.
		 	Name:	 	James H. Cunningham, Jr.
		 	Title:	 	President and CFO

  
  

			
	TENANT:
	
	CENTREXION THERAPEUTICS CORPORATION a Delaware corporation
		
	By:	 	/s/ Kerry Brady
		 	Kerry Brady
		 	Chief Business Officer

  
 34 

 EXHIBIT A 
  

 

  
 1 

 EXHIBIT B 

200 STATE STREET 
 BOSTON,
MASSACHUSETTS 
 RULES AND REGULATIONS 

Provided the same are consistently applied and enforced, Tenant shall faithfully observe and comply with the following Rules and Regulations.
Landlord shall not be responsible to Tenant for the nonperformance of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of the Building. In the event of any conflict between the
Rules and Regulations and the other provisions of this Lease, the latter shall control. 
 1. Tenant shall not alter any lock or install any
new or additional locks or bolts on any doors or windows of the Premises or install a security system without obtaining Landlord’s prior written consent. Tenant shall bear the cost of any lock changes or repairs required by Tenant. Upon the
termination of this Lease, Tenant shall restore to Landlord all keys or security cards of stores, offices, and lavatories, either furnished to, or otherwise procured by, Tenant and in the event of the loss of keys or cards so furnished, Tenant shall
pay to Landlord the cost of replacing same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes. The initial set of security cards will be issued for Tenant’s employees without
charge. 
 2. All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.

 3. Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary
for comparable buildings in the county where the Building is located. Tenant, its employees and agents must be sure that the doors to the Building are securely closed and locked when leaving the Premises if it is after the normal hours of business
for the Building. Any tenant, its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when it is considered to be after normal business hours for the Building, may be required to sign
the Building register. Access to the Building may be refused unless the person seeking access has proper identification or has a previously arranged pass for access to the Building. Landlord will furnish passes to persons for whom Tenant requests
same in writing. Tenant shall be responsible for all persons for whom Tenant requests passes and shall be liable to Landlord for all acts of such persons. The Landlord and his agents shall in no case be liable for damages for any error with regard
to the admission to or exclusion from the Building of any person. In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building or the Condominium during the continuance thereof
by any means it deems appropriate for the safety and protection of life and property. 
 4. No furniture, freight or equipment of any kind
shall be brought into the Building without prior notice to Landlord. All moving activity into or out of the Building shall be scheduled with Landlord and done only at such time and in such manner as Landlord designates. Landlord shall have the right
to prescribe the weight, size and position of all safes and other heavy property brought into the Building and also the times and manner of moving the same in and out of the Building. Safes and other heavy objects shall, if considered necessary by
Landlord, stand on supports of such thickness as is necessary to properly distribute the weight. Landlord will not be responsible for loss of or damage to any such safe or property in any case. Any damage to any part of the Building, its contents,
occupants or visitors by moving or maintaining any such safe or other property shall be the sole responsibility and expense of Tenant. 

  
 - 1 - 

 5. No furniture, packages, supplies, equipment or merchandise will be received in the
Building or carried up or down in the elevators, except between such hours, in such specific elevator and by such personnel as shall be designated by Landlord. 

6. The requirements of Tenant will be attended to only upon application at the management office for the Building or at such office location
designated by Landlord. Employees of Landlord shall not perform any work or do anything outside their regular duties unless under special instructions from Landlord. 

7. No sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by Tenant on any part of the Premises or the
Building without the prior written consent of the Landlord. Tenant shall not disturb, solicit, peddle, or canvass any occupant of the Building and shall cooperate with Landlord and its agents of Landlord to prevent same. 

8. The lavatories, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed,
and no foreign substance of any kind whatsoever shall be thrown therein. The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the tenant who, or whose servants, employees, agents, visitors or
licensees shall have caused same. 
 9. Tenant shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into
the partitions, woodwork or drywall or in any way deface the Premises or any part thereof without Landlord’s prior written consent. 

10. Except for vending machines intended for the sole use of Tenant’s employees and invitees, no vending machine or machines other than
fractional horsepower office machines shall be installed, maintained or operated upon the Premises without the written consent of Landlord. 

11. Tenant shall not use or keep in or on the Premises or the Building any kerosene, gasoline, explosive material, corrosive material,
material capable of emitting toxic fumes, or other inflammable or combustible fluid chemical, substitute or material. Tenant shall provide material safety data sheets for any Hazardous Substance used or kept on the Premises. 

12. Tenant shall not without the prior written consent of Landlord use any method of heating or air conditioning other than that supplied by
Landlord. 
 13. Tenant shall not use, keep or permit to be used or kept, any foul or noxious gas or substance in or on the Premises, or
permit or allow the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Building by reason of noise, odors, or vibrations, or interfere with other tenants or those having business therein,
whether by the use of any musical instrument, radio, phonograph, or in any other way. Tenant shall not throw anything out of doors, windows or skylights or down passageways. 

  
 - 2 - 

 14. Tenant shall not bring into or keep within the Building or the Premises any animals,
birds, aquariums, or, except in areas designated by Landlord, bicycles or other vehicles. 
 15. No cooking shall be done or permitted on
the Premises, nor shall the Premises be used for the storage of merchandise, for lodging or for any improper, objectionable or immoral purposes. Notwithstanding the foregoing, Underwriters’ laboratory-approved equipment and microwave ovens may
be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages for employees and visitors, provided that such use is in accordance with all applicable federal, state, county and city laws, codes, ordinances,
rules and regulations. 
 16. The Premises shall not be used for manufacturing or for the storage of merchandise except as such storage may
be incidental to the use of the Premises provided for in the Basic Lease Information. Tenant shall not occupy or permit any portion of the Premises to be occupied as an office for a messenger-type operation or dispatch office, public stenographer or
typist, or for the manufacture or sale of liquor, narcotics, or tobacco in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau without the express prior written consent of Landlord. Tenant shall not engage
or pay any employees on the Premises except those actually working for such tenant on the Premises nor advertise for laborers giving an address at the Premises. 

17. Landlord reserves the right to exclude or expel from the Building any person who, in the judgment of Landlord, is intoxicated or under the
influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations. 
 18. Tenant, its
employees and agents shall not loiter in or on the entrances, corridors, sidewalks, lobbies, courts, halls, stairways, elevators, vestibules or any Common Areas for the purpose of smoking tobacco products or for any other purpose, nor in any way
obstruct such areas, and shall use them only as a means of ingress and egress for the Premises. 
 19. Tenant shall not waste electricity,
water or air conditioning and agrees to cooperate fully with Landlord to ensure the most effective operation of the Building’s heating and air conditioning system, and shall refrain from attempting to adjust any controls. Tenant shall
participate in recycling programs undertaken by Landlord. 
 20. Tenant shall comply with all safety, fire protection and evacuation
procedures and regulations established by Landlord or any governmental agency. 
 21. Any persons employed by Tenant to do janitorial work
shall be subject to the prior written approval of Landlord, and while in the Building and outside of the Premises, shall be subject to and under the control and direction of the Building manager (but not as an agent or servant of such manager or of
Landlord), and Tenant shall be responsible for all acts of such persons. 
 22. No awnings or other projection shall be attached to the
outside walls of the Building without the prior written consent of Landlord, and no curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord standard
window covering. All electrical ceiling fixtures hung in the Premises or spaces along the perimeter of the Building must be fluorescent and/or of a 

  
 - 3 - 

 
quality, type, design and a warm white bulb color approved in advance in writing by Landlord. Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without the
prior written consent of Landlord. Tenant shall be responsible for any damage to the window film on the exterior windows of the Premises and shall promptly repair any such damage at Tenant’s sole cost and expense. Tenant shall keep its window
coverings closed during any period of the day when the sun is shining directly on the windows of the Premises. Prior to leaving the Premises for the day, Tenant shall draw or lower window coverings and extinguish all lights. Tenant shall abide by
Landlord’s regulations concerning the opening and closing of window coverings which are attached to the windows in the Premises, if any, which have a view of any interior portion of the Building or Common Areas. 

23. The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into the halls, passageways or other public
places in the Building shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed on the windowsills. 

24. Tenant must comply with requests by the Landlord concerning the informing of their employees of items of importance to the Landlord. 

25. Tenant must comply with all applicable “NO-SMOKING” and sorting of recyclable
waste or similar ordinances. If Tenant is required under the ordinance to adopt a written smoking policy, a copy of said policy shall be on file in the office of the Building. 

26. Tenant hereby assumes all responsibility for the protection of Tenant and its officers, partners, contractors, subcontractors,
consultants, licensees, agents, concessionaires, subtenants, servants, employees, customers, guests, invitees or visitors, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises
closed, whether or not Landlord, at its option, elects to provide security protection for the Building or any portion thereof. Tenant further assumes the risk that any safety and security devices, services and programs which Landlord elects, in its
sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage to the
extent Tenant desires protection against losses related to such occurrences. Tenant shall cooperate in any reasonable safety or security program developed by Landlord or required by law. 

27. All office equipment of any electrical or mechanical nature shall be placed by Tenant in the Premises in settings approved by Landlord, to
absorb or prevent any vibration, noise and annoyance. 
 28. Tenant shall not use in any space or in the public halls of the Building any
hand trucks except those equipped with rubber tires and rubber side guards. 
 29. No auction, liquidation, fire sale, going-out-of-business or bankruptcy sale shall be conducted in the Premises without the prior written consent of Landlord. 

30. No tenant shall use or permit the use of any portion of the Premises or the Building for living quarters, sleeping apartments or lodging
rooms. 

  
 - 4 - 

 31. Tenant shall not purchase spring water, ice, towels, janitorial or maintenance or other
similar services from any company or persons not approved by Landlord. Landlord shall approve a sufficient number of sources of such services to provide Tenant with a reasonable selection, but only in such instances and to such extent as Landlord in
its judgment shall consider consistent with the security and proper operation of the Building. 
 32. Tenant shall install and maintain, at
Tenant’s sole cost and expense, an adequate, visibly marked and properly operational fire extinguisher next to any duplicating or photocopying machines or similar heat producing equipment, which may or may not contain combustible material, in
the Premises. 
 Landlord reserves the right at any time upon written notice to Tenant to change or rescind any one or more of these Rules
and Regulations, or to make such other and further reasonable Rules and Regulations as in Landlord’s judgment may from time to time be necessary for the management, safety, care and cleanliness of the Premises, Building, and the Common Areas,
and for the preservation of good order therein, as well as for the convenience of other occupants and tenants therein. Notwithstanding the foregoing, no such change or rescission of these Rules and Regulations, nor new Rule and Regulations that
would increase Tenant’s obligations, materially adversely impact Tenant rights, or impede or materially restrict Tenant’s access to or use of Common Areas or other facilities and amenities that are material to Tenant’s use and
occupancy of the Premises shall not be enforceable on Tenant without its prior written approval. Landlord may waive, in limited circumstances, any one or more of these Rules and Regulations for the benefit of any particular tenants, but no such
waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules or Regulations against any or all tenants of the Building. Landlord shall not
be liable to Tenant for violation of the Rules and Regulations by any other tenant. Tenant shall be deemed to have read these Rules and Regulations and to have agreed to abide by them as a condition of its occupancy of the Premises. 

  
 - 5 - 

 EXHIBIT C 

WORK LETTER 
 As
used in this Work Letter, the “Premises” shall be deemed to mean the Premises, as initially defined in the attached Lease. 
  

	1.	 This Work Letter shall set forth the obligations of Landlord and Tenant with respect to the initial
improvements to be performed with respect to the Premises for Tenant’s use. 

  

	2.	 All improvements described in this Work Letter to be constructed in and upon the Premises by Tenant are
hereinafter referred to as the “Tenant Work”. It is agreed that construction of the Tenant Work will be completed at Tenant’s sole cost and expense (subject to Landlord’s obligation with respect to the Tenant Allowance as
hereinafter defined) and in accordance with the requirements set forth herein. 

  

	3.	 Tenant Work shall be done in a good and workmanlike manner in compliance with all applicable Laws and insurance
requirements. Tenant will cause the Tenant Work to be performed in accordance with the construction standard procedures and specifications for the Building and using materials and finishes currently in quality at least equal to the quality
designated by Landlord as the minimum standard for the Building. 

  

	4.	 Tenant, following the delivery of the Premises by Landlord and the full and final execution and delivery of the
Lease to which this Exhibit is attached, shall have the right to perform the Tenant Work. Notwithstanding the foregoing, Tenant and its contractors shall not have the right to perform the Tenant Work in the Premises unless and until Tenant has
complied with all of the terms and conditions of Section 9.C of the Lease including, without limitation, approval by Landlord (not to be unreasonably withheld or delayed) of the final plans for the Tenant Work and the contractors to be retained
by Tenant to perform the Tenant Work. Tenant shall be responsible for all elements of the design of Tenant’s plans (including, without limitation, compliance with Law, functionality of design, the structural integrity of the design, the
configuration of the Premises and the placement of Tenant’s furniture, appliances and equipment), and Landlord’s approval of Tenant’s plans shall in no event relieve Tenant of the responsibility for such design. Landlord’s
approval of the contractors to perform the Tenant Work shall not be unreasonably withheld, conditioned or delayed. Landlord hereby approves The Richmond Company (“Approved Contractor”) as Tenant’s general contractor for the
performance of the Tenant’s Work, provided that the Approved Contractor employs union labor. The parties agree that if Tenant does not use the Approved Contractor, Landlord’s approval of any other general contractor to perform the Tenant
Work shall not be considered to be unreasonably withheld if any such other general contractor (i) does not provide, on request of Landlord, trade references reasonably acceptable to Landlord, (ii) does not maintain insurance as reasonably
required by Landlord, or (iii) is not licensed as a contractor in the state/municipality in which the Premises is located. Tenant acknowledges the foregoing is not intended to be an exclusive list of the reasons why Landlord may reasonably
withhold its consent to a general contractor. Tenant will be responsible for Landlord’s out-of-pocket fees in approving Tenant’s plans and specifications and
Tenant’s contractors. 

  
 -1- 

	5.	 Provided an Event of Default by Tenant does not then exist (in which case, Landlord shall have the right to
withhold disbursement of the amount requested until such Event of Default is cured or otherwise resolved to Landlord’s satisfaction), Landlord agrees to contribute the sum of $574,300.00 ($50.00 per Rentable Square Footage of the Premises) for
the Tenant Work (the “Tenant Allowance”). The Tenant Allowance shall be used for the cost of the following in connection with the Tenant Work in and for the Premises: hard costs, including, without limitation, all labor and materials
costs, construction costs, and project or construction management fees (the “Construction Allowance”) and not more than 20% of the Tenant Allowance may be used for Soft Costs (as hereinafter defined). Soft Costs shall include
(i) engineering and architectural fees, including, without limitation, for the preparation of space plans and layout plans, and of any other plans and/or specifications of the Premises, and for consultation in the design of the Premises
(collectively, “Design Fees”); (ii) Cable and Tenant’s security system; (iii) filing fees and costs incurred in obtaining a building permit, zoning permits, or other governmental permits and approvals necessary to perform the
Tenant Work, and any legal and/or consultant fees incurred in connection with seeking same (“Permitting Costs”); (iv) costs and expenses in relocating Tenant’s business and operations to the Premises, including, without limitation,
the cost of moving Tenant’s furniture, fixtures, equipment and other personal property and (where applicable) installing them in the Premises and/or (v) as an offset against Rent. The Construction Allowance shall be paid to Tenant or, at
Tenant’s option, to the order of the general contractor that performs the Tenant Work, in periodic disbursements within twenty-five (25) days after receipt of the following documentation: (i) contractor’s, subcontractor’s
and material supplier’s waivers of liens (or conditional waivers of liens) which shall cover all Tenant Work for which disbursement is being requested and all other statements and forms required for compliance with the mechanics’ lien Laws
of the Commonwealth of Massachusetts, together with all such invoices, contracts, or other supporting data as Landlord may reasonably require; and (ii) a cost breakdown for each trade or subcontractor performing the Tenant Work. Notwithstanding
of the foregoing, at such time as the aggregate disbursements reach 95% of the Construction Allowance, the final 5% of the Construction Allowance (the “Residue”) shall be held until the conditions for the Final Disbursement (defined below)
have been satisfied. Upon completion of the Tenant Work, and prior to final disbursement of the Residue of Construction Allowance (the “Final Disbursement”), Tenant shall furnish Landlord with: (1) general contractor and
architect’s completion affidavits, (2) full and final waivers of lien, (3) receipted bills covering all labor and materials expended and used, (4) as-built plans of the Tenant Work (if the
Tenant Work has involved installation or relocation of any walls within the Premises), and (5) the certification of Tenant’s architect that the Tenant Work has been installed in a good and workmanlike manner in accordance with the approved
plans. In no event shall Landlord be required to disburse the Construction Allowance more than one time per month. If the construction costs for the Tenant Work are estimated to exceed the Construction Allowance, Tenant shall be entitled to the
Construction Allowance in accordance with the terms hereof, but each individual disbursement of the Construction Allowance shall be disbursed in the proportion that the Construction Allowance bears to the total estimated construction costs for the
Tenant Work (subject to holding of the final 5% Residue, as referenced above). By way of example and without limiting the generality of the foregoing, if the estimated construction costs for the Tenant Work are $650,000.00, then each individual
disbursement of the Construction Allowance for the Premises shall be $574,300/$650,000 or 88.35% of each contractor’s invoice (subject to holding the final 5% Residue referenced above). 

 

	6.	 Any portion of the Tenant Allowance for which reimbursement is sought otherwise remaining after
December 1, 2018 (“Unused Allowance”) shall accrue to the sole benefit of Landlord, it being agreed that Tenant shall not be entitled to any credit, offset, abatement or payment with respect thereto. 

  
 -2- 

	7.	 This Exhibit shall not be deemed applicable to any additional space added to the Premises at any time or from
time to time, whether by any options under the Lease or otherwise, or to any portion of the original Premises or any additions to the Premises in the event of a renewal or extension of the original Term of the Lease, whether by any options under the
Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement to the Lease. 

  
 -3- 

 EXHIBIT C-1 

200 STATE STREET 

BOSTON, MASSACHUSETTS 

COMMENCEMENT DATE LETTER 
 Date:
                                         
              
 Tenant
                                         
            
 Address:
                                         
         
  

	 	Re:	 Office Lease dated October    _____, 2016 between GLL 200 State Street,
L.P., a Delaware limited partnership (“Landlord”), and Centrexion Therapeutics Corporation, a Delaware corporation (“Tenant”), concerning premises on the 6th floor of the office building located at 200 State Street, Boston, Massachusetts (the “Lease”) 

Gentlemen: 
 In accordance with
the terms and conditions of the Lease, Tenant agrees as follows: 
 The Commencement Date of the Lease is __________. 

The Rent Commencement Date of the Lease is
                         

The First Lease Year expires on
                         

The Termination Date of the Lease is
                        , subject to extension in accordance with the Extension Option. 

 

			
	“Landlord”:
	
	GLL 200 State Street, L.P., a Delaware limited partnership
	By:	 	GLL 200 State Street Corp., its general partner
		
	By:	 	 
		 	Edward Rime, Vice President

  

			
	Agreed to and Accepted as of                     , 2017. “Tenant”:
	
	Centrexion Therapeutics Corporation a Delaware corporation

			
		
	By:	 	 
		 	

  
 - 1 - 

 EXHIBIT D 

Letter of Credit Form 
 IRREVOCABLE STANDBY
LETTER OF CREDIT NUMBER                     

ISSUE DATE:                      

ISSUING BANK: 
 SILICON VALLEY BANK 

3003 TASMAN DRIVE 
 2ND FLOOR, MAIL SORT HF210 

SANTA CLARA, CALIFORNIA 95054 
 BENEFICIARY: 

GLL 200 STATE STREET, L.P. 
 200 SOUTH ORANGE AVENUE 

SUITE 1375 
 ORLANDO, FLORIDA 32801 

USA 
 DEAR SIR/MADAM: 

BY ORDER OF OUR CLIENT, CENTREXION THERAPETICS CORPORATION (THE “APPLICANT”), WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO.
SVBSF        IN YOUR FAVOR AVAILABLE BY YOUR DRAFTS DRAWN ON US AT SIGHT IN THE FORM OF EXHIBIT “A” ATTACHED AND ACCOMPANIED BY THE FOLLOWING DOCUMENTS: 

 

	1.	 THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY. 

 

	2.	 BENEFICIARY’S DATED AND SIGNED STATEMENT, STATING AS FOLLOWS: 

“BENEFICIARY IS ENTITLED TO THE AMOUNT OF THE SIGHT DRAFT PURSUANT TO A LEASE DATED
            , 2016 BY AND BETWEEN BENEFICIARY, AS LANDLORD, AND THE APPLICANT, AS TENANT, RELATING TO SPACE ON THE 6TH FLOOR OF THE OFFICE BUILDING AT 200 STATE STREET IN BOSTON,
MASSACHUSETTS, USA.” 
 PARTIAL DRAWS AND MULTIPLE PRESENTATIONS ARE ALLOWED. IN THE EVENT YOU ELECT TO DRAW UPON LESS THAN THE FULL STATED AMOUNT
HEREOF, THE STATED AMOUNT OF THIS IRREVOCABLE STANDBY LETTER OF CREDIT SHALL BE AUTOMATICALLY REDUCED BY THE AMOUNT OF SUCH PARTIAL DRAW. 
 THIS LETTER OF
CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT, FROM THE PRESENT OR EACH FUTURE EXPIRATION DATE UNLESS AT LEAST 30 DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE SEND YOU A NOTICE BY REGISTERED MAIL
OR OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESS (OR ANY OTHER ADDRESS INDICATED BY YOU, IN A WRITTEN NOTICE TO US THE RECIEPT OF WHICH WE HAVE ACKNOWLEDGED, AS THE ADDRESS TO WHICH WE SHOULD SEND SUCH NOTICE)THAT THIS LETTER OF CREDIT WILL NOT BE
EXTENDED BEYOND THE CURRENT EXPIRATION DATE. IN NO EVENT SHALL THIS LETTER OF CREDIT BE AUTOMATICALLY EXTENDED BEYOND JULY 15, 2024 WHICH IS THE FINAL EXPIRATION DATE OF THIS LETTER OF CREDIT. UPON RECEIPT OF SUCH NOTICE YOU MAY DRAW YOUR SIGHT
DRAFTS ON US, IN THE FORM ATTACHED HERETO AS 

  
 -5- 

 
EXHIBIT “A”, FOR THE AVAILABLE AMOUNT UNDER THIS STANDBY LETTER OF CREDIT ACCOMPANIED BY YOUR DATED AND SIGNED STATEMENT, STATING AS FOLLOWS: 

“WE ARE IN RECEIPT OF YOUR NOTICE THAT YOU HAVE ELECTED NOT TO EXTEND SILICON VALLEY BANK IRREVOCABLE STANDBY LETTER OF CREDIT NO.
SVBSFO          AND THE UNDERLYING OBLIGATION REMAINS OUTSTANDING.” 
 THIS LETTER OF CREDIT IS
TRANSFERABLE ONE OR MORE TIMES, BUT IN EACH INSTANCE ONLY TO A SINGLE BENEFICIARY AS TRANSFEREE AND ONLY UP TO THE THEN AVAILABLE AMOUNT, ASSUMING SUCH TRANSFER TO SUCH TRANSFEREE WOULD BE IN COMPLIANCE WITH THEN APPLICABLE LAW AND REGULATION,
INCLUDING BUT NOT LIMITED TO THE REGULATIONS OF THE U. S. DEPARTMENT OF TREASURY AND U. S. DEPARTMENT OF COMMERCE. AT THE TIME OF TRANSFER, THE ORIGINAL LETTER OF CREDIT AND ORIGINAL AMENDMENT(S), IF ANY, MUST BE SURRENDERED TO US AT OUR ADDRESS
INDICATED IN THIS LETTER OF CREDIT TOGETHER WITH OUR TRANSFER FORM ATTACHED HERETO AS EXHIBIT “B” DULY EXECUTED. THE CORRECTNESS OF THE SIGNATURE AND TITLE OF THE PERSON SIGNING THE TRANSFER FORM MUST BE VERIFIED BY BENEFICIARY’S
BANK. APPLICANT SHALL PAY OUR TRANSFER FEE OF  1⁄4 OF 1% OF THE TRANSFER AMOUNT (MINIMUM US$250.00) UNDER THIS LETTER OF CREDIT. EACH TRANSFER SHALL BE
EVIDENCED BY OUR ENDORSEMENT ON THE REVERSE OF THE LETTER OF CREDIT AND WE SHALL FORWARD THE ORIGINAL OF THE LETTER OF CREDIT SO ENDORSED TO THE TRANSFEREE. 

DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT. 

ALL DEMANDS FOR PAYMENT SHALL BE MADE EITHER IN PERSON OR BY OVERNIGHT COURIER BY PRESENTATION OF THE ORIGINAL APPROPRIATE DOCUMENTS DURING
REGULAR BUSINESS HOURS ON A BUSINESS DAY AT OUR OFFICE (THE “BANK’S OFFICE”) AT: SILICON VALLEY BANK, 3003 TASMAN DRIVE, MAIL SORT HF210, SANTA CLARA, CALIFORNIA 95054, ATTENTION: GLOBAL FINANCIAL SERVICES—STANDBY LETTER OF
CREDIT DEPARTMENT; OR BY FACSIMILE TRANSMISSION AT: (408) 969-6510 OR (408) 496-2418 AND SIMULTANEOUSLY UNDER TELEPHONE ADVICE TO: (408)
654-6274 OR (408) 654-7716, ATTENTION: STANDBY LETTER OF CREDIT NEGOTIATION DEPARTMENT WITH ORIGINALS TO FOLLOW BY OVERNIGHT COURIER SERVICE, PROVIDED, HOWEVER, THAT
DELIVERY OF SUCH ORIGINALS AND THE ABSENCE OF SUCH TELEPHONE ADVICE SHALL NOT BE A CONDITION TO THE EFFECTIVENESS OF THE DRAW AND THE BANK WILL DETERMINE TO HONOR OR DISHONOR ON THE BASIS OF PRESENTATION BY FACSIMILE ALONE, AND WILL NOT EXAMINE THE
ORIGINALS. 
 PAYMENT AGAINST CONFORMING PRESENTATIONS HEREUNDER PRIOR TO 10:00 A.M. CALIFORNIA TIME, ON A BUSINESS DAY SHALL BE MADE BY BANK DURING NORMAL
BUSINESS HOURS OF THE BANK’S OFFICE ON THE NEXT SUCCEEDING BUSINESS DAY. PAYMENT AGAINST CONFORMING PRESENTATIONS HEREUNDER AFTER 10:00 A.M. CALIFORNIA TIME, ON A BUSINESS DAY SHALL BE MADE BY BANK DURING NORMAL BUSINESS HOURS OF THE
BANK’S OFFICE ON THE SECOND SUCCEEDING BUSINESS DAY. 
 WE HEREBY AGREE WITH THE BENEFICIARY THAT THE DRAFTS DRAWN UNDER AND IN ACCORDANCE WITH THE
TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO US ON OR BEFORE THE EXPIRATION DATE OF THIS LETTER OF CREDIT. 
 IF
ANY INSTRUCTIONS ACCOMPANYING A DRAWING UNDER THIS LETTER OF CREDIT REQUEST THAT PAYMENT IS TO BE MADE BY TRANSFER TO YOUR ACCOUNT WITH ANOTHER BANK, WE WILL ONLY EFFECT SUCH PAYMENT BY FED WIRE TO A U.S. REGULATED BANK, AND WE AND/OR SUCH OTHER
BANK MAY RELY ON AN ACCOUNT NUMBER SPECIFIED IN SUCH INSTRUCTIONS EVEN IF THE NUMBER IDENTIFIES A PERSON OR ENTITY DIFFERENT FROM THE INTENDED PAYEE. 

  
 -6- 

 THIS LETTER OF CREDIT IS SUBJECT TO THE INTERNATIONAL STANDBY PRACTICES ISP98, INTERNATIONAL CHAMBER OF
COMMERCE, PUBLICATION NO. 590 (“ISP98”), AND AS TO MATTERS NOT ADDRESSED BY THE ISP98, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF MASSACHUSETTS. 

 

			
	(BANK USE ONLY)	  	(BANK USE ONLY)
		
	                                      
                      	  	                                      
                      
	AUTHORIZED SIGNATURE	  	AUTHORIZED SIGNATURE

  
 -7- 

 EXHIBIT “A” [To Letter of Credit] 

 

					
	 	 	 
	 DATE:
                                         
       
	  		  	REF. NO.
                                        

	 		 
	 AT SIGHT OF THIS DRAFT
	  		  	 
	 
	
PAY TO THE ORDER
OF                                        
                                         
           
US$                                        
                    

	 
	
USDOLLARS
                                         
                                         
                                         
                                         
            

	 
	
                      
                                         
                                         
                                         
                                         
              

	 
	
DRAWN UNDER SILICON VALLEY BANK, SANTA CLARA, CALIFORNIA, STANDBY

LETTER OF CREDIT NUMBER NO.
                                         
   DATED                                    
                

	 	  		  	 
	 		 
	 TO: SILICON VALLEY BANK

        3003TASMAN DRIVE

        SANTACLARA, CA 95054
	  		  	 
	 	  		  	(BENEFICIARY’S NAME)
	 		 
	 	  		  	 
	 	  	 	  	 Authorized Signature

 

 GUIDELINES TO PREPARE THE DRAFT 

 

	1.	 DATE: ISSUANCE DATE OF DRAFT. 

 

	2.	 REF. NO.: BENEFICIARY’S REFERENCE NUMBER, IF ANY. 

 

	3.	 PAY TO THE ORDER OF: NAME OF BENEFICIARY AS INDICATED IN THE L/C (MAKE SURE BENEFICIARY ENDORSES IT ON THE
REVERSE SIDE). 

  

	4.	 US$: AMOUNT OF DRAWING IN FIGURES. 

 

	5.	 USDOLLARS: AMOUNT OF DRAWING IN WORDS. 

 

	6.	 LETTER OF CREDIT NUMBER: SILICON VALLEY BANK’S STANDBY L/C NUMBER THAT PERTAINS TO THE DRAWING.

  

	7.	 DATED: ISSUANCE DATE OF THE STANDBY L/C. 

 

	8.	 BENEFICIARY’S NAME: NAME OF BENEFICIARY AS INDICATED IN THE L/C. 

 

	9.	 AUTHORIZED SIGNATURE: SIGNED BY AN AUTHORIZED SIGNER OF BENEFICIARY. 

IF YOU HAVE QUESTIONS RELATED TO THIS STANDBY LETTER OF CREDIT PLEASE CONTACT US AT
                    . 

  
 -8- 

 EXHIBIT “B” [To Letter of Credit] 

TRANSFER FORM 

DATE:                     

 

	TO:	 SILICON VALLEY BANK 

3003 TASMAN DRIVE    RE: IRREVOCABLE STANDBY LETTER OF CREDIT 

SANTA CLARA, CA 95054    
NO.                 ISSUED BY SILICON VALLEY 
 BANK,
ATTN:INTERNATIONAL DIVISION. 
 STANDBY LETTERS OF CREDIT        L/C
AMOUNT:                     
 GENTLEMEN: 

FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO: 
  

			
	 	  	
	(NAME OF TRANSFEREE)	  	
	 	  	
	(ADDRESS)	  	

 ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE
AS OF THE DATE OF THIS TRANSFER. 
 BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE.
TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED
DIRECTLY TO THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY. 
 THE ORIGINAL OF SUCH LETTER OF CREDIT IS
RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER. 
  

					
	 SIGNATURE AUTHENTICATED
 The names(s),
title(s), and signature(s) conform to that/those on file with us for the company and the signature(s) is/are authorized to execute this instrument.
	  	  

(BENEFICIARY’S NAME)

By:                         
                       
	  	
			
	      

(Name of Bank)
	  	Printed Name:                                   
 	  	
			
	      

(Address of Bank)
	  	
Title:                  
                              
	  	
			
	      

(City, State, Zip Code)
	  		  	
			
	      

(Print Authorized Name and Title)
	  		  	
			
	      

(Authorized Signature)
	  		  	
			
	      

(Telephone Number)
	  		  	

  
 -9- 

 EXHIBIT E 

200 STATE STREET 
 BOSTON,
MASSACHUSETTS 
 JANITORIAL SPECIFICATIONS 

OFFICE AREA 
  

	Daily:	 (Monday through Friday, inclusive, Holidays excepted) 

 

	1.	 Empty all waste receptacles and recycling receptacles in individual offices and cubicles, and return to proper
locations with liners. 

  

	2.	 Sweep and dust mop all uncarpeted areas. 

 

	3.	 Vacuum all rugs and carpeted areas. 

 

	4.	 Dust all horizontal surfaces or furniture and equipment within normal reach. 

 

	5.	 Clean and sanitize all drinking fountains and water coolers. 

 

	6.	 Remove fingermarks from glass doors. 

 

	7.	 Wipe clean all brass and other metal surfaces within normal reach. 

 

	8.	 All lights turned off and doors locked after cleaning. 

 

	9.	 Dust and wipe down all kitchenette countertops. Sweep and mop all kitchenette floors. 

Monthly: 
  

	1.	 Remove all fingermarks from doors, door jambs, and light switches, 

 

	2.	 Edge vacuum all edges in office areas. 

Quarterly: 
  

	1.	 Dust all pictures, frames, chart boards and similar wall hangings. 

 

	2.	 Dust all surfaces not reached in daily cleaning. 

  
 -1- 

 LAVATORIES 
  

	Daily:	 (Monday through Friday, inclusive, Holidays excepted) 

 

	1.	 Sweep and mop floors. 

 

	2.	 Clean and sanitize all floors, toilet seats, bowls, urinals and fixtures. 

 

	3.	 Clean all mirrors and shelves. 

 

	4.	 Refill dispensers, soap dispensers, tissue/toilet paper/paper towel holders; and sanitary napkin and tampon
dispensers, materials to be furnished by Landlord 

  

	5.	 Empty paper towel receptacles and replace liners as needed. 

 

	6.	 Dust all partitions. 

Monthly: 
  

	1.	 Wash all partitions, dispensers, and splash areas. 

 

	2.	 Dust all light fixtures and ventilating grilles. 

 

	3.	 Machine scrub lavatory floors. 

Quarterly: 
  

	1.	 Wash all tile walls and partitions. 

EXTERIOR WINDOWS 
  

	1.	 Window washing services in a manner consistent with other comparable buildings in downtown Boston, but no less
than twice annually. 

  
 -2- 

 EXHIBIT F 

ADDITIONAL PROVISIONS 
  

	1.	 EXTENSION OPTION. 

 

	 	A.	 Grant of Option; Conditions. Tenant shall have the right to extend the Term (the “Extension
Option”) for one additional period of 5 years commencing on the day following the expiration of the initial Term and ending on the 5th anniversary of the original Termination Date (the
“Extension Term”), if: 

  

	 	1.	 Landlord receives notice of exercise (“Initial Extension Notice”) not less than 12 full calendar
months prior to the expiration of the initial Term and not more than 15 full calendar months prior to the expiration of the initial Term; and 

  

	 	2.	 No Event of Default by Tenant exists under the Lease at the time that Tenant delivers its Initial Extension
Notice or at the time Tenant delivers its Binding Notice (as defined below); and 

  

	 	3.	 No part of the Premises is sublet without Landlord’s consent (other than pursuant to a Permitted Transfer
as defined in Section 12.E of the Lease) at the time that Tenant delivers its Initial Extension Notice or at the time Tenant delivers its Binding Notice; and 

 

	 	4.	 The Lease has not been assigned except with Landlord’s consent (or except pursuant to a Permitted Transfer
as defined in Section 12.E of the Lease), prior to the date that Tenant delivers its Initial Extension Notice or prior to the date Tenant delivers its Binding Notice. 

 

	 	B.	 Terms Applicable to Premises During Extension Term. 

 

	 	1.	 The initial Base Rent rate per rentable square foot for the Premises during the Extension Term shall equal the
Prevailing Market (hereinafter defined) rate per rentable square foot for the Premises. Base Rent during the Extension Term shall increase, if at all, in accordance with the increases assumed in the determination of Prevailing Market rate. Base Rent
attributable to the Premises shall be payable in monthly installments in accordance with the terms and conditions of Article 4 of the Lease. 

  

	 	2.	 Tenant shall pay Additional Rent (i.e. Tenant’s Pro Rata Share of Tax Excess and Expense Excess) for the
Premises during the Extension Term in accordance with Article 4 of the Lease, provided that the Base Years for Taxes and Expenses shall be adjusted to the then current Fiscal Year and calendar year, respectively, such adjustment to be among the
factors considered in determining the Prevailing Market rate for the Extension Term. 

  
 -1- 

	 	C.	 Initial Procedure for Determining Prevailing Market. Within 30 days after receipt of Tenant’s
Initial Extension Notice, Landlord shall advise Tenant of the applicable Base Rent rate for the Premises for the Extension Term. Tenant, within 15 Business Days after the date on which Landlord advises Tenant of the applicable Base Rent rate for the
Extension Term, shall either (i) give Landlord final binding written notice (“Binding Notice”) of Tenant’s exercise of its Extension Option, or (ii) if Tenant disagrees with Landlord’s determination, provide Landlord
with written notice of rejection (the “Rejection Notice”). If Tenant fails to provide Landlord with either a Binding Notice or Rejection Notice within such 15 Business Days period, Tenant’s Extension Option shall be null and void and
of no further force and effect. If Tenant provides Landlord with a Binding Notice, Landlord and Tenant shall enter into the Extension Amendment (as defined below) upon the terms and conditions set forth herein within 15 Business Days thereafter. If
Tenant provides Landlord with a Rejection Notice, Landlord and Tenant shall work together in good faith to agree upon the Prevailing Market rate for the Premises during the Extension Term. When Landlord and Tenant have agreed upon the Prevailing
Market rate for the Premises, such agreement shall be reflected in a written agreement between Landlord and Tenant, whether in a letter or otherwise, and Landlord and Tenant shall enter into the Extension Amendment in accordance with the terms and
conditions hereof. Notwithstanding the foregoing, if Landlord and Tenant are unable to agree upon the Prevailing Market rate for the Premises within 30 days after the date Tenant provides Landlord with the Rejection Notice, Tenant, by written notice
to Landlord (the “Arbitration Notice”) within 5 Business Days after the expiration of such 30 day period, shall have the right to have the Prevailing Market rate determined in accordance with the arbitration procedures described in Section
D below. If Landlord and Tenant are unable to agree upon the Prevailing Market rate for the Premises within the 30 day period described above and Tenant fails to timely exercise its right to arbitrate, Tenant’s Extension Option shall be deemed
to be null and void and of no further force and effect. 

  

	 	D.	 Arbitration Procedure. 

 

	 	1.	 If Tenant provides Landlord with an Arbitration Notice, Landlord and Tenant, within 10 Business Days after the
date of the Arbitration Notice, shall each simultaneously submit to the other, in a sealed envelope, its good faith estimate of the Prevailing Market rate for the Premises during the Extension Term (collectively referred to as the
“Estimates”). If the higher of such Estimates is not more than 105% of the lower of such Estimates, then Prevailing Market rate shall be the average of the two Estimates. If the Prevailing Market rate is not resolved by the exchange of
Estimates, then, within 7 days after the exchange of Estimates, Landlord and Tenant shall each select an appraiser to determine which of the two Estimates most closely reflects the Prevailing Market rate for the Premises during the Extension Term.
Each appraiser so selected shall be certified as an MAI appraiser or as an ASA appraiser and shall have had at least 5 years experience within the previous 10 years as a real estate appraiser working in the financial district of downtown Boston,
Massachusetts, with working knowledge of current rental rates and practices. For purposes hereof, an “MAI” appraiser means an individual who holds an MAI designation conferred by, and is an independent

  
 -2- 

	 	
member of, the American Institute of Real Estate Appraisers (or its successor organization, or in the event there is no successor organization, the organization and designation most similar), and
an “ASA” appraiser means an individual who holds the Senior Member designation conferred by, and is an independent member of, the American Society of Appraisers (or its successor organization, or, in the event there is no successor
organization, the organization and designation most similar). 

  

	 	2.	 Upon selection, Landlord’s and Tenant’s appraisers shall work together in good faith to agree upon
which of the two Estimates most closely reflects the Prevailing Market rate for the Premises. The Estimate chosen by such appraisers shall be binding on both Landlord and Tenant as the Base Rent rate for the Premises during the Extension Term. If
either Landlord or Tenant fails to appoint an appraiser within the 7 day period referred to above, the appraiser appointed by the other party shall be the sole appraiser for the purposes hereof. If the two appraisers cannot agree upon which of the
two Estimates most closely reflects the Prevailing Market rate within 20 days after their appointment, then, within 10 days after the expiration of such 20 day period, the two appraisers shall select a third appraiser meeting the aforementioned
criteria. Once the third appraiser (i.e. arbitrator) has been selected as provided for above, then, as soon thereafter as practicable but in any case within 14 days, the arbitrator shall make his determination of which of the two Estimates most
closely reflects the Prevailing Market rate and such Estimate shall be binding on both Landlord and Tenant as the Base Rent rate for the Premises. If the arbitrator believes that expert advice would materially assist him, he may retain one or more
qualified persons to provide such expert advice. The parties shall share equally in the costs of the arbitrator and of any experts retained by the arbitrator. Any fees of any appraiser, counsel or experts engaged directly by Landlord or Tenant,
however, shall be borne by the party retaining such appraiser, counsel or expert. 

  

	 	3.	 If the Prevailing Market rate has not been determined by the commencement date of the Extension Term, Tenant
shall pay Base Rent upon the terms and conditions in effect during the last month of the initial Term for the Premises until such time as the Prevailing Market rate has been determined. Upon such determination, the Base Rent for the Premises shall
be retroactively adjusted to the commencement of the Extension Term for the Premises. If such adjustment results in an underpayment of Base Rent by Tenant, Tenant shall pay Landlord the amount of such underpayment within 30 days after the
determination thereof. If such adjustment results in an overpayment of Base Rent by Tenant, Landlord shall credit such overpayment against the next installment of Base Rent due under the Lease and, to the extent necessary, any subsequent
installments, until the entire amount of such overpayment has been credited against Base Rent. 

  
 -3- 

	 	E.	 Extension Amendment. If Tenant is entitled to and properly exercises its Extension Option, Landlord
shall prepare an amendment (the “Extension Amendment”) to reflect changes in the Base Rent, Term, Termination Date and other appropriate terms for the Extension Term and otherwise on terms and conditions consistent with this Lease. The
Extension Amendment shall be sent to Tenant within a reasonable time after Landlord’s receipt of the Binding Notice or other written agreement by Landlord and Tenant regarding the Prevailing Market rate, and Tenant shall return the Extension
Amendment to Landlord within 15 days after Tenant’s receipt of same, either executed by Tenant or with comments, but, upon final determination of the Prevailing Market rate applicable during the Extension Term as described herein, an otherwise
valid exercise of the Extension Option shall be fully effective whether or not the Extension Amendment is executed. 

  

	 	F.	 Definition of Prevailing Market. For purposes of this Extension Option, “Prevailing Market”
shall mean the arms length fair market annual rental rate per rentable square foot under leases and extension and expansion amendments entered into by private sector tenants for a comparable term on or about the date on which the Prevailing Market
is being determined hereunder for space comparable to the Premises in the Building and office buildings comparable to the Building in the financial district of downtown Boston, Massachusetts.. The determination of Prevailing Market shall take into
account all relevant factors, such as rent abatements, construction costs and other concessions and the manner, if any, in which the landlord under any relevant lease is reimbursed for operating expenses and taxes. 

 

	2.	 PARKING. 

 

	 	A.	 During the Term of the Lease, Landlord agrees to make available for lease to Tenant a total of 4 unreserved
parking spaces (the “Spaces”) in the Building garage (“Garage”) for the use of Tenant and its employees. No deductions or allowances shall be made for days when Tenant or any of its employees does not utilize the
parking facilities or for Tenant utilizing less than all of the Spaces. Tenant shall not have the right to lease or otherwise use more than the number of reserved and unreserved Spaces set forth above, but Landlord shall make additional spaces
available to Tenant on a monthly tenant-at-will basis. 

  

	 	B.	 During the Term of the Lease, Tenant shall pay Landlord, as Additional Rent in accordance with Article IV of
the Lease, the then current rate for parking in the Garage, as such rates may be adjusted from time-to-time to reflect the then current rate for parking in the Garage,
plus applicable tax thereon, if any, for each unreserved Space leased by Tenant hereunder. The current rate for parking is $520.00 per space, per month. 

  

	 	C.	 Except for particular spaces and areas designated by Landlord for reserved parking, all parking in the Garage
shall be on an unreserved, first-come, first-served basis. 

  
 -4- 

	 	D.	 Landlord shall not be responsible for money, jewelry, automobiles or other personal property lost in or stolen
from the Garage regardless of whether such loss or theft occurs when the Garage or other areas therein are locked or otherwise secured. Except as caused by the negligence or willful misconduct of Landlord, Landlord shall not be liable for any loss,
injury or damage to persons using the Garage or automobiles or other property therein, it being agreed that, to the fullest extent permitted by Law, the use of the Spaces shall be at the sole risk of Tenant and its employees. 

 

	 	E.	 Landlord shall have the right from time to time to promulgate reasonable rules and regulations regarding the
Garage, the Spaces and the use thereof, including, but not limited to, rules and regulations controlling the flow of traffic to and from various parking areas, the angle and direction of parking and the like. Tenant shall comply with and cause its
employees to comply with all such rules and regulations as well as all reasonable additions and amendments thereto. 

  

	 	F.	 Tenant shall not store or permit its employees to store any automobiles in the Garage without the prior written
consent of Landlord, which consent shall not be unreasonably withheld or delayed. Except for emergency repairs, Tenant and its employees shall not perform any work on any automobiles while located in the Garage. If it is necessary for Tenant or its
employees to leave an automobile in the Garage overnight, Tenant shall provide Landlord with prior notice thereof designating the license plate number and model of such automobile. 

 

	 	G.	 Landlord shall have the right to temporarily close the Garage or certain areas therein in order to perform
necessary repairs, maintenance and improvements to the Garage. 

  

	 	H.	 Tenant shall not assign or sublease any of the Spaces (except in connection with a Permitted Transfer, as
defined in Section 12.E of the Lease or other assignment or sublease made with the consent of Landlord) without the consent of Landlord. Landlord shall have the right to terminate Tenant’s parking rights with respect to any Spaces that
Tenant sublets or assigns in violation of the foregoing sentence. 

  

	 	I.	 Landlord may elect to provide parking cards or keys to control access to the Garage. In such event, Landlord
shall provide Tenant with one card or key for each Space that Tenant is leasing hereunder, provided that Landlord shall have the right to require Tenant or its employees to place a deposit on such access cards or keys and to pay a fee for any lost
or damaged cards or keys. 

  

	 	J.	 Landlord hereby reserves the right to enter into a management agreement or lease with an entity for the Garage
(“Garage Operator”). In such event, Tenant, upon request of Landlord, shall enter into a parking agreement with the Garage Operator and pay the Garage Operator the monthly charge established hereunder, and Landlord shall have no
liability for claims arising through acts or omissions of the Garage Operator unless caused by Landlord’s negligence or willful misconduct. It is understood and agreed that the identity of the Garage Operator may change from time to time during
the Term. In connection therewith, any parking lease or agreement entered into between Tenant and a Garage Operator shall be freely assignable by such Garage Operator or any successors thereto. 

  
 -5- 

	3.	 RIGHT OF FIRST OFFER. 

 

	 	A.	 Landlord hereby grants to Tenant the one-time option to lease, upon the
terms and conditions hereinafter set forth, any rentable space on the sixth (6th) floor of the Building (the “Offer Space”) which becomes available for leasing (as determined in
accordance with paragraph (B) below) during the Offer Period (hereinafter defined), prior to entering into a lease for such space with another party. 

  

	 	B.	 The Offer Space shall be deemed to be “available for leasing” when Landlord is prepared for
the first time only to offer to lease the Offer Space to any party other than the current occupant of the Offer Space. 

  

	 	C.	 Prior to Landlord’s marketing the Offer Space that is available for leasing during the Offer Period,
Landlord shall give Tenant a written notice (the “Offer Notice”) setting forth (i) the location, (ii) the rentable area, (iii) the proposed rental rate, (iv) all other proposed material economic terms and (v) the
anticipated availability date (the “Offer Space Commencement Date”). 

  

	 	D.	 Tenant’s right to lease the Offer Space shall be exercisable by written notice (the “Acceptance
Notice”) from Tenant to Landlord delivered not later than ten (10) Business Days after the Offer Notice is delivered to Tenant, time being of the essence. Tenant may not elect to lease less than the entire portion of Offer Space described
in the Offer Notice. If Tenant does not exercise the right to lease the Offer Space, then Landlord shall have the right thereafter to lease such space to another prospective tenant on the same terms and conditions as set forth in the Offer Notice
(which terms and conditions will remain the same for 12 months following the date of the Offer Notice). If the Offer Space is not leased within said 12-month period, Landlord shall provide a new Offer Notice
to Tenant which may contain different terms and conditions than were contained in the original Offer Notice. Tenant’s rights with respect to the new Offer Notice shall be governed by the terms and conditions of this Paragraph 3 except that if
Tenant does not exercise the right to lease the Offer Space pursuant to the new Offer Notice, then Tenant’s rights with respect to the Offer Space shall terminate without further offering such space to Tenant, and within ten (10) Business
Days of Landlord’s request therefor, Tenant shall execute and deliver to Landlord a certification, in recordable form, confirming the Tenant’s failure to exercise (or waiver of) such right, and Tenant’s failure to so execute and
deliver such certification shall (without limiting Landlord’s remedies on account thereof) entitle Landlord to execute and deliver to any third party, and record, an affidavit confirming the failure or waiver, which affidavit shall be binding
on Tenant and may be conclusively relied on by third parties. If Tenant has validly exercised its option to lease the Offer Space, then the Offer Space shall be included in the Premises, subject to all the agreements, terms and conditions of the
Lease as modified by the terms set forth in the applicable Offer Notice. 

  

	 	E.	 Tenant’s right to lease Offer Space is subject to the following additional terms and conditions:

  

	 	1.	 This Lease must be in full force and effect on the date on which Tenant exercises its option of first offer to
lease Offer Space and on the Offer Space Commencement Date; 

  
 -6- 

	 	2.	 No Event of Default by Tenant exists under this Lease, either on the date Tenant exercises its option to lease
Offer Space or on the Offer Space Commencement Date, unless Landlord, in its sole and absolute discretion, agrees in writing to permit Tenant to lease such Offer Space notwithstanding such default; and 

 

	 	3.	 Tenant shall not have assigned this Lease (except in connection with a Permitted Transfer or an assignment to
which Landlord has consented). 

  

	 	F.	 If Tenant has validly exercised its option to lease the Offer Space, then effective as of the Offer Space
Commencement Date, the Offer Space shall be included in the Premises, subject to all of the terms, conditions and provisions of this Lease except that: 

  

	 	1.	 The Rentable Area in the Premises shall be increased by the number of square feet of rentable area in the Offer
Space and such Rentable Area in the Premises, as so increased, shall be used in calculating the increases in Tenant’s Pro Rata Share; 

  

	 	2.	 The Annual Base Rent for the Offer Space shall be the Annual Base Rent per Rentable Square Foot specified in
the Offer Notice; 

  

	 	3.	 The Lease Term with respect to the Offer Space shall commence on the Offer Space Commencement Date and shall
expire simultaneously with the expiration or earlier termination of the Lease Term, including any extension or renewal thereof; and 

  

	 	4.	 The Offer Space shall be rented in its “as is” condition as of the Offer Space Commencement Date,
without representation or warranty by Landlord or any other party acting on behalf of Landlord and in no event shall Landlord have any obligation to perform any work to the Offer Space for use or occupancy by Tenant or provide Tenant any allowance
therefor, except to the extent otherwise set forth in the Offer Notice. 

  

	 	G.	 If Landlord fails to deliver possession on the Offer Space Commencement Date of the Offer Space because of any
act or occurrence beyond the reasonable control of Landlord, then Landlord shall not be subject to any liability for failure to deliver possession, and such failure to deliver possession shall not affect either the validity of the Lease or the
obligations of either Landlord or Tenant thereunder or be construed to extend the expiration of the Lease Term either as to the Offer Space or the balance of the Premises; provided, however, that under such circumstances, (i) Landlord shall
make reasonable efforts to obtain possession of such portion of the Offer Space and (ii) Rent shall not commence as to such portion of the Offer Space until Landlord is able to deliver possession thereof to Tenant. 

  
 -7- 

	 	H.	 Upon the valid exercise by Tenant of its option to lease Offer Space, Landlord and Tenant shall promptly enter
into a written amendment to this Lease reflecting the terms, conditions and provisions applicable to such portion of the Offer Space, as determined in accordance herewith. 

 

	 	I.	 In the event any portion of the Offer Space is leased to Tenant other than pursuant to the right of first offer
described herein, such portion of the Offer Space shall thereupon be deleted from the Offer Space. 

  

	 	J.	 As used herein, the term “Offer Period” shall mean the period commencing on the date of this
Lease and expiring on the date which is twelve (12) months prior to the expiration of the initial Term, but if Tenant exercises its Extension Option, then the Offer Period shall expire twenty-four (24) months prior to the extended
Termination Date, provided, however, that Tenant’s rights to the Offer Space shall expire with respect to any portion of the Offer Space once the said portion is leased to a third party. 

 

	4.	 Retained FF&E. 

Landlord and Tenant acknowledge that the prior tenant of the Premises has relinquished and left in the Premises certain furniture, fixtures,
equipment and other property, as identified on the schedule attached hereto and incorporated herein as Schedule A (the “Retained FF&E”). Landlord shall, prior to and as a condition to delivery of the Premises to Tenant transfer
title to the Retained FF&E to Tenant through a Bill of Sale and/or such other instruments of transfer, in form and content reasonably acceptable to Tenant. The Retained FF&E shall become and be part of Tenant’s Property. 

  
 -8- 

 Schedule A 

FF&E Schedule 
  

	1.	 Built-in desks and cabinets in all the private offices except the five
(5) internal private offices to be demolished as part of Tenant’s build-out 

  

	2.	 All low black filing cabinets, including the five (5) low black filing cabinets currently located in the
to be demolished internal offices. 

  

	3.	 Large conference room table and twenty (20) matching conference room chairs currently located in the large
and medium conference rooms 

  

	4.	 All desk chairs (but not the side/guest chairs) 

 

	5.	 Light wood bookcase located in the west corner office 

 

	6.	 Two (2) built-in cream colored filing cabinets located between the
east corner offices 

  

	7.	 Rolling shelving in the server room 

 

	8.	 Phones and associated tel/data equipment in the server room 

  
 -9-EX-10.6.1

 Exhibit 10.6.1 

Confidential Treatment Requested Centrexion Therapeutics Corporation 

 
  

PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 
 dated 

NOVEMBER 11, 2015 
 by
and between 
 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 

hereinafter “BII” 

and 
 CENTREXION THERAPEUTICS
CORPORATION 
 hereinafter “CENTREXION” 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL 
 EXECUTION VERSION - BII - CENTREXION -
PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 LIST OF EXHIBITS 

 

			
		
	Exhibit 1.4	  	Assigned Patents
	Exhibit 1.25	  	Development Compounds 
	Exhibit 2.1	  	Assignment Form
	Exhibit 4.2	  	Development Plan

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 PATENT ASSIGNMENT AND LICENSING AGREEMENT 

This Patent Assignment and Licensing Agreement (“Agreement”) is entered into on November 11, 2015 (“Effective
Date”) 
 by and between 
 Boehringer Ingelheim
International GmbH (“BII”), a German limited liability company, with offices at Binger Straße 173, 55216 Ingelheim am Rhein, Germany; and 

Centrexion Therapeutics Corporation (“CENTREXION”), a Delaware Corporation, with offices at 509 South Exeter Street, Baltimore,
Maryland 21202, U.S.A. 
 BII and CENTREXION may be referred to as individually a “Party”, and collectively the “Parties”.

 RECITALS 
 WHEREAS, BII is a global
pharmaceutical company within the Boehringer Ingelheim group of companies; 
 WHEREAS, CENTREXION is a biotech company focused on the treatment of
pain; 
 WHEREAS, BII is in the process of terminating its activities in relation to the CCR2, CB2 and SSTR4 programs (each a “Development
Program”) for the treatment of pain and reallocating its R&D and other personnel working on these programs. Accordingly, BII is willing to transfer to CENTREXION its technology related to CCR2, CB2 and SSTR4 and to grant to CENTREXION
an exclusive, worldwide, royalty-bearing license to Develop, Manufacture and Commercialize Products in the Field during the Term, and CENTREXION is willing to further Develop, Manufacture and Commercialize Products in the Field during the Term
(terms as defined below) and to make certain upfront, milestone and royalty payments in exchange for such transfer and license. 
 NOW, THEREFORE, in
consideration of the mutual covenants, agreements and stipulations set forth herein, the receipt and legal sufficiency of which are hereby mutually acknowledged, the Parties hereby agree as follows: 

 

	1.	 DEFINITIONS. 

For purposes of this Agreement, the following capitalized terms shall have the following meanings, whether used in the singular or plural: 

 

	1.1	 “Affiliate” shall mean, with respect to a Party, any legal entity which, at the time such
determination is being made, is controlled by, controlling or under common control with such Party. As used in this definition, the term “control”, whether used as a noun or verb, refers to the possession, directly or indirectly, of the
power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting rights (e.g., fifty per cent (50%) or more of the equity, the ordinary voting power or the general partnership
interest), by contract or otherwise. 

  

	1.2	 “Agreement” shall have the meaning given in the Preamble. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

2 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	1.3	 “Applicable Laws” shall mean all applicable provisions of all statutes, laws, rules,
regulations, administrative codes, ordinances, decrees, orders, decisions, guidance documents, injunctions, awards, judgments, and permits, including licenses of or from Regulatory Authorities and any rules, regulations, guidelines or other
requirements of national and international patent offices and Regulatory Authorities, each as in effect from time to time. 

  

	1.4	 “Assigned Patents” shall mean the Patents listed in Exhibit 1.4. 

 

	1.5	 “BII Claim” shall have the meaning given in Section 11.3.2. 

 

	1.6	 “BII Losses” shall have the meaning given in Section 11.3.2.

  

	1.7	 “BII Party” shall have the meaning given in Section 11.3.2. 

 

	1.8	 “Breaching Party” shall have the meaning given in Section 12.1.3. 

 

	1.9	 “Business Day” shall mean any other day than Saturday, Sunday or any other day on which
commercial banks in Ingelheim, Germany or Baltimore, Maryland, USA are authorized or required by law to remain closed. 

  

	1.10	 “Calendar Quarter” shall mean a period of three calendar months ending on 31 March,
30 June, 30 September or 31 December in any calendar year. 

  

	1.11	 “Centrexion Claim” shall have the meaning given in Section 11.3.1.

  

	1.12	 “Centrexion Losses” shall have the meaning given in Section 11.3.1.

  

	1.13	 “Centrexion Party” shall have the meaning given in Section 11.3.1. 

 

	1.14	 “CMO” shall mean a contract manufacturing organization. 

 

	1.15	 “Combination Product” shall mean a pharmaceutical formulation containing as its active
ingredients both a Compound and one or more other therapeutically active ingredients. 

  

	1.16	 “Commercialization” shall mean any and all activities directed to the preparation for sale of,
offering for sale of, or sale of the Product, including activities related to marketing, promoting, distributing, importing and exporting the Product, and interacting with Regulatory Authorities regarding any of the foregoing. For the avoidance of
doubt, “Commercialization” shall not include the Manufacture of Product. When used as a verb, to “Commercialize” and “Commercializing” shall mean to engage in Commercialization, and
“Commercialized” has a correlative meaning. 

  

	1.17	 “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by,
and the resources to be employed by, a Party with respect to any objective, the reasonable, diligent and good faith efforts, and commercially reasonably financial investment to accomplish such objective as such Party or a company with a
corresponding industry focus, size and global reach would normally use to accomplish a similar objective under similar circumstances. It is understood and agreed that with respect to the Development and Commercialization of Product by CENTREXION,
such efforts shall be substantially equivalent to those efforts and resources commonly used by CENTREXION or a company with a corresponding industry focus, size and global reach, for pharmaceutical development candidates or products owned by it or
to which it has rights, which development candidate or product is at a similar stage in its development or product life and is of similar market potential, taking into account all scientific, commercial and other factors that CENTREXION or a company
with a corresponding industry focus, size and global reach would take into account, including efficacy, safety, expected and actual cost and time to develop, expected and actual profitability, approved labelling, the competitiveness of

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

3 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
alternative products in the marketplace, the expected and actual market exclusivity (including patent and other proprietary position and regulatory exclusivity) of the Product, the expected and
actual amounts of marketing and promotional expenditures and the likelihood of receipt of a Regulatory Approval given the Regulatory Authority involved. 

  

	1.18	 “Competing Product” shall have the meaning given in Section 5.3. 

 

	1.19	 “Compounds” shall mean any Development Compounds or any Family Compounds.

  

	1.20	 “Confidential Information” shall mean all information not publicly available,
including: 

  

	 	(a)	 the existence and terms of this Agreement and any discussions and negotiations in relation to the subject
matter of this Agreement; 

  

	 	(b)	 the Licensed Know-How and Results; and 

 

	 	(c)	 Development Data relating to the Compounds and Products, the Field, or the business, affairs, research and
development activities, results of pre-clinical and clinical trials, national and multinational regulatory proceedings and affairs, finances, plans, contractual relationships and operations of the Parties
including reports and other information provided pursuant to Section 6 (Reporting Obligations). 

  

	1.21	 “Control” or “Controlled” shall mean with respect to the subject item or
right, the ability (whether by ownership, license or otherwise, other than pursuant to this Agreement) of a Party to grant to the other Party access or a license as provided herein under such item or right without violating the terms of any
agreement or other arrangement with any Third Party. 

  

	1.22	 “Co-Packaged Product” shall mean a single packaged
product containing a Product and one or more other therapeutically or prophylactically active ingredient as separate components in a co-packaged form. 

 

	1.23	 “CRO” shall mean a contract research organization. 

 

	1.24	 “Development” shall mean all research, non-clinical
and clinical testing and drug development activities conducted in respect of the Compounds and Products, including those necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of
obtaining or maintaining Regulatory Approvals and to successfully Develop, Manufacture and Commercialize the Products for use in the Field. “Development” shall include test method development and stability testing, formulation development,
delivery system development, non-clinical testing, mechanism studies, toxicology, pharmacokinetics, clinical trials, quality assurance/quality control, regulatory affairs activities, statistical analysis and
report writing, submission of documents, market research and pharmaco-economic studies. 

  

	1.25	 “Development Compounds” shall mean the CCR2, CB2 and SSTR4 compounds, including front runner
and backup compounds specified in Exhibit 1.25. 

  

	1.26	 “Development Data” shall mean any non-clinical or
clinical data relating to the Development or the use of the Compounds and Products in the Field, including but not limited to results, pre-clinical, clinical, safety, manufacturing and quality control data and
information (in-cluding trial designs and protocols), registration (IND/regulatory) dossiers, assay and biological methodology, any reports of non-clinical studies and
clinical trials, and all other documentation containing or embodying such data. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

4 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	1.27	 “Development Plan” shall have the meaning given in Section 4.2. 

 

	1.28	 “Development Program” shall have the meaning given in the Preamble. 

 

	1.29	 “Disclosing Party” shall have the meaning given in Section 10.1. 

 

	1.30	 “Effective Date” shall have the meaning given in the Preamble. 

 

	1.31	 “Family Compounds” shall mean any compound covered by a claim in the Assigned Patents.

  

	1.32	 “Field” shall mean the treatment or prevention of any and all diseases or conditions in humans
and/or animals. 

  

	1.33	 “First Commercial Sale” shall mean, on a country-by-country and Product-by-Product basis, the first sale of Products by or on behalf of CENTREXION, its Affiliates or
Sublicensees to a Third Party end user in such country in exchange for cash or some equivalent to which value can be assigned after such Product has been granted all necessary Regulatory Marketing Approvals by a Regulatory Authority having
jurisdiction for such country. 

  

	1.34	 “Intellectual Property” shall mean any and all Know How (including copyright and other rights
therein), Patents, trademarks, design rights and other rights in designs, copyrights, database rights, and all other intellectual property rights in each case whether registered or unregistered, and including applications for the grant of any such
rights and rights of renewal in respect of any such rights, and all other forms of protection having similar or equivalent effect in any part of the world. 

  

	1.35	 “Know-How” shall mean all methods, materials, data,
reports, analyses and other technical, scientific and other know-how and information, results, non-clinical, clinical, safety, process and Manufacturing and quality
control data and information (including trial designs and protocols), registration dossiers, in each case, solely to the extent confidential and proprietary and in written, electronic or any other form. 

 

	1.36	 “Licensed Know-How” shall mean all Know-How owned or controlled by BII as of the Effective Date necessary for, or specifically related to, the discovery, development, manufacture or use of Compounds and/or Products. 

 

	1.37	 “Major Market Country” shall mean the USA, Germany, France, Great Britain, Italy, Spain, PRC
and Japan. 

  

	1.38	 “Manufacture” shall mean all activities related to the synthesis, making, production,
processing, purifying, formulating, filling, finishing, shipping and holding of the Licensed Product, or any intermediate thereof, including process development, process qualification and validation, scale-up,
pre-clinical, clinical and commercial production and analytical development, product characterization, stability testing, quality assurance, and quality control. 

 

	1.39	 “Marketing Authorization” shall mean the Regulatory Approval which is required to
Commercialize a Product in a particular country or region of the Territory. For the avoidance of doubt, Market Authorization shall include a provisional or conditional approval provided and as long as it grants the right to Commercialize a Product.

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

5 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	1.40	 “Net Sales” shall mean the gross amount of sales of Products invoiced by CENTREXION, its
Affiliates and Sublicensees to unaffiliated Third Parties, less: 

  

	 	(a)	 sales returns and allowances actually paid, granted or accrued, including trade, quantity and cash discounts
and any other adjustments, including those granted on account of price adjustments or billing errors; 

  

	 	(b)	 rejected goods, damaged or defective goods, recalls, returns; 

 

	 	(c)	 rebates, chargeback rebates, compulsory rebates, reimbursements or similar payments granted or given to
wholesalers or other distributors, buying groups, health care insurance carriers or other institutions; 

  

	 	(d)	 adjustments arising from consumer discount programs or other similar programs; 

 

	 	(e)	 non-collectable receivables related to Product; 

 

	 	(f)	 customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes);
or 

  

	 	(g)	 charges for packing, freight, shipping and insurance (to the extent that CENTREXION, its Affiliates and
Sublicensees bear the cost for Products). 

 Each of the foregoing deductions shall be determined as incurred in the
ordinary course of business in type and amount consistent with good industry practice and in accordance with generally accepted accounting principles or more specifically, the principles of the German commercial code
(“Handelsgesetzbuch” or “HGB”) on a basis consistent with CENTREXION’s audited consolidated financial statements. For sake of clarity and avoidance of doubt, sales by CENTREXION, its Affiliates or Sublicensees of a
Product to a permitted Recognized Agent or Third Party Distributor of such Product in a given country shall be considered a sale to an unaffiliated Third Party. All such discounts, allowances, credits, rebates, and other deductions shall be fairly
and equitably allocated to the Products and other products of CENTREXION and its Affiliates and Sublicensees such that the Product does not bear a disproportionate portion of such deductions. 

Supply of Products other than for cash shall be substituted to price on bona fide arms length sales; whereas the price shall be the
average price of sold product for cash during the period based on quantity of drug substance sold. 
 Any Product used for promotional or
advertising purposes or used for clinical trials or other research purposes shall not be included in Net Sales. Donations for charity reasons shall also not be Net Sales. 

Recognized Agent or Third Party Distributor for the purpose of this definition shall mean any third party which distributes products directly
to customers in countries where CENTREXION has no Affiliate or Sublicensee 
  

	1.41	 “Non-Breaching Party” shall have the meaning given in
Section 12.1.3. 

  

	1.42	 “Patents” shall mean all patents and patent applications including divisions, continuations, continuations-in-part, reissues, re-examinations, extensions and the like; the term shall also include utility models
(Gebrauchsmuster). 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

6 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	1.43	 “Phase I Clinical Trial” shall mean a study of a Product in human volunteers or patients
principally for determining initial tolerance, safety and/or pharmacokinetic (including, inter alia, drug-drug interactions and food effects) as well as first preliminary efficacy information in single dose, single ascending dose, multiple
dose and/or multiple ascending dose regimens. 

  

	1.44	 “Phase IIa Clinical Trial” shall mean a study of a Product in human patients principally to
determine clinical efficacy, safety, pharmacokinetics and/or dose finding before embarking on Phase IIb Clinical Trials. 

  

	1.45	 “Phase IIb Clinical Trial” shall mean a study of a Product in human patients principally to
determine clinical efficacy, safety, pharmacokinetics and/or dose finding before embarking on Phase III Clinical Trials. 

  

	1.46	 “Phase III Clinical Trial” shall mean, with respect to the United States, any human clinical
trial, that, if the defined end-points are met, is intended to be a pivotal trial for obtaining Regulatory Approval in the indication being studied or to otherwise establish safety and efficacy in patients
with the indication being studied for purposes of filing for Marketing Authorization with the United States Food and Drug Administration (or its successor) as required under 21 C.F.R. §312.21(c), or, with respect to a jurisdiction other than
the United States, an equivalent clinical study. In the event that a human clinical trial that would otherwise meet the definition of a Phase II Clinical Trial would, if the defined end-points are met, be
sufficient to obtain Marketing Authorization in the indication being studied then, for the purposes of this Agreement, such trial shall be considered a Phase III Clinical Trial. 

 

	1.47	 “Product(s)” shall mean any Product containing a Development Compounds or any Family
Compounds; for clarification, all Products containing the same Compound shall be considered one Product. 

  

	1.48	 “Receiving Party” shall have the meaning given in Section 10.1. 

 

	1.49	 “Regulatory Approval(s)” shall mean and include any license, permit, authorization and
approval of, and registration, filing and other notification to, any Regulatory Authority within the Territory, which grant the approval to Develop, Manufacture and/or Commercialize a Product in a particular country or region of the Territory. For
the avoidance of doubt, Regulatory Approvals shall include a provisional or conditional approval provided and as long as it grants the right to Develop, Manufacture and Commercialize a Product. Regulatory Approvals shall include Marketing
Authorizations. 

  

	1.50	 “Regulatory Authority” shall mean any national, supra-national, regional, state or local
regulatory agency, department, bureau, commission, council or other governmental entity in each country in the Territory involved in the reviewing, granting or revoking of Regulatory Approvals for the Products. Regulatory Authorities include FDA and
EMA. 

  

	1.51	 “Results” shall have the meaning given in Section 9.3.1. 

 

	1.52	 “Royalties” shall have the meaning given in Section 8.2.1. 

 

	1.53	 “Royalty Period” shall have the meaning given in Section 8.3.3. 

 

	1.54	 “Royalty Term” shall have the meaning given in Section 8.2.3. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

7 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	1.55	 “Sublicensee” shall mean any Third Party licensee (aside from a Party’s Affiliates and
any Third Party contractors used by a Party in the Development, Manufacture or Commercialization of the applicable Compounds or Products on a Party’s behalf) which obtains rights to use the Assigned Patents, Licensed Know-How or Results for the Development, Manufacture and/or Commercialization of Compounds and/or Products, regardless of whether such license is granted by a Party, its Affiliates, its licensees or any Sublicensee.

  

	1.56	 “Territory” shall mean the entire world. 

 

	1.57	 “Third Party” shall mean any party other than CENTREXION and its Affiliates and BII and its
Affiliates. 

  

	1.58	 “Third Party License” shall mean a license granted by BII to the Assigned Patents or Licensed Know-How. 

  

	1.59	 “Valid Claim” shall mean with respect to a particular country, and in each case to the extent
contained within an Assigned Patent, 

  

	 	(a)	 any claim of an issued and unexpired patent in such country that (i) has not lapsed or been revoked, has
not been held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction, which decision is un-appealable or un-appealed within
the time allowed for appeal; and (ii) has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, post grant review or disclaimer or otherwise in such country; or 

 

	 	(b)	 a claim of a pending patent application, which claim has not been abandoned or finally disallowed without the
possibility of appeal or re-filing of the application; provided, however, that if a claim has been pending for more than ten (10) years after filing or following nationalization of a patent
application, such claim shall not constitute a Valid Claim for purposes of the License Agreement unless and until a patent issues with such claim. 

The word “including” or any variation thereof means “including without limitation” or any variation thereof and
shall not be construed to limit any general statement which it follows to the specific or similar items or matters immediately following it. 
  

	2.	 ASSIGNMENT AND LICENSE. 

 

	2.1	 Patent. Conditional solely upon receipt of all upfront payments by BII, BII hereby assigns and transfers
to CENTREXION the Assigned Patents, and CENTREXION accepts such assignment and transfer. The Assignment will refer to CENTREXION’s business address at 509 South Exeter Street, Baltimore, Maryland 21202, U.S.A.. An Assignment form is
attached to this Agreement as Exhibit 2.1 CENTREXION shall register and record the transfer of ownership right of the Assigned Patents with the competent patent offices worldwide, at its own effort and cost. 

BII retains an exclusive, cost-free, perpetual, worldwide, transferrable and sublicenseable (in multiple tiers) right to use the Assigned
Patents solely for non-clinical research purposes. 
  

	2.2	 License grant. BII hereby grants to CENTREXION, during the term of this Agreement and in accordance with
the terms and conditions of this Agreement, and CENTREXION hereby accepts, an exclusive, royalty-bearing license to the Licensed Know-How, to Develop, Manufacture and Commercialize Products in the Field in the
Territory. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

8 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	2.3	 Right to Sublicense. CENTREXION is entitled to sublicense its rights under Section 2.2, to any of
its Affiliates, provided that it shall inform BII of such sublicense. Any sublicense to a Third Party shall require the prior written consent of BII, such consent not to be unreasonably withheld or delayed. The right to sublicense is subject to
(i) the sublicense agreement containing terms and conditions that are not inconsistent with those contained in this Agreement, and shall include, inter alia, provisions regarding confidentiality, indemnification, audit, record-keeping,
termination and consequences of termination for BII’s protection that are consistent with the corresponding terms and conditions provided herein. CENTREXION shall remain liable to BII for all obligations under this Agreement, including its
obligation to pay any amounts due on account of sales or other disposition of Compounds and Products by Sublicensees. CENTREXION shall send to BII a copy of the signed sublicensing agreement within [***] after its execution, subject to reasonable
redaction of Confidential Information. The Parties acknowledge that any and all information provided by CENTREXION to BII under this Section 2.3 shall be deemed to be Confidential Information of CENTREXION and shall be subject to the terms of
Section 10. 

  

	2.4	 No additional rights. Nothing in this Agreement shall be deemed or implied to be, and the Parties
disclaim all implied rights to, the grant by BII to CENTREXION of any right, title or interest in any product, Intellectual Property, any formulation technology, operating procedures, marketing materials or strategies, intangibles, material or
proprietary rights of BII, except as are expressly set forth in this Agreement. 

  

	3.	 TECHNOLOGY TRANSFER. 

 

	3.1	 Transferred Data. During the due diligence, BII has made available to CENTREXION a data package relating
to Development Compounds including (i) all regulatory applications, submissions and approvals, and (ii) copies of pre-clinical and clinical data owned or controlled by BII. All Transferred Data shall
be delivered to CENTREXION or its designee pursuant to the technology transfer agreement entered into by the parties as of the Effective Date (the “Tech Transfer Agreement”). Conditional solely upon receipt of all upfront payments
by BII, BII hereby assigns and transfers to CENTREXION BII’s rights to all such documents, and CENTREXION accepts such assignment and transfer. 

  

	3.2	 Technology Transfer. Promptly following the Effective Date and receipt of all upfront payments by
BII, BII shall conduct a technology transfer to CENTREXION with respect to the Development Compounds, such transferred technology to include manufacturing technology and other technology as further specified in the Tech Transfer Agreement. BII shall
provide the support and services described in the Tech Transfer Agreement subject to CENTREXION’s satisfaction of its reimbursement or payment obligations as set forth in the Tech Transfer Agreement. 

 

	3.3	 Inventory Transfer. Promptly following the Effective Date and receipt of all upfront payments by BII,
BII shall conduct an inventory transfer to CENTREXION with respect to the Development Compounds, such transferred inventory to include drug substance as further specified in the Tech Transfer Agreement. BII shall provide the transfer of the
inventory described in the Tech Transfer Agreement subject to CENTREXION’s satisfaction of its reimbursement or payment obligations as set forth in the Tech Transfer Agreement. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

9 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	4.	 DEVELOPMENT. 

  

	4.1	 Diligence. CENTREXION shall be solely responsible for the Development of Products in the Field in the
Territory, and CENTREXION, together with its Affiliates and Sublicensees, and with or through the use of CMOs and CROs, shall use Commercially Reasonable Efforts to Develop the Products in the Field in the Territory. CENTREXION shall bear all costs
related to such Development, including the Manufacture of Compounds and Products required for such Development, in accordance with this Section 4. CENTREXION shall perform its obligations and the defined Development activities in accordance
with Applicable Laws. 

  

	4.2	 Development Plan. The Development activities shall be performed by CENTREXION and/or a CRO or CMO in
accordance with the development plan in Exhibit 4.2 hereto (“Development Plan”). CENTREXION shall perform the Development within the timelines set forth in the Development Plan. 

 

	4.3	 Development Milestones. CENTREXION shall achieve the following development milestones
(“Development Milestones”): 

  

	 	(a)	 CCR2: [***] before [***]; 

 

	 	(b)	 CB2: [***] before [***]; and 

 

	 	(c)	 SSTR4: [***] before [***]. 

 

	4.4	 Extensions of Time. If CENTREXION is unlikely to accomplish a specific development or
commercialization-related task under this Agreement or the Development Plan, it shall promptly inform BII hereof. If such delay is caused by bona fide and documented scientific, technical or regulatory reasons, then CENTREXION and BII shall
negotiate in good faith towards a reasonable extension of time for CENTREXION to achieve the specific task or event, and BII shall not unreasonably deny or condition such extension, provided, however, that BII shall have no obligation
to grant an extension of the Development Milestones specified in Section 4.3. 

  

	4.5	 Responsibility for Manufacture. Subject to specific provisions in the CENTREXION shall have the sole
responsibility for the manufacture of Development Compounds and/or Products, including, but not limited to, clinical supply of Development Compounds and/or Products. 

 

	5.	 COMMERCIALIZATION. 

 

	5.1	 Diligence obligations. CENTREXION shall be solely responsible for the Commercialization of Products in
the Field in the Territory, and, together with its Affiliates and Sublicensees, will use Commercially Reasonable Efforts to Commercialize the Products in the Field. Without limiting the generality of the Commercially Reasonable Efforts obligations
under this Section 5.1, CENTREXION shall 

  

	 	(a)	 when appropriate, based on satisfactory data obtained during the Development, use its Commercially Reasonable
Efforts to secure all required Marketing Authorizations and reimbursement authorizations in at least each Major Market Country for at [***] in the Field;  

 

	 	(b)	 shall be responsible for timely filing all applications, reports and other documents required to be filed in
order to obtain and maintain any Marketing Authorizations for Products; and 

  

	 	(c)	 make the First Commercial Sale of at least [***] in each Major Market Country within [***] following the
issuance of the Marketing Authorizations required for the Commercialization of the respective Products in each Major Market Country. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

10 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	5.2	 Costs. CENTREXION shall bear any and all costs regarding the Commercialization of the Compounds and
Products in the Field, including the costs of its own commercial supplies of and the post-marketing surveillance studies (Phase 4).  

  

	5.3	 Competing Products. In the event CENTREXION, any of its Affiliates or any of its Sublicensees outside
the scope of this Agreement commences Clinical Trials or Commercializes any product that modulates the same target as a Product as its primary mechanism of action and that is developed for the treatment or prevention of pain in humans and/or animals
(“Competing Product”), and irrespective of whether CENTREXION used Assigned Patents or Licensed Know-How to Develop such Competing Product, BII shall be entitled (i) to terminate the
exclusivity of the license under Section 2.2 above, so that CENTREXION shall retain a non-exclusive right to use under Section 2.2, (ii) to obtain a
non-exclusive, cost-free, sublicensable (in multiple tiers), transferable, perpetual back-license under the Assigned Patents and (ii) to independently exploit the respective Compounds and Products in the
Field. CENTREXION shall grant to BII a non-exclusive license to use the Results for any independent exploitation of the respective Compounds and Products in the Field. 

 

	6.	 REPORTING. 

  

	6.1	 Development Reporting. CENTREXION shall inform BII, on an at least biannually basis, of the development
activities performed in connection with the Products, any Results achieved or generated and timelines until next milestone. CENTREXION shall inform BII in cases of material changes to the development including but not limited to significant delays
in the time lines towards the next milestone within [***] of the event triggering such delay. 

  

	6.2	 Commercialization Reporting. After the First Commercial Sale of Products by CENTREXION, its Affiliate or
Sublicensee, CENTREXION shall furnish BII with Calendar Quarterly reports of (i) all of its sales of Products and (ii) a summary of its Commercialization activities performed in at least each Major Market Country under this Agreement. Each
such Calendar Quarterly report shall (i) be furnished to BII within [***] after the end of the Calendar Quarter to which it relates; and (ii) state the total sales of the Products, broken down by country and by Product, during the Calendar
Quarter, the Net Sales derived by CENTREXION, its Affiliates and Sublicensees from such sales, and the Royalties and milestone payments, if any, payable by CENTREXION to BII with respect to such Net Sales. 

 

	7.	 REGULATORY MATTERS. 

 

	7.1	 Regulatory responsibilities of CENTREXION. After the Effective Date, CENTREXION shall be
solely responsible for all regulatory matters including the filing for approvals for the Compounds and Products in the Field, and shall own, directly or through its Affiliates or Sublicensees, all Regulatory Approvals for the Compounds and Products
in the Field. CENTREXION shall satisfy and perform any and all global pharmacovigilance responsibilities, such as but not limited to global safety database maintenance, global literature screening, periodic safety report generation (e.g., the
Development Safety Update Reports (“DSUR”)), signal detection, risk management, Company Core Data Sheet (“CCDS”) maintenance, management of authority requests, arising under any applicable laws as of the execution date of this
agreement with regard to the Product. 

  

	7.2	 Regulatory responsibilities of BII. BII shall satisfy and perform any and all pharmacovigilance
responsibilities related to the Products arising under any applicable laws prior to the Effective Date. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

11 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	7.3	 Safety Reports. BI has no Individual Case Safety Reports (ICSR) related to the Products in its
global safety database and no other safety reports (e.g., Development Safety Update Reports (DSUR) have been written (collectively, “Safety Reports”). As Studies are closed, no further Safety Reports are expected.
Accordingly, the Parties agree that BII will not provide any Safety Reports to CENTREXION. 

  

	8.	 PAYMENT AND PAYMENT TERMS. 

 

	8.1	 Upfront and milestone payments. In partial consideration for the transfer of the Assigned Patents and
the licenses granted under this Agreement, CENTREXION agrees to pay to BII the following upfront payments, development milestone payments and commercial milestone payments: 

 

	8.1.1	 Upon execution of this Agreement, CENTREXION shall pay to BII the following upfront payments:

  

					
		 	CCR2:	 	[***]
		 	CB2:	 	[***]
		 	SSTR4:	 	[***]

  
  
  

	8.1.2	 In addition to the upfront payment, CENTREXION will pay to BII milestone payments as follows:

  

					
		 	 (a)   upon [***]:
	  	
			
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]
			
		 	 (b)   upon [***]:
	  	
			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
			
		 	 (c)   upon [***]:
	  	
			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
			
		 	 (d)   upon [***]:
	  	
			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]
			
		 	 (e)   upon [***]:
	  	
			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]
			
		 	 (f)   Upon [***]:
	  	
			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

12 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 For clarity, if at the time any milestone payment is due for a Product under this
Section 8.1.2,, the payment for any preceding milestone(s) shall become due at the time the most recent milestone event is achieved. For example, in case of the [***] immediately after the completion of [***] the milestone payment for the [***]
shall also become due. 
  

	8.1.3	 In further consideration of the exclusive licenses granted by BII to CENTREXION hereunder, and subject to the
terms and conditions set forth in this Agreement, CENTREXION shall make the following commercial milestone payments upon achievement of the following aggregate Net Sales [***] for each Development Program: 

 

					
		
		 	 (a)   Annual Net Sales of [***]:

			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]
		
		 	 (b)   Annual Net Sales of [***]:

			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]
		
		 	 (c)   Annual Net Sales of [***]:

			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]

  

	8.1.4	 The milestone payments above will be made, separately for each of the Development Programs, only for the first
achievement of a given milestone by a Product. 

  

	8.1.5	 CENTREXION shall inform BII on the occurrence of a regulatory milestone event under Section 8.1.2 and a
commercial milestone event under Section 8.1.3 as soon as possible, but in no event later than within [***] after the occurrence thereof. 

  

	8.1.6	 All payments to be made by CENTREXION to BII under Sections 8.1.1 to 8.1.3 hereof are not refundable for any
reason. None of the payments to be made by CENTREXION to BII under Sections 8.1.1 to 8.1.3 may be credited against any of CENTREXION’s Royalty obligations under Section 8.2. 

 

	8.2	 Royalties.  

  

	8.2.1	 In further consideration for the transfer of the Assigned Patents and the licenses granted under this
Agreement, CENTREXION shall pay to BII royalties on Net Sales of the Products as follows (“Royalties”): 

  

 

					
		
		 	 (a)   Annual Net Sales up to [***]:

			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

13 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

					
		
		 	 (b)   Annual Net Sales [***]-[***]:

			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]
		
		 	 (c)   Annual Net Sales >[***]:

			
		 	 CCR2:
	  	[***]
		 	 CB2:
	  	[***]
		 	 SSTR4:
	  	[***]

  

	8.2.2	 Net Sales. The Royalties shall be calculated on the basis of the global annual aggregated Net Sales,
which in turn shall be calculated on a Product by Product and country-by-country basis from the First Commercial Sale until the expiration of the Royalty Term.

  

	8.2.3	 Royalty Term. The obligation to pay Royalties shall begin, on a country-by-country and Product by Product basis, with the First Commercial Sale. The obligation to pay Royalties with respect to the Product would expire on a country-by-country and Product-by-Product basis by the last to occur of the following (“Royalty Term”):

  

	 	(a)	 the date on which such Product is no longer covered by a Valid Claim of an Assigned Patent;

  

	 	(b)	 the date on which such Product is no longer covered by any other governmental grant of exclusivity (e.g., data,
regulatory or marketing exclusivity) in such country in the indication; or 

  

	 	(c)	 ten (10) years from first launch of the respective Product in the country, provided the Licensed Know-How is still proprietary, or such Licensed Know-How is no longer proprietary owing to a breach of CENTREXION’s confidentiality obligations hereunder or such
obligations of its Affiliates or Sublicensees. 

  

	8.2.4	 Royalty Reductions.  

 

	 	(a)	 In the event Royalties are payable in any given country only on the basis of Section 8.2.3(c) above, then
the Royalty otherwise payable for such Product in such country will be reduced in such country by [***]. 

  

	 	(b)	 In the event CENTREXION is required to obtain a license from a third party in order to avoid infringing such
third party’s patent(s) in the development, manufacture, use, or sale of any Product (a “Required Third Party License”). CENTREXION may deduct up to [***] of any royalties due under Required Third Party Licenses from any
royalties due under this Agreement; provided, however, that the royalties due hereunder shall not be reduced by more than [***] of the royalties that would have been payable absent the effects of this Section 8.2.4(b).

  

	8.2.5	 Combination Product or Co-Packaged Product. In the event a
Product is sold as a Combination Product or Co-Packaged Product, Net Sales of the Combination Product or Co-Packaged Product will be calculated as follows:

  

	 	(a)	 If the Combination Product or Co-Packaged Product, the Product and the
other product are sold separately, Net Sales of the Product portion of Combination Products and Co-Packaged Products will be calculated by [***]. 

 

	 	(b)	 If the Combination Product or the Co-Packaged Product and the Product
are sold separately, but the average gross selling price of the other product(s) cannot be determined, Net Sales of the Combination Product or the Co-Packaged Product shall be equal to [***].

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

14 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	(c)	 If the Combination Product or the Co-Packaged Product and the other
product(s) are sold separately, but the average gross selling price of the Product cannot be determined, Net Sales of the Combination Product and/or Co-Packaged Product shall be equal to [***].

  

	 	(d)	 If the Combination Product or Co-Packaged Product are sold separately,
but the average gross selling price of neither the Product nor the other product(s) can be determined, Net Sales of the Combination Product or Co-Packaged Product shall be equal [***]. 

The average gross selling price for such other product(s) contained in the Combination Product or
Co-Packaged Product shall be calculated for each calendar year by [***], as published by IMS or another mutually agreed independent source. 

In the initial calendar year during which a Combination Product or Co-Packaged Product is sold, a
forecasted average gross selling price shall be used for the Product, other product(s), or Combination Product and/or Co-Packaged Product. Any over or under payment due to a difference between forecasted and
actual average gross selling prices shall be paid or credited in the second Royalty payment of the following calendar year. In the following calendar year the average gross selling price of the previous year shall apply from the second Royalty
payment on. 
  

	8.2.6	 Blended Rates. The Parties acknowledge and agree that the Assigned Patents transferred and the
Licensed Know-How licensed under this Agreement may justify Royalty rates and/or Royalty terms of differing amounts for sales of Products, which rates could be applied separately to Products involving the
exercise of Assigned Patents and/or the incorporation of Licensed Know-How, and that if such Royalties were calculated separately, Royalties relating to the Assigned Patents and Royalties relating to the
Licensed Know-How would last for different terms. The Parties have determined in light of such considerations and for reasons of mutual convenience that blended Royalty rates for the Assigned Patents and the
Licensed Know-How licensed hereunder will apply during a single Royalty term (which blended Royalty rates would be advantageous for both Parties) for sales of Products. Consequently, the Parties have agreed to
adopt the Royalty rates set forth in this Section 8.2 with respect to the sales of Products as blended Royalty rates. 

  

	8.3	 Payment Terms. 

 

	8.3.1	 Upfront payment. The upfront payment shall be due and payable within [***] after the later of
(i) the Parties’ execution of this Agreement by facsimile or email transmission, and (ii) CENTREXION’s receipt of an invoice of such amount from BII; provided that such amount shall not become payable until such time as
CENTREXION has received a duly signed original of the Agreement by BII. 

  

	8.3.2	 Milestone Payments. Each milestone payment shall be due and payable to BII within [***] after
receipt of an invoice from BII, which shall be provided to CENTREXION as soon as practicable after CENTREXION has notified BII that the particular milestone has been achieved (whether achieved by or on behalf of BII or any of its Affiliates or
Sublicensees). CENTREXION will notify BII within [***] after the achievement of any milestone event for which a payment to BII is required under Section 8.1 and BII shall send to CENTREXION an invoice for the corresponding milestone payment.

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

15 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	8.3.3	 Royalty Payments. Royalties shall be paid on a Calendar Quarterly basis (“Royalty
Period”). Within [***] after the end of each Royalty Period in which any Net Sales occur, CENTREXION shall calculate the Royalty payments owed to BII and shall inform BII about the amount owed to BII in writing and BII shall send to CENTREXION
an invoice for the corresponding Royalty payments. All Royalty payments shall be computed by converting the Net Sales in each country in the Territory into the currency of Euros, using the monthly exchange rates published by the European Central
Bank in Frankfurt/Main, Germany. In calculating the Royalties in each quarter, the average Royalty rate will first be calculated based on the cumulative year to date aggregate Net Sales in the Territory, other than in countries where the Reduced
Royalty Rate applies. In case during a calendar year Royalties payable change from Full Royalty Rate to Reduced Royalty Rate or vice versa, the whole Net Sales in such year shall be included in the aggregate Net Sales. At the end of such calendar
year the Parties shall reconcile together with the first royalty report of the following year the exact Royalty due for such change in order to account for the calendar month when such change occurred. The Royalty payable in each quarter will then
be the sum of the amounts payable for Territories where Full Royalty Rates apply, less the aggregate amount of royalties previously paid in respect of these countries and of such year, plus the Royalties payable for countries where the Reduced
Royalty Rate applies. 

  

	8.3.4	 Reports. Each Royalty payment shall be accompanied by a written report describing the Net Sales of the
Product sold by or on behalf of CENTREXION, its Affiliates and Sublicensees during a Calendar Quarter in each country in the Territory in which such Product occurred in the Calendar Quarter covered by such statement, specifying: the gross sales (if
available) and Net Sales in each country’s currency, including an accounting of deductions taken in the calculation of Net Sales; the applicable exchange rate to convert from each country’s currency to Euros; and the Royalties payable in
Euros. 

  

	8.3.5	 Records. CENTREXION, its Affiliates and/or its Sublicensees shall keep and maintain complete and
accurate records pertaining to sale or other disposition of the Product(s) in sufficient detail so that the Royalties payable and the Royalty reports will be verified. Such records shall be open to inspection during business hours for at least three
(3) full calendar years following the end of the calendar year to which they pertain, but in any event not more than once per calendar year, by a nationally recognized independent certified public accountant selected by BII to whom CENTREXION
has no reasonable objections and retained at BII’s expense. Said accountant shall sign a confidentiality agreement prepared by CENTREXION and reasonably acceptable to BII and shall then have the right to examine the records kept pursuant to
this Agreement and report to BII the findings (but not the underlying data) of said examination of records as are necessary to evidence that the records were or were not maintained and used in accordance with this Agreement. A copy of any report
provided to BII by the accountant shall be given concurrently to CENTREXION. If said examination of records reveals any underpayment(s) of the Royalty payable, then CENTREXION shall promptly pay the balance due to BII, and if the underpayment(s)
is/are more than [***], then CENTREXION shall also bear the expenses of said accountant. If said examination of records reveals any overpayment(s) of Royalty payable, then BII shall credit the amount overpaid against CENTREXION’s future Royalty
payment(s) during the next [***] period, and if such payments are insufficient to provide an adequate credit, then BII shall pay the remaining amounts within [***] to CENTREXION. 

 

	8.3.6	 Taxes. If applicable laws or regulations require withholding of CENTREXION of any taxes imposed upon by
BII on account of any royalties and payments, paid under this Agreement, such taxes shall be deducted by CENTREXION as required by law from such remittable royalty and payment and shall be paid by CENTREXION to the proper tax authorities. Official
receipts of payment of any withholding tax shall be secured and sent to BI as evidence of such payment. The parties shall exercise their best efforts to ensure that any withholding taxes imposed are

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

16 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
reduced as far as possible under the provisions of any relevant tax treaty. CENTREXION supports BII to get the required certificate of withholding tax exemption from US taxes regulated by the
double taxation treaty between USA and Germany and CENTREXION supports BII to get the withheld US taxes refunded, if required. 

  

	8.3.7	 Overdue Payments. Payments not paid within [***] after the due date shall bear interest at an annual
rate of [***] above the three-month-LIBOR rate of the respective currency for the time period in which such amount is outstanding, as disclosed from time to time by the European Central Bank which applied on the due date. Calculation of interest
will be made for the exact number of days in the interest period based on a year of 360 days (actual/360) by CENTREXION. 

  

	8.3.8	 Financial Standards. All financial terms and standards (including any calculation of Net Sales,
Development costs and financial payments due under this Agreement) shall be governed by and determined in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and shall be consistent with
CENTREXION’s audited consolidated financial statements. Notwithstanding the above and notwithstanding the requirements or principles of U.S. GAAP, Net Sales shall be calculated in accordance with the formula specified in Section 1.41.

  

	9.	 INTELLECTUAL PROPERTY. 

 

	9.1	 Assigned Patents. 

 

	9.1.1	 Patent Transfer. BII shall provide CENTREXION with copies of the patent files of all Assigned Patents
available at BII on the Effective Date (via electronic delivery) except for such files kept with the local patent representatives which shall remain with the respective representative until further instruction from CENTREXION. Except as otherwise
provided in this Agreement, CENTREXION will be responsible for the maintenance and prosecution of the Assigned Patents after the Effective Date. If BII receives any bills or invoices for such work performed after the Effective Date, then BII will
forward to CENTREXION such bills or invoices for payment by CENTREXION and BII shall have no liability for CENTREXION’s failure to timely pay such bills or invoices. 

 

	9.1.2	 Local Patent Representatives. BII shall inform in writing all of its local patent representatives in the
Territory within [***] after the Effective Date that: (i) the Assigned Patents have been assigned to CENTREXION, (ii) any future correspondence and further invoices regarding the Assigned Patents should be
directly sent to CENTREXION and (iii) local patent representatives immediately inform CENTREXION about the further due dates related to Assigned Patents. For a period of [***] after the Effective Date BII shall forward to
CENTREXION any correspondence it nevertheless receives from its local patent representatives or any patent offices regarding the Assigned Patents. 

  

	9.1.3	 Maintenance and Prosecution of the Assigned Patents prior to the Effective Date. BII will be responsible
for the maintenance and prosecution of the Assigned Patents on and prior to the Effective Date. BII will pay all prosecution fees, maintenance fees and/or such other fees due and required by the relevant patent offices for maintenance of the
Assigned Patents on or prior to the Effective Date and will pay all bills and invoices for work performed on or prior to the Effective Date in connection with the maintenance and/or prosecution of the Assigned Patents. CENTREXION shall reimburse BII
all fees and external costs paid by BII in relation to the maintenance and/or prosecution of the Assigned Patents after [***], in particular fees and costs paid in order to ensure that due dates prescribed for (i) the entry of International
Patent Applications listed in Exhibit 1.4 into the regional/national Phase according to Art. 22 and 39 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

17 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
PCT and (ii) the validation of the European Patents listed in Exhibit 1.4 pursuant Art. 65 EPC are met. For clarity, work relating to the transfer of the Assigned Patents to
CENTREXION, whether performed before or after the Effective Date shall not constitute work performed in connection with the maintenance or prosecution of the Assigned Patents for purposes of this Section. 

 

	9.1.4	 Prosecution. CENTREXION shall be responsible for preparing, filing, prosecuting and maintaining,
throughout the world, all of the Assigned Patents, CENTREXION shall inform BII on an at least biannually basis about the status of the Patents and of the patent prosecution of all Assigned Patents. Should BII inquire about the status of specific
Assigned Patents, CENTREXION shall provide upon BII’s written request any substantive communications with the competent patent offices that may affect the scope of such Assigned Patents and give BII reasonable opportunity to review and comment
upon the text of any communication with the competent patent offices for Assigned Patents, and that CENTREXION shall not unreasonably refuse to address any of BII’s comments. CENTREXION shall use Commercially Reasonable Efforts to prosecute and
maintain these Assigned Patents. 

  

	9.1.5	 Royalties. The Parties agree that the assignment and transfer of the Assigned Patents shall only
facilitate the prosecution, maintenance and exploitation of these Assigned Patents and shall not affect the term of the Royalty payments. Accordingly, as long as these Assigned Patents contain a Valid Claim, CENTREXION shall be obligated to pay
Royalties thereon. 

  

	9.1.6	 Discontinuance. If CENTREXION decides to discontinue maintaining any Assigned Patent, CENTREXION will
notify BII of such decision in writing well in advance (e.g., at the latest [***] prior to any applicable regulatory deadline, if any), and BII will have the right to request the cost-free assignment and transfer of the Assigned Patent. If
CENTREXION discontinues maintaining an Assigned Patent without notifying BII and the Assigned Patent lapses, CENTREXION shall pay to BII contractual damages based on the estimated amount of Royalties that would be payable by CENTREXION to BII during
the remainder of the statutory term of such Assigned Patent if the Assigned Patent had not lapsed. 

  

	9.1.7	 Enforcement. If a Party becomes aware of any infringement, anywhere in the world, of any issued Patent
within the Assigned Patents, it will promptly notify the other Party in writing to that effect. CENTREXION shall have the primary right, but not the obligation, to take action to obtain a discontinuance of infringement or bring suit against a Third
Party infringer of the Assigned Patents. CENTREXION shall bear all expenses of such suit. If CENTREXION elects not to take action or to bring suit to prosecute such infringement, it shall notify BII of such election within [***] after receipt of the
notice of the infringement or immediately after the election to stop any such suit. If after the expiration of the [***] period (or, if earlier, the date upon which CENTREXION provides written notice that it does not plan to bring such action),
CENTREXION has neither obtained a discontinuance of infringement of the Assigned Patent, as the case may be, nor filed suit against any such Third Party infringer of such Patents, then BII shall have the right, but not the obligation, to take action
or bring suit against such Third Party infringer of such Patents, provided that BII shall bear all the expenses of such suit. The non-enforcing Party shall provide such assistance as the enforcing Party shall
reasonably request in connection with any action or suit hereunder to prevent or enjoin any such infringement or unauthorized use of an Assigned Patent, including agreeing to be joined as a party to such action or suit and executing legal documents.
Such assistance will be provided by the non-enforcing Party at the enforcing Party’s cost. 

  

	9.1.8	 Sharing of recoveries. Any recoveries obtained as a result of any proceeding against a Third Party
infringer (where the infringement relates to the Development, Manufacture and/or Commercialization of any Product) shall be allocated as follows: 

  

	 	(a)	 Such recovery shall first be used to reimburse each Party for all reasonable litigation costs in connection
with such litigation paid by that Party; 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

18 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	(b)	 such recovery shall then be used to compensate each Party for the respective damages suffered from the
infringement of the respective Patent, provided that in the event the remaining portion of the recovery is not sufficient to compensate each Party’s damages, such compensation shall be paid on a pro-rata
share based on the respective damages suffered; and 

  

	 	(c)	 the remaining portion of such recovery, if any, shall be distributed to the enforcing Party.

  

	9.2	 Licensed Know-How. BII retains all rights to the Licensed
Know-How, subject only to the licenses granted hereunder. For the avoidance of doubt, CENTREXION shall only be entitled to utilize the Licensed Know-How in accordance
with CENTREXION’s rights and obligations under this Agreement. 

  

	9.3	 Results.  

 

	9.3.1	 BII hereby acknowledges that CENTREXION is the owner of all inventions, data and other results developed by
CENTREXION under this Agreement (“Results”), and BII shall acquire no rights, title or interest whatsoever in or to any such Results, except as specifically provided under this Agreement. 

 

	9.3.2	 CENTREXION shall be responsible for filing, prosecuting and maintaining, throughout the world, all Patents
based on the Results. The costs of filing, prosecuting and maintaining such Patents shall be borne by CENTREXION, subject to CENTREXION’s right to elect to discontinue the patent prosecution and maintenance as set forth in Section 9.3.3
below. 

  

	9.3.3	 If CENTREXION elects to cease the filing, prosecution and/or maintenance of a Result in any country of the
Territory, CENTREXION shall provide BII with written notice immediately upon the decision to discontinue the filing, prosecution, maintenance and/or defense of such Patent, as the case may be, in any event, however, not later than [***] before any
relevant deadline relating to or any public disclosure of the relevant Result. In such event, CENTREXION shall permit BII, at BII’s sole discretion, to take over or continue, as the case may be, the filing, prosecution, maintenance and defense
of such Patent at BII’s own expense. If BII to take over and continue such prosecution, maintenance and defense, CENTREXION shall transfer ownership in such Patent and execute such documents and perform such acts, at BII’s expense, as may
be reasonably necessary to permit BII to take over and continue the filing, prosecution, maintenance and/or defense of such Patent at its own cost; such Patent shall no longer be considered a Result. 

 

	9.4	 Third Party Rights. If the Development, Manufacture and/or Commercialization of any Product is alleged
by a Third Party to infringe a Third Party’s Intellectual Property, the Party becoming aware of such allegation shall promptly notify the other Party. CENTREXION shall be responsible for defending such allegation and any suit brought by a Third
Party based on such allegation. If a Third Party sues BII alleging that BII’S activities pursuant to this Agreement infringe or will infringe said Third Party’s Intellectual Property, CENTREXION shall, upon BII’s request, assume the
responsibility for and the costs of such suit and hold BII harmless against any claims or costs related to such suit. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

19 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	10.	 CONFIDENTIALITY. 

 

	10.1	 Obligation of confidentiality. As of the Effective Date, all Confidential Information disclosed,
revealed or otherwise made available to one Party (“Receiving Party”) by or on behalf of the other Party (“Disclosing Party”) under, or as a result of, this Agreement are made available to the Receiving Party solely
to permit the Receiving Party to exercise its rights, and perform its obligations, under this Agreement. The Receiving Party shall not use any of the Disclosing Party’s Confidential Information for any other purpose, and shall not disclose,
reveal or otherwise make any of the Disclosing Party’s Confidential Information available to any other person, firm, corporation or other entity, without the prior written authorization of the Disclosing Party, except as explicitly stated in
this Section 10. 

  

	10.2	 Additional obligations. 

 

	10.2.1	 Appropriate safeguards. In furtherance of the Receiving Party’s obligations under Section 10.1
hereof, the Receiving Party shall take all reasonable steps, and shall implement all appropriate and reasonable safeguards, to seek to prevent the unauthorized use or disclosure of any of the Disclosing Party’s Confidential Information.

  

	10.2.2	 Recipients of Confidential Information. Without limiting the generality of this Section 10.2, the
Receiving Party shall disclose any of the Disclosing Party’s Confidential Information only to those of its Affiliates, officers, employees, assignees, licensees, Sublicensees, contract service providers, and its potential assignees, licensees
and Sublicensees, and consultants and investors and potential investors that have a need to know the Disclosing Party’s Confidential Information, in order for the Receiving Party to exercise or confirm its rights and/or to perform its
obligations under this Agreement, and only if such officers, employees, assignees, licensees, Sublicensees, contract service providers, and its potential assignees, licensees and Sublicensees, and consultants and investors and potential investors
have executed appropriate non-disclosure agreements containing substantially similar terms regarding confidentiality and non-use as those set out in this Agreement or
are otherwise bound by obligations of confidentiality effectively prohibiting the unauthorized use or disclosure of the Disclosing Party’s Confidential Information. 

 

	10.2.3	 Unauthorized use or disclosure. The Receiving Party shall furnish the Disclosing Party with written
notice immediately of it becoming aware of any unauthorized use or disclosure of any of the Disclosing Party’s Confidential Information by any officer, employee, assignee, licensee or Sublicensee, or potential assignee, contract service
provider, and its licensee or Sublicensee, or consultant, investor or potential investor of the Receiving Party, and shall take all actions reasonably required in order to prevent any further unauthorized use or disclosure of the Disclosing
Party’s Confidential Information. 

  

	10.3	 Limitations. The Receiving Party’s obligations under Sections 10.1 and 10.2 hereof shall not apply
to the extent that the Receiving Party can demonstrate by competent evidence that any of the Disclosing Party’s Confidential Information: 

  

	 	(a)	 is in the public domain, or becomes generally available to the public through no fault of the Receiving Party;

  

	 	(b)	 was known to the Receiving Party, without restriction of use or disclosure, prior to being made available
hereunder; 

  

	 	(c)	 is disclosed, revealed or otherwise made available to the Receiving Party by a Third Party, without restriction
of use or disclosure, that is under no obligation of non-disclosure and/or non-use to the Disclosing Party in relation to the subject item; or 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

20 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	(d)	 is required to be disclosed under Applicable Law, or in connection with any application by the Receiving Party
for any Regulatory Approvals; provided, however, that the Receiving Party shall furnish the Disclosing Party’s with as much prior written notice of such disclosure requirement as reasonably practicable, to permit the Disclosing Party, in
its sole discretion, to take appropriate action, including seeking a protective order, in order to prevent the Disclosing Party’s Confidential Information from passing into the public domain or becoming generally available to the public.

  

	10.4	 Return of Confidential Information. Subject to Section 12.2, upon termination (but not
expiration) of this Agreement for any reason whatsoever, the Receiving Party shall cease all use of and return to the Disclosing Party, or destroy, as the Disclosing Party shall specify in writing promptly upon such termination, all copies of all
documents and other materials that contain or embody any of the Disclosing Party’s Confidential Information, except to the extent that the Receiving Party is (i) required by Applicable Laws to retain such documents and materials or
(ii) remains entitled under this Agreement to use such Confidential Information, and provided further that each Party may keep a single copy of all Confidential Information within its legal archives solely to assure compliance with the
provisions of this Section 10. Within [***] after the date of termination of this Agreement, the Receiving Party shall furnish the Disclosing Party with a certificate, duly executed by an officer of the Receiving Party, confirming that the
Receiving Party has complied with its obligations under this Section 10.4. 

  

	10.5	 Survival. All of the Receiving Party’s obligations under Sections 10.1 and 10.2 hereof, with
respect to the protection of the Disclosing Party’s Confidential Information, shall for a period of [***] survive the expiration or termination of this Agreement for any reason whatsoever. 

 

	10.6	 Public announcements. During the term of this Agreement, no public announcement concerning the existence
of, terms, or subject matter of this Agreement shall be made, either directly or indirectly, by any Party, without first obtaining the prior written approval of the other Party and agreement upon the nature and text of such public announcement; such
agreement and approval shall not be unreasonably withheld or delayed. Each Party agrees that it shall co-operate fully with the other with respect to all disclosures regarding this Agreement to any
governmental or regulatory agencies, including requests for confidential treatment of proprietary information of either Party included in any such disclosure. 

 

	10.7	 Applicable laws. Nothing in this Agreement shall be construed as preventing or in any way inhibiting
either Party from complying with Applicable Laws governing activities and obligations undertaken pursuant to this Agreement, in any manner which it reasonably deems appropriate, including, for example, by disclosing to Regulatory Authorities
Confidential Information or other information received from the other Party, subject to Section 10.3(d) and 11.6. 

  

	10.8	 Scientific Publications. BII acknowledges that CENTREXION may have a legitimate interest to publish in a
journal, paper or magazine or to present at professional meetings or to make similar disclosures of the Development Data or other information relating to the Compounds and Products generated by BII (“Scientific Publications”). Such
Scientific Publications shall comply with widely accepted scientific standards. BII’s contribution shall be acknowledged in any Scientific Publication by co-authorship or acknowledgment, whichever is
appropriate in accordance with customary scientific practice. In case of joint publications, the citation order and respective functions of the authors (e.g. first author, last author, corresponding author) shall be determined in good faith by the
Parties, in accordance with the rules applicable in the scientific community. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

21 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	11.	 WARRANTIES; LIABILITIES; INDEMNIFICATION AND INSURANCE. 

 

	11.1	 Warranties. 

  

	11.1.1	 Representations and warranties of each Party. Each of BII and CENTREXION hereby represents and warrants
to the other Party hereto that as of the Effective Date: 

  

	 	(a)	 it is a corporation or entity duly organized and validly existing under the laws of the state or other
jurisdiction of its incorporation or formation; 

  

	 	(b)	 its execution, delivery and performance of this Agreement by such Party does not conflict with any other
agreement by which it is bound, and has been duly authorized by all requisite corporate action and does not require any shareholder action or approval; and 

  

	 	(c)	 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder.

 Furthermore, each of BII and CENTREXION hereby covenants to the other Party that it shall at all times comply with all
Applicable Laws relating to its activities under this Agreement. 
  

	11.1.2	 Representations and warranties of BII. Subject to the disclosures in Exhibit 11.1 hereto, BII hereby
represents and warrants that, as of the Effective Date: 

  

	 	(a)	 to its knowledge, it Controls (free and clear of any liens, mortgages, security interests, charges,
encumbrances or otherwise) the entire right, title and interest in the Assigned Patents and the Licensed Know-How; 

  

	 	(b)	 it has the right to enter into this Agreement and to grant the licenses contained herein;

  

	 	(c)	 it has no knowledge of (i) any Intellectual Property of a Third Party that would be infringed by the
practice of the Assigned Patents and the Licensed Know-How and could reasonably be considered a material impediment of the rights granted herein; or (ii) any correspondence from any Third Party notifying
it of such potentially relevant issued patents Controlled by such Third Party; and 

  

	 	(d)	 to its knowledge, there are no Third Party Licenses; and 

 

	 	(e)	 to its knowledge it has not received any claims or correspondence from any Third Party asserting that the
development or commercialization of the Compounds would constitute an infringement or misappropriation of such intellectual property owned or controlled by a Third Party. 

 

	11.1.3	 Diligence warranty of CENTREXION. CENTREXION acknowledges and agrees that BII has answered all questions
of CENTREXION relating to the due diligence of the Compounds and Products, and CENTREXION warrants that it has diligently reviewed all such information, including information relating to the Assigned Patents and Licensed Know-How, the Compounds and the Products provided by BII. 

  

	11.1.4	 Disclaimer. Except as specifically and expressly set forth in this Section 11, each Party makes no
representation or warranty and specifically disclaims any guarantee, express or implied, relating to the Assigned Patents and the Licensed Know-How, or any other information disclosed, revealed or otherwise
made available to the other Party under this Agreement or otherwise, including, but not limited to any representation or warranty that the Development of 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

22 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
the Compounds and Products will be successful, in whole or in part, that the Assigned Patents and Licensed Know-How will be suitable for exploitation
or that the Compounds and Products conform to the requirements of any Applicable Laws. Subject only to Section 11.1.2 above, BII expressly disclaims any warranties or conditions, express, implied, statutory or otherwise with respect to the
Assigned Patents and Licensed Know-How, the Compounds and Products, including any warranty of merchantability, fitness for a particular purpose or non-infringement.

  

	11.2	 Limitation of Liability. Except in the case of willful or intentional misconduct or gross negligence,
neither Party shall be liable to the other Party for any indirect, punitive or consequential damages, whether based on contract or tort, or arising under Applicable Law or otherwise. 

 

	11.3	 Indemnification. 

 

	11.3.1	 BII’s obligations to indemnify. BII shall indemnify, defend and hold CENTREXION, its Affiliates,
and its and their employees, agents, officers, and directors (individually and/or collectively referred to hereinafter as a “Centrexion Party”) harmless from and against any and all losses, liabilities, damages, expenses or fees
paid or payable by CENTREXION or a Centrexion Party to a Third Party (collectively, “Centrexion Losses”) to the extent that such Centrexion Losses result from or arise in connection with a claim, suit or other proceeding made or
brought by a Third Party against CENTREXION or a Centrexion Party (a “Centrexion Claim”) based on, resulting from, or arising in connection with: 

 

	 	(a)	 any material breach of any of BII’s representations or warranties set forth in this Agreement;

  

	 	(b)	 any other grossly negligent, willful or intentional misconduct, error or omission on the part of BII, or any
officer, director, employee, agent or representative of BII; 

 provided, however, that BII shall not be obligated
to indemnify, defend or hold harmless CENTREXION or a Centrexion Party from any Centrexion Claim or for any Centrexion Loss incurred by CENTREXION or a Centrexion Party to the extent CENTREXION is responsible for indemnifying, defending and holding
BII and BII Parties harmless for such Claims as set forth in Section 11.3.2. 
  

	11.3.2	 CENTREXION’s obligations to indemnify. CENTREXION shall indemnify, defend and hold BII, its
Affiliates and its and their officers, directors, trustees, agents and employees (individually and/or collectively referred to herein as an “BII Party”) harmless from and against any and all losses, liabilities, damages, expenses or
fees paid or payable by BII or a BII Party to a Third Party (collectively, “BII Losses”) to the extent that such BII Losses result from or arise in connection with a claim, suit or other proceeding made or brought by a Third Party
against BII or a BII Party (an “BII Claim”) based on, resulting from, or arising in connection with: 

  

	 	(a)	 any material breach of any of CENTREXION’s obligations, representations, warranties or covenants set forth
in this Agreement; 

  

	 	(b)	 any other grossly negligent, willful or intentionally wrongful act, error or omission on the part of
CENTREXION, or any officer, director, employee, agent or representative of CENTREXION; 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

23 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	(c)	 any claim that the Development, Manufacture and/or Commercialization of a Compound or a Product fails to
conform to the requirements of any Applicable Laws; 

  

	 	(d)	 any product liability claim regarding the Products to the extent Commercialized by CENTREXION; or

  

	 	(e)	 any Third Party claim regarding an allegation that the Manufacture or Commercialization by CENTREXION of
Compounds or Products pursuant to and consistent with the provisions of this Agreement infringes such Third Party’s Intellectual Property; 

provided, however, that CENTREXION shall not be obligated to indemnify, defend or hold harmless BII or an BII Party from any BII Claim
or for any BII Loss incurred by BII or an BII Party to the extent BII is responsible for indemnifying, defending and holding CENTREXION and Centrexion Parties harmless for such Claims as set forth in Section 11.3.1. 

 

	11.3.3	 Indemnification procedures. 

 

	 	(a)	 Each indemnified Party shall notify the indemnifying Party (and in reasonable detail) of the Claim within [***]
after receipt by such indemnified Party of notice of the CENTREXION Claim or BII Claim, as the case may be, or otherwise becoming aware of the existence or threatened existence thereof (such CENTREXION Claim or BII Claim being referred to as a
“Claim”). Failure to give such notice shall not constitute a defense, in whole or in part, to any Claim by an indemnified Party hereunder except to the extent the rights of the indemnifying Party are materially prejudiced by such
failure to give notice. The indemnifying Party shall notify in English the indemnified Party of its intentions as to the defense of the Claim or potential Claim within [***] after receipt of notice of the Claim. If the indemnifying Party assumes the
defense of a Claim against an indemnified Party, the indemnifying Party shall have no obligation or liability under this Section 11 as to any Claim for which settlement or compromise of such Claim or an offer of settlement or compromise of such
Claim is made by an indemnified Party without the prior written consent of the indemnifying Party, which consent shall not be unreasonably withheld. 

  

	 	(b)	 The indemnifying Party shall assume exclusive control of the defense and settlement (including all decisions
relating to litigation, defense and appeal) of any such Claim (so long as it has confirmed its indemnification obligation responsibility to such indemnified Party under this Section 11.3 with respect to a given Claim); provided, however,
that the indemnifying Party may not settle such Claim in any manner that would require payment by the indemnified Party, or would materially adversely affect the rights granted to the indemnified Party hereunder, or would materially conflict with
the terms of this Agreement, or adversely affect other products, without first obtaining the indemnified Party’s prior written consent, which consent shall not be unreasonably withheld. 

 

	 	(c)	 The indemnified Party shall reasonably cooperate with the indemnifying Party in its defense of the Claim
(including, without limitation, making documents and records available for review and copying and making persons within its control available for pertinent testimony in accordance with the confidentiality provisions of Section 10, and neither
Party shall be required to divulge privileged material to the other) at the indemnifying Party’s expense. If the indemnifying Party assumes defense of the Claim, an indemnified Party may participate in, but not control, the defense of such
Claim using attorneys of its choice and at its sole cost and expense, with such cost and expense not being covered by the indemnifying Party. If an indemnifying Party does not agree

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

24 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
to assume the defense of the Claim asserted against the indemnified Party (or does not give notice that it is assuming such defense), or if the indemnifying Party assumes the defense of the Claim
in accordance with this Section 11.3 yet fails to defend or take other reasonable, timely action, in response to such Claim asserted against the indemnified Party, the indemnified Party shall have the right to defend or take other reasonable
action to defend its interests in such proceedings, and shall have the right to litigate, settle or otherwise dispose of any such Claim; provided, however, that no Party shall have the right to settle a Claim in a manner that would adversely
affect the rights granted to the other Party hereunder, or would materially conflict with this Agreement, or would require a payment by the Party, or adversely affect the Party (its Affiliates) or its products in or outside the territory, without
the prior written consent of the Party entitled to control the defense of such Claim, which consent shall not be unreasonably withheld. 

  

	11.3.4	 Insurance. CENTREXION shall obtain and maintain during the term of this Agreement reasonable and
adequate general liability insurance, patients insurance and product liability insurance. CENTREXION shall provide to BII written proof of the existence of such insurance upon request. 

 

	12.	 TERM AND TERMINATION; CONSEQUENCES OF TERMINATION. 

 

	12.1	 Term and Termination. 

 

	12.1.1	 Term. This Agreement shall become effective as of the Effective Date and shall expire on a Product-by-Product and country-by-country basis upon the expiration of the last payment
obligation by CENTREXION.  

  

	12.1.2	 Termination for convenience. CENTREXION shall have the right to terminate this Agreement at its own
discretion at any time by providing [***] prior written notice to BII. 

  

	12.1.3	 Termination for cause. 

 

	 	(a)	 In the event that either Party (“Breaching Party”) commits a material breach or default of any
of its obligations hereunder, such material breach to include a breach by CENTREXION of the Development and diligence obligations under Section 4, the other Party hereto (“Non-Breaching
Party”) may give the Breaching Party written notice of such material breach or default, and shall request that such material breach or default be cured as soon as reasonably practicable. Subject to Section 12.1.4, in the event that the
Breaching Party fails to cure such breach or default within [***] after the date of the Non-Breaching Party’s written notice thereof (in the event of default of payment within [***] after the date of the Non-Breaching Party’s notice), the Non-Breaching Party may terminate this Agreement by giving written notice of termination to the Breaching Party. In the event the
Breaching Party indicates in writing that it will be unable or is unwilling to cure the breach, this Agreement may be terminated by the Non-Breaching Party with immediate effect. 

 

	 	(b)	 BII may terminate this Agreement in the event CENTREXION or any of its Affiliates directly or indirectly
challenges the validity of the Assigned Patents in a legal proceeding or supports a Third Party in the challenge of an Assigned Patent in a legal proceeding (in each case before a court of competent jurisdiction). In the event a Sublicensee of
CENTREXION challenges the validity of an Assigned Patent, BII may terminate this Agreement hereunder, if CENTREXION does not terminate such sublicense agreement with immediate effect. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

25 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	12.2	 Consequences of Termination. 

 

	12.2.1	 Expiration. Upon expiration of this Agreement, CENTREXION shall, on a Product-by-Product and country-by-country basis, retain a perpetual, fully paid-up, non-exclusive and cost-free right to use the Licensed Know-How solely for the Products in such country and in the Field. 

 

	12.2.2	 Termination for convenience by CENTREXION or for cause by BII. If this Agreement is terminated by
CENTREXION in accordance with Section 12.1.2 or by BII in accordance with Section 12.1.3, 

  

	 	(a)	 CENTREXION shall no longer have any right to use the Assigned Patents and ownership of all Assigned Patents
shall automatically transfer back to BII; 

  

	 	(b)	 CENTREXION’s licenses under Section 2 of this Agreement shall automatically lapse and all of
BII’s rights to the Licensed Know How automatically revert back to BII; and 

  

	 	(c)	 CENTREXION shall retain a right to distribute and sell its existing inventory of the Products for a period of
not more than [***] following the date of the effective termination hereof, subject to CENTREXION’s continuing obligation to pay sales milestones and Royalties with respect to the Net Sales derived from the distribution and sale of such
existing inventory of the Products, in accordance with the requirements of Section 8 hereof. 

  

	 	(d)	 BII shall have the right to request in writing within [***] after the effective date of such termination, at
CENTREXION’s cost and expense, solely to the extent reasonably necessary for BII to continue the Development, Manufacture and Commercialization of the Products: 

 

	 	(i)	 a complete set of all Development Data, in particular IND/regulatory dossiers, to be provided in original form
(i.e., with the relevant signatures and as suitable for submission for Regulatory Approval) and other Know How of CENTREXION regarding the Compounds and the Products and requested by BII, such Development Data and other Know How to also be
provided in electronic form within [***] after receipt of such notice; 

  

	 	(ii)	 the transfer of Regulatory Approvals, pricing approvals and reimbursement agreements held by CENTREXION, its
Affiliates or Sublicensees; 

  

	 	(iii)	 if Regulatory Approvals have not been obtained by CENTREXION, its Affiliates or Sublicensees, that
CENTREXION(i) either transfers to BII all applications to Regulatory Authorities, i.e. the Investigational New Drug Application (IND) and the status of an application for the Regulatory Approvals and notifies the competent
Regulatory Authority thereof and supplies BII with all documents already prepared by CENTREXION, its Affiliates or Sublicensees for the filing of applications for Regulatory Approvals (with CENTREXION using all efforts to promptly undertake such
actions), or (ii) applies for the closing of any application with the Regulatory Authorities; and 

  

	 	(iv)	 the grant of a non-exclusive, cost-free, perpetual, worldwide,
transferrable and sublicenseable (in multiple tiers) license to the Results and Background IP of CENTREXION, to the extent such Results and Background IP of CENTREXION have been used, or are necessary, for the Development, Manufacture and/or
Commercialization of the Products, in each instance for the continued Development, Manufacture and Commercialization of Products. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

26 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 CENTREXION shall ensure that its Affiliates and Sublicensees grant respective licenses to
Results and Background IP to BII. 
  

	12.2.3	 Termination for cause by Centrexion. If this Agreement is terminated by CENTREXION in accordance with
Section 12.1.3, CENTREXION shall elect to either (i) terminate the Agreement and pursue whatever remedies may be available to CENTREXION hereunder or at law or in equity or (ii) continue the Agreement; provided that the Agreement
shall automatically be amended, with no action required by either Party, such that CENTREXION’s obligations hereunder shall terminate except for its obligations under Sections 6.2, 7, 8, 9, 10 and 11, and the licenses granted by BII to
CENTREXION hereunder shall continue in full force and effect, on a perpetual, irrevocable basis, sublicenseable in multiple tiers, in accordance with Section 2, and subject to CENTREXION’s payment of the payments specified in
Section 9. 

  

	12.2.4	 Accrued payment claims. Termination of this Agreement for any reason whatsoever shall not relieve
CENTREXION of its obligations to pay all Royalties and other amounts payable to BII which have accrued prior to, but remain unpaid as of, the date of expiration or termination hereof, or which accrue thereafter, in accordance with
Section 12.2.2(c) hereof. Upon termination of this Agreement any accrued payment obligations shall become immediately due and payable. 

  

	12.2.5	 Termination for cause. Termination of this Agreement in accordance with Section 12.1.3 shall not
affect or impair the Non-Breaching Party’s right to pursue any legal remedy, including the right to recover damages, for any harm suffered or incurred by the
Non-Breaching Party as a result of such breach or default. 

  

	12.2.6	 Survival. Sections 1, 6, 8, 10, 11, 12, and 14 shall survive the expiration or termination of this
Agreement. 

  

	13.	 GOVERNMENT APPROVALS. 

Government approvals. As of and after the Effective Date, CENTREXION and BII will reasonably cooperate and use respectively all
Commercially Reasonable Efforts to obtain all approvals required and make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all other consents, transfers, approvals, orders, qualifications
authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. 
  

	14.	 GENERAL PROVISIONS. 

 

	14.1	 Assignment. Neither Party shall have the right or the power to assign any of its rights or obligations
under this Agreement, without the prior written consent of the other Party, except that it may assign this Agreement to the successor to all or substantially all of the assets of such assigning Party as are relevant to this Agreement. 

  

	14.2	 Force majeure. If the performance of any part of this Agreement by either Party, or any obligation under
this Agreement, is prevented, restricted, interfered with or delayed by reason of any cause beyond the reasonable control of the Party liable to perform, unless conclusive evidence to the contrary is provided, the Party so affected shall, upon
giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

27 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
interference or delay, provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and
shall continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise, the Parties shall discuss what, if any, modification of the terms of this Agreement may be required in order to arrive at an
equitable solution. 

  

	14.3	 Notices. All notices hereunder shall be in writing in the English language and shall be delivered by
personal delivery, by registered mail / international courier, or by facsimile and confirmed by registered mail / international courier on the next Business Day after the transmission, and shall be deemed given (a) on the date of delivery if
delivered by personal delivery on a Business Day; (b) on the third Business Day from and including the day of sending in the case of a delivery by registered mail / international courier; or (c) on the next Business Day following the day
of transmission in the case of a delivery by facsimile (confirmed by a copy sent as provided above). All notices shall be given: 

if to BII, addressed to: 

Boehringer Ingelheim International GmbH 

[***] 
 [***] 

Binger Str. 173 
 55216 Ingelheim

 Germany 
 Telephone: [***]

 Facsimile: [***] 
 With a
copy to: 
 [***] 
 Address as
above 
 if to CENTREXION, addressed to: 

[***] 
 CENTREXION Therapeutics
Corporation 
 509 South Exeter Street, Suite 202 

Baltimore, Maryland 21202 
 U.S.A.

 Email: [***] 
 Telephone:
[***] 
 Facsimile: [***] 
  

	14.4	 Governing law. This Agreement and all disputes arising hereunder, shall be exclusively governed by, and
interpreted and enforced in accordance with the laws of Switzerland, without regard to its conflict of law rules. 

  

	14.5	 Jurisdiction. Exclusive jurisdiction shall lie with the courts in Zurich, Switzerland.

  

	14.6	 Severability. If any provision of this Agreement is determined by any court or administrative tribunal
of competent jurisdiction to be invalid or unenforceable, the Parties shall negotiate in good faith a replacement provision that is commercially equivalent, to the maximum extent

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

28 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

	 	
permitted by Applicable Laws, to such invalid or unenforceable provision. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of
the other provisions of this Agreement. Nor shall the invalidity or unenforceability of any provision of this Agreement in one country or jurisdiction affect the validity or enforceability of such provision in any other country or jurisdiction in
which such provision would otherwise be valid or enforceable. 

  

	14.7	 Entire Agreement and Amendments. This Agreement, together with all Exhibits attached hereto, constitutes
the entire agreement between the Parties regarding the subject matter hereof, and supersedes all prior agreements, understandings and communications between the Parties, with respect to the subject matter hereof, provided, however, that
confidentiality agreements between of the Parties regarding the subject matter hereto and entered into before the Effective Date, including the confidential disclosure agreement entered into by and between the Parties dated [to be completed], shall
remain effective with respect to information exchanged between the Parties before the Effective Date. No modification or amendment of this Agreement shall be binding upon the Parties unless in writing and executed by the duly authorized
representative of each of the Parties; this shall also apply to any change of this Section. 

  

	14.8	 Waivers. The failure by either Party hereto to assert any of its rights hereunder, including the right
to terminate this Agreement due to a breach or default by the other Party hereto, shall not be deemed to constitute a waiver by that Party of its right thereafter to enforce each and every provision of this Agreement in accordance with its terms.

  

	14.9	 Independent Contractors. The Parties are independent contractors and this Agreement shall not constitute
or give rise to an employer-employee, agency, partnership or joint venture relationship among the Parties and each Party’s performance hereunder is that of a separate, independent entity. 

 

	14.10	 Headings. The headings are placed herein merely as a matter of convenience and shall not affect the
construction or interpretation of any of the provisions of this Agreement. 

 - signature page
follows - 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

29 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 IN WITNESS WHEREOF, this Agreement has been signed by the Parties hereto in two originals, each Party
acknowledging receipt of one original. 
  

									
	Boehringer Ingelheim International GmbH	 		 	CENTREXION Therapeutics Corporation
					
	By:	 	/s/ Jürgen Beck	 		 	By:	 	/s/ Kerrie Brady
	Name:	 	Jürgen Beck	 		 	Name:	 	Kerrie Brady
	Title:	 	Authorized Signatory	 		 	Title:	 	Chief Business Officer

  

			
	By:	 	/s/ Dorothee Schwall-Rudolph
	Name:	 	Dorothee Schwall-Rudolph
	Title:	 	Authorized Signatory

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

30 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Exhibit 1.4 Assigned Patents 

Patent portfolio of the SSTR4 program 

Patent Family: [***] 
 Title: [***] 

 

									
	 Country/Docket
	  	 Filing date
	  	 Application no.
	  	 Publication no.
	  	 Status

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

 Patent Family: [***] 
 Title:
[***] 
  

							
	 Country / Docket
	  	 Filing date
	  	 Application no.
	  	 Publication no.

	 [***]
	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

31 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent portfolio of the CCR2 program 

Patent family [***] 
 Title: [***] 

 

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patent number

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

32 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent family [***] 

Title: [***] 
  

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patent number

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

33 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent family [***] 

Title: [***] 
  

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patent number

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

34 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent portfolio of the CB2 program 

Patent family [***] 
 Title: [***] 

 

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patent number

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

35 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Exhibit 1.25 Development Compounds 

CCR2 (BI 416970) 
 CB2 (BI
1206016) 
 SSTR4 (BI 440290) 

SSTR4BU (BI443438) 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

36 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Exhibit 2.1 Assignment Form 

PATENT ASSIGNMENT 
 THIS ASSIGNMENT
is made on “DATE” between 
 Boehringer Ingelheim International GmbH (“BII”), a German limited liability company, with
offices at Binger Straße 173, 55216 Ingelheim am Rhein, Germany 
 And 

Centrexion Therapeutics Corporation (“CENTREXION”), a Delaware Corporation, with offices at 509 South Exeter Street, Baltimore,
Maryland 21202, U.S.A 
 WHEREAS BII owns and controls certain patents and patent applications related to SSTR4 agonists, CCR2 antagonists and CB2
agonists. 
 NOW THEREFORE in consideration of the premises contained herein and for other valuable consideration that has been exchanged,
CENTREXION requests and the BII HEREBY ASSIGNS to CENTREXION, who accepts, the Patents (which are the patents and patent applications listed on the attached Annex 1 and all other patents and patent applications in any country that
(i) claim priority to a patent or patent application listed on the attached Annex 1 or (ii) have a common priority with a patent or patent application listed on the attached Annex 1), all rights to claim priority from any of
the Patents, all the right, title and interest therein and to all inventions disclosed therein, and all the rights, powers and privileges conferred on the proprietor thereof by the grant of the Patents, including the right to sue for damages and
other remedies in respect of any infringement of the Patents which may have occurred prior to the date hereof TO HOLD the same unto the Assignee absolutely. 

AND BII hereby gives explicit consent to CENTREXION to register and record the transfer of ownership right with the respective intellectual property offices
worldwide. 
 In consideration for the above assignment, the CENTREXION has paid to BII the amount of EUR 1 (+ VAT, if applicable), receipt of which is
acknowledged by BII. 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

37 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 This Agreement shall be governed by and construed in accordance with German law. 

EXECUTED the date and year first above written 
 Boehringer
Ingelheim International GmbH 
 Ingelheim, Date 
  

									
	by	 		 		 	
					
	ppa.	 		 		 	ppa.	 	
		 	Authorized Signatories	 		 		 	

  

	
	Centrexion Therapeutics Corporation
	by
	
	   

  

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

38 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Annex 1 

Patent portfolio of the SSTR4 program 

Patent Family: [***] 
 Title: [***] 

 

									
	 Country / Docket
	  	 Filing date
	  	 Application no.
	  	 Publication no.
	  	 Status

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

 Patent Family: [***] 
 Title:
[***] 
  

							
	 Country / Docket
	  	 Filing date
	  	 Application no.
	  	 Publication no.

	 [***]
	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

39 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent portfolio of the CCR2 program 

Patent family [***] 
 Title: [***] 

 

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patentnumber

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

40 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent family [***] 

Title: [***] 
  

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patentnumber

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

41 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent family [***] 

Title:    [***] 
  

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patentnumber

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

42 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Patent portfolio of the CB2 program 

Patent family [***] 
 Title: [***] 

 

									
	 Country / Docket
	  	 Application date
	  	 Application number
	  	 Publication number
	  	 Patent number

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

  

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

43 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

 Exhibit 4.2 Development Plan 

[***] 

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

44 

 Confidential Treatment Requested Centrexion Therapeutics Corporation 

STRICTLY CONFIDENTIAL AND ATTORNEY-CLIENT-PRIVILEGED 
 DRAFT - BII
- CENTREXION - PATENT ASSIGNMENT AND LICENSING AGREEMENT 
  

													
	 	  	 Proposed
Indication at
Start of

Development
	  	 Phase 1

(first
patient in)
	  	 Phase 2a

(first
patient in)
	  	 Phase 2b

(first
patient in)
	  	 Phase 3

(first
patient in)
	  	 NDA
filing

	 BI-CCR2
	  	OA pain	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 BI-CB2
	  	Neuropathic pain	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 BI-SSTR4
	  	Chronic pain	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Confidential Portions of
this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]